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ABSTRACT 
Unlike humans, the primary signal for maternal recognition of pregnancy in ruminants 
is the Type 1 interferon (1FN) IFN1:. IFN1: is produced by the conceptus and acts upon 
the endometrium where it inhibits the production of prostaglandin F 2a and subsequent 
luteolysis of the corpus luteum. It is difficult to establish what precise role interferon-
like signalling might play in human reproduction due to ethical barriers. However, 
indirect investigations are possible by in vitro investigation of human endometrial 
response to Type 1 IFN stimulation. 
Type 1 IFNs (a, ~ and 1:) activate a common tyrosine kinase signalling pathway 
involving the Janus kinase (JAK) and signal transducer and activator of transcription 
(STAT) proteins. However, the Type 1 IFNs elicit different cellular responses. 
The aim of this thesis is to establish that, whilst it is known that the Type 1 IFNs 
trigger the JAKISTAT activation pathway, there is a simultaneous activation of 
different phospholipase pathways which determines the specificity of the response. 
This hypothesis was investigated using human endometrial tissue which is known to 
respond to Type 1 IFNs. 
Long-term primary human endometrial cell cultures were established from tissue 
taken from the proliferative and secretory phases of the menstrual cycle. Cell function 
and viability were determined by measuring placental proteins and cytokines. 33p 
labelled endometrial cells exposed to IFNs a and 1: showed hydrolysis of 
phosphatidylinositol 4,5-bisphosphate (PIP2) with corresponding production of 
diacylglycerol (DAG). IFNa and IFN1: also stimulated hydrolysis of 
phosphatidylinositol-4- phosphate (PIP). These IFNs did not demonstrate activation of 
any other phospholipase. There was no phospholipid turnover via any phospholipase 
11 
in response to IFN(3. Using immunoprecipitation, SDS-PAGE and Western blotting it 
was possible to show the presence of phosphorylated STATlu in unstimulated 
endometrial cells. In response to stimulation by IFN u and (3 there was an increase in 
phosphorylated STATlu, STAT2 and Tyk2 (a member of the Janus kinase family). In 
contrast, IFN't activated the phosphorylation of Tyk2 but not STATlu or STAT2. 
There was no stimulation of JAKI phosphorylation by any of the IFNs. In summary, 
Type I IFN s u, (3 and 't each elicit a different pattern of signal transduction response 
in cultured human endometrial cells, not only via the JAKISTAT pathway but also via 
phospholipase activation. 
The ability of IFN't to stimulate a signalling pathway, distinct from that of IFNu and 
(3 is sufficient circumstantial evidence to suggest that at least a residual signalling 
pathway for IFN't exists in the human endometrium and further investigation is 
warranted. 
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CHAPTER! 
INTRODUCTION 
1 
1.1 The menstrual cycle and the role of the endometrium 
One of the most important structures of the human female reproductive system is the 
uterus (Figure 1.1 ). 
myometrium Fallopian tube 
-----4- cervix 
vagina 
Figure 1.1 The human female reproductive system. Adapted from 
www.nlm.nih.gov (2006). 
The uterus is a pear-shaped organ 7.5 cm long, 5 cm wide and 2.5 cm deep. The 
lumen, the cavity of the uterus, is connected to the peritoneal cavity by Fallopian 
tubes at the top and to the exterior by the vagina below. At the ends of the Fallopian 
tubes lie the ovaries. The wall of the lumen is 1-2 cm thick. This wall is comprised 
2 
of two layers - the myometrium and the endometrium. The myometrium makes up 
the bulk of the uterine wall and is made up of bundles of smooth muscle fibres held 
together by connective tissue. 
The endometrium is the constantly changing layer of the uterine lumen. The change 
is due to the effects of ovarian hormones, oestrogen and progesterone. At 
menstruation most of the endometrium breaks down and is shed leaving a layer about 
0.5 mm thick of residual basement endometrium. Regeneration takes place followed 
by the proliferative phase due to the influence of oestrogen. By mid-cycle the 
endometrium attains a thickness of 2-3 mm. It is lined by columnar epithelial cells 
which invaginate into the endometrial stroma at regular intervals to form straight or 
slightly curved glands with a narrow lumen (Figure 1.2). 
surface 
epithelium 
stromal 
fibroblasts 
glandular 
epithelium 
Figure 1.2 The human proliferative endometrium showing stromal and 
epithelial cells. From Llewellyn-Jones (1978). 
3 
The tips of the glands reach the myometrium and remain after menstruation gIVIng 
rise to the pars basalis from which re-epithelialisation may occur. The stroma 
consists of a reticular connective tissue rich in spindle-shaped muclei. In the second 
half of the menstrual cycle progesterone, from the corpus luteum, leads to further 
thickening of the endometrium by 5-6mm and this is known as the secretory phase. 
The glands become increasingly elongated, tortuous and sacculated. Fat, protein and 
glycogen accumulate in the epithelial cells and displace their nuclei nearer to the cell 
surface. The secretory products of these cells then appear in the lumina of the glands. 
Three layers of endometrium now become distinguishable. The zona compacta is 
thin and superficial; the glands are straight and narrow and surrounded by oedematous 
stroma. The middle layer, zona spongiosa, occupies most of the mucosa; the glands 
are tortuous, dilated and sacculated and the spiral arteries are in abundance. The 
deepest narrow layer, zona basalis, which is adjacent to the myometrium remains 
virtually unaltered. 
During menstruation, ischaemia (insufficient flow of blood) is followed by necrosis, 
haemorrhage and discharge of the detached portions of endometrium. Menstruation 
and repair probably occur simultaneously in different parts of the endometrium. If 
pregnancy occurs menstruation does not take place and the endometrium becomes 
even thicker, 10-12 mm, and the stromal cells are converted into large glycogen-laden 
decidual cells. During pregnancy the endometrium is called the decidua. 
The changes in endometrial morphology and cellular functions throughout the 
menstrual cycle are strongly influenced by oestrogen and progesterone and these are 
indirectly controlled by the gonadotrophic hormones; follicle stimulating hormone 
(FSH) and luteinising hormone (LH). 
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Under the influence of FSH, released by the pituitary gland, several Graafian follicles 
develop in the ovary. One follicle will develop more than the others and it is from 
this follicle that the ovum will be released. The stimulated follicles synthesise and 
secrete the oestrogen, oestradioI17~. This secretion is important in the regeneration 
of the endometrium after menstruation and the initiation of the proliferative phase of 
the menstrual cycle. The serum increase in oestradiol 17~ causes a positive feedback 
on the hypothalamus and pituitary which results in a sudden increase in the release of 
LH. This LH surge causes the release of the ovum on about day 14 of the menstrual 
cycle. The follicle, which had contained the ovum, collapses and its cells are altered, 
under the continuing influence of LH, to synthesise oestradiol 17~ and progesterone. 
The addition of progesterone activity to the oestrogen effect is to convert the 
proliferative phase endometrium into a secretory one. 
The follicular cells become luteinised and the collapsed follicle is called the corpus 
luteum. In the absence of fertilisation, the corpus luteum regresses, the levels of 
oestrogen and progesterone fall and the endometrium can no longer be maintained. 
Shrinkage occurs when there is constriction of the spiral arteries leading to necrosis 
and bleeding. The deeper basal layers of the endometrium are able to maintain a 
blood supply but the upper layers break down and are shed as menstrual flow (Figure 
1.3). 
If fertilisation occurs it does so in the Fallopian tube within 24-48 hours after 
ovulation. The initial stages of development from fertilised ovum to morula (a mass 
of 12-16 cells) occurs as the embryo passes down the Fallopian tube. The transfer of 
the conceptus after fertilisation from the oviduct to the uterus is facilitated by the 
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changing endocrine environment of the early secretory phase with its rising ratio of 
progesterone to oestrogens which affects the tubal and uterine musculature. 
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Figure 1.3 Diagrammatic representation of the menstrual cycle showing 
hormonal and endometrial changes. Modified from Johnson and Everitt (1988). 
All the morphological and physiological changes that the human endometrium 
undergoes throughout the menstrual cycle are geared towards maximising the chances 
of fertilisation, implantation and subsequently a successful pregnancy. 
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1.2 Implantation 
Once inside the lumen of the uterus implantation of the conceptus occurs. By this 
time there is tqlllsition of the morula to the blastocyst with accompanying formation 
of the trophoblast. 
Implantation is a complex process which involves the 'invasion' of the maternal 
endometrium by the trophoblast surrounding the developing blastocyst. In response 
to this interaction there is a cellular reaction within the endometrium which has some 
features analagous to invasion by a tumour and some which are more characteristic of 
an inflammatory response. Implantation can be divided into a series of steps known 
as apposition, adhesion and invasion. Apposition is the positioning of the blastocyst 
within the uterine cavity. Adhesion follows as the cells of the trophoblast fix to 
maternal tissues and to each other via a group of cell adhesion molecules, including 
laminin and fibronectin, together with cell surface receptors for these molecules 
(integrins). Invasion then occurs allowing the trophoblast, through proteolytic 
processes, to penetrate into the maternal decidua and endometrial spiral arteries. 
The blastocyst interacts with the mother in two ways. Firstly, there is the 
establishment of physical contact with the maternal blood system to ensure a supply 
of essential nutrients. Secondly, the blastocyst makes the maternal pituitary-ovarian 
axis aware of its presence thus preventing the normal mechanisms of luteal regression 
occurring with subsequent fall in progesterone levels and the loss of the pregnancy. 
For the above processes to take place successfully the endometrium must be 
receptive. There are histologic changes of the endometrium under the influence of 
oestrogen and progesterone but there are other processes that are thought to be 
necessary for implantation and these include other hormones, growth factors and 
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cytokines. One of the most important cytokines involved in implantation and secreted 
by the endometrium is Leukaemia Inhibitory Factor (LIF) levels of which rise in the 
secretory phase of the menstrual cycle. A reduction of LIF at this time is associated 
with recurrent pregnancy loss (Stewart et al 1992). Production of human chorionic 
gonadotrophin (he G) by the trophoblast maintains progesterone release from the 
corpus luteum until the placenta takes over this function at about 8 weeks of 
pregnancy and hepatocyte growth factor (HGF) enhances cytotrophoblast invasion 
(Norwitz et a12001) (Table 1.1) (Figures 1.4;1.5;1.6). 
Table 1.1 Some factors associated with implantation and the maintenance of 
early pregnancy 
Hormones 
changes in 
endometrial 
luminal 
epithelium 
cytokines and 
growth factors 
immunologic 
factors 
(Norwitz et aI2001). 
oestradiol 17~ 
progesterone 
heG 
pinopodes 
alterations in the 
expression of adhesion 
molecules 
LIF 
HGF 
IL-IO 
HLA-G 
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proliferation and differentiation of epithelial and 
stromal cells 
maintains P4 release from corpus luteum 
facilitate blastocyst capture and attachment 
promote trophoblast differentiation and 
invasion 
important for decidualisation and implantation 
enhances cytotrophoblast invasion 
immunosuppression 
prevents immunorecognition and rejection of 
fetal semi-allograft 
Rt'~ulation of 
pro~ta9lDndin 
production 
Hormon~ 
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En<hn1etri~1 
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E ndom~trio I 
gl"nd~ 
Figure 1.4 Blastocyst apposition and adhesion. The diagram represents the 
events that occur as the blastocyst, about 6-7 days after fertilisation, prepares to 
implant in the endometrium. The processes shown are those that are thought to 
be involved in preparing the endometrium for implantation and blastocyst 
apposition and adhesion. COX-2 = cyclooxygenase-2, EGF = epidermal growth 
factor and LIF = leukaemia inhibitory factor. From Norwitz et al (2001). 
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Figure I.S The diagram shows the blastocyst, 9-10 days after fertilisation, 
implanting and the processes involved in trophoblast invasion. From 
Norwitz et al (2001). 
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Fi~ure 1.6. The dia~ram represents the implanted embryo, about 14 days 
post-fertilisation, and the processes involved in maintaining pregnancy. 
VEGF = vascular endothelial growth factor, HLA-G = human leucocyte 
antigen-G. From Norwitz et al (2001). 
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1.3 Maternal recognition of pregnancy 
Central to the maintenance of pregnancy are maternal adjustments which take place to 
allow the retention of the embryo within the uterus. At the tum of the century it was 
demonstrated that the corpus luteum was essential for the maintenance of pregnancy 
in the rabbit and it is now considered that the mechanisms involved in the 
maintenance of the corpus luteum in mammalian pregnancies constitute the 'maternal 
recognition of pregnancy' - a term first described by Short (Short 1969). 
Progesterone is the critical hormone secreted by the corpus luteum in humans for 
establishing and maintaining the first 7-9 weeks of pregnancy. However, levels of 
progesterone secreted by the corpus luteum begins to decline around the 8-10th day 
post-ovulation - a critical period for nidation of the blastocyst if pregnancy is to 
follow. In pregnancy, the corpus luteum is maintained by hCG production by the fetal 
syncytiotrophoblast and consequently progesterone production continues. HCG 
production peaks at about 8-10 weeks of pregnancy and then declines rapidly. At this 
stage placental production of progesterone takes over from that of the corpus luteum. 
This process is called the corpus luteum-placental shift. HCG maintains the corpus 
luteum by mimicking the action of LH and acting on the LH receptor. 
In ruminants, successful pregnancy requires the maintenance of the corpus luteum and 
production of progesterone. However, this process is not controlled through the 
action of a chorionic gonadotrophin but by interferon 't (IFN't) which has anti-
luteolytic effects through the inhibition of oestrogen receptors (Figure 1.7). 
Therefore, it is IFN't which is the initial signal for the maternal recognition of 
pregnancy in ruminants. 
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Figure 1.7 Diagram representing the role of IFN't' in the maintenance of 
pregnancy in ruminants. Adapted from Demmers et al (2001). 
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1.4 Interferons 
Possibly the first described effect of interferon was in 1935 when Hoskins reported 
the protective action of a neurotropic yellow fever virus against a viserotropic strain 
of the same virus in monkeys (Hoskins 1935). Although this viral interference was 
investigated further the underlying mechanism and the first use of the word 
'interferon' did not happen until 1957 when Isaacs and Lindemann isolated a 
substance from virally-infected chicken cell cultures which conferred an anti-viral 
effect in fresh chicken cell cultures (Isaacs and Lindemann 1957). The fact that it 
produced a protective anti-viral effect aroused much scientific and medical interest. 
By 1957 antibiotics were widely available to combat bacterial infections but viral 
infections, on the other hand, remained untreatable and so interferon became the 
substance that raised many hopes and possibilities for future treatments. However, it 
was difficult to characterise interferon immediately because it was only produced 
naturally in very low concentrations. With the advent of large scale production 
combined with efficient purification methods, sufficient amounts of partially pure 
interferon protein became available for scientific research (Cantell and Hirvonen 
1977; Rubinstein et al 1978). 
There are two types of interferon which are defined on the basis of their anti-viral 
activity to withstand acidic conditions of pH 2. Type I interferons are those which 
are acid-stable and Type II interferons those which are acid-labile. The Type I 
interferons include those produced by virally infected leukocytes and fibroblasts. In 
contrast, Type II interferons are only produced by stimulated human peripheral blood 
mononuclear cells (PBMC) - Th1 and NK cells - and are often referred to as immune 
interferons (Stewart 1979). As evidence grew for the existence of distinct molecular 
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forms of interferon, the Greek alphabetical system was applied to these separate 
forms. Leukocyte IFN was designated IFNa, fibroblast IFN - IFN~ and immune 
IFN - IFNy. Later cloning of cDNAs encoding IFNa-like proteins (Capon et al1985) 
lead to the naming of an IFN as IFNa subclass II. This IFN has since been renamed 
IFNO). It is antigenically distinct from IFNa and ~ and qualifies as a separate type of 
IFN (Adolf 1987). 
In humans there are, at least, 18 IFN a genes and together with the single IFN~ gene 
constitute an IFNa/~ superfamily of genes. These genes are arranged on the short 
arm of chromosome 9 and they share the feature of being intron-less (Capon et al 
1985). This suggests a very ancient origin of a common ancestral gene. It is 
proposed that the original Type I IFN gene arose approximately 500 million years ago 
with the splitting to form the IFNa and IFN~ genes around 100 million years later 
(Wilson et aI1983). A further 300 million years later an IFNa gene derived from the 
main group gave rise to the IFN 0) gene family which is present in most mammals, 
except mice and dogs (Roberts et aI1992). 
The amino acid sequence of human IFNa reveals four conserved cysteine residues 
which form two disulphide bonds and no glycosylation sites. The bond between Cys 
1 and Cys 99 is not essential whereas the bond between Cys 29 and Cys 139 is 
required for biological activity. The amino acids adjacent to Cys 29, Leu 30, Asp32-
Arg33 are conserved in all the IFNa proteins and in IFN~. These are essential for 
biological activity but not for binding to the receptor (Marcucci and De Maeyer 
1986). The protein sequence of human IFN~ contains 3 cysteine residues, with a 
disulphide bond between Cys 31 and Cys 141 and a glycosylation site at position 180 
on the precursor molecule. 
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Figure 1.8 Amino acid sequence and secondary structure of the Type I 
interferons IFNa (A) and IFN~ (B). From the Protein Data Bank 
(www.rcsb.org). 
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Interferon 0) has two disulphide bonds at the same positions as IFNa and a 
glycosylation site at position 78 (Adolf et al 1991). 
The mature IFNa proteins are monomers of 166 amIno acids with a calculated 
molecular mass of 18.5 kDa. IFN(3 is a protein of 166 amino acids. There is 300/0 
homology between human IFNa and IFN(3 proteins. The same degree of homology is 
found between IFN(3 and IFNO), but 60% homology is found between IFNa and 
IFNO). The homology between IFNa and IFN(3 is shown in Figure 1.8. 
The paracrine secretion of IFN s results in a series of responses aimed at limiting viral 
spread in target cells. Type I IFNs induce an antiviral state in response to viral 
infection and modulates the immune response. These IFN s are negative regulators of 
cell proliferation and are involved in the induction of apoptosis. 
Type I IFNs have a broad anti-viral activity. Cells challenged with a virus will 
secrete Type I IFNs which bind to other cell receptors and activate a number of IFN-
stimulated genes (ISGs) in neighbouring cells. Several of the proteins encoded by 
ISGs, such as 2'-5' oligoadenylate synthetase (2'-5' OAS), PKR kinase and Mx 
(monomeric GTPase) proteins, have a direct antiviral activity. 
In addition to their anti-viral activity, Type I IFNs stimulate cell-mediated immunity 
and interact either synergistically or antagonistically with inflammatory cytokines. 
Thus IFNs a and (3 stimulate the expression of MHC class I antigens which are 
crucial for the recognition of foreign antigens. IFN a will stimulate production of a 
subset ofT helper cells (THl) which produce IL-2 and IFNy and direct cell immunity. 
Type I IFNs have been shown to play an important role in specific T cell memory 
(Tough et a11996) and to inhibit IL-7-induced growth and survival ofB cells (Su et al 
1997). 
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Apart from their anti-viral effects, Type I IFNs have an antiproliferative effect on 
most cells. IFNa and (3 prolong all the phases of the cell life cycle without affecting 
the rate of DNA, RNA or protein synthesis and block growth factor-induced entry into 
S phase. There is mounting evidence that both IFNs a and (3 playa critical role in 
the apoptosis of virally infected cells and tumour cells although there is evidence that 
IFNs a and (3 prevent activated T cell death during infections (Marrack et al 1999). 
Table 1.2 shows a summary of the many biological activities ofIFNs. 
Table 1.2 Some biological effects ofIFNs (from Chard and lies 1992) 
Inhibition of cell proliferation in culture 
Suppression of stimulatory effects of growth factors 
Inhibition of tumour growth in the whole organism 
Inhibition of viral replication 
Enhancement or inhibition of cell differentiation 
Reversion of neoplastic phenotypes 
Induction of specific protein synthesis ((3-2-microglobulin), 2',5' A 
synthetase 
Monomeric GTPase (Mx) proteins 
Secretion of proteases and protease-inhibitors 
Immunomodulatory effects 
Induction of synthesis of class I HLA antigens 
Suppression of cellular proto-oncogenes 
Prevention of luteolysis 
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1.5 Interferons and early pregnancy 
IFNs are generally produced in response to viral or parasitic infection and upon 
exposure to cytokines and growth factors. However, in the 1980s, a group of proteins 
were discovered which, in the absence of a viral stimulus, were secreted by the 
trophectoderm of the preimplantation conceptuses of ruminants. One of these 
proteins, designated ovine trophoblast protein-l (oTP-l) (Godkin et al 1984), was 
found to be released into culture medium by ovine blastocysts which were between 
13-21 days old (Godkin et al 1982). This secretory protein consisted of several 
isoforms with molecular weights of about 18,000 Da - interestingly IFNa has a 
molecular weight of approximately 18,500 Da. Soon after this discovery, it was 
demonstrated that bovine concepti produced a similar complex of proteins (bovine 
trophoblast protein-I) (bTP-l) (Bartol et al 1985) which cross-reacted with oTP-l 
antiserum (Helmer et al 1987) although these proteins were of a higher molecular 
weight ranging from 22,000 to 24,000 Da. The differences in molecular weight 
between oTP-1 and bTP-1 could be attributed to the presence of carbohydrate found 
in bTP-1 (Anthony et al 1988). 
Evidence that these proteins were involved in the maintainance of pregnancy came 
when it was found that purified oTP-1 administered directly into the uterus of ewes 
delayed luteal regression (Godkin et al 1984). In non-pregnant ewes endometrial 
secretion of prostaglandin F2a causes regression of the corpus luteum. In pregnancy_ 
oTP-1 blocks endometrial prostaglandin F2a production to prevent luteolysis and as a 
result the corpus luteum continues to secrete progesterone which is required for the 
establishment of pregnancy (Fincher et al 1986). Maintainance of the corpus luteum 
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at this time is one of the earliest endocrine adaptations to pregnancy and has been 
termed 'the maternal recognition of pregnancy' (Short 1969) (see Section 1.3). 
Later, as a result of molecular cloning of cDNA and protein sequencing, oTP-l and 
bTP-l were revealed to be interferons (Stewart et al 1987; Imakawa et al 1987). 
Sequencing of the 40 N-terminal amino acids of the trophoblast proteins showed that 
the molecule shared a striking homology with the Type I IFNs; 50% homology to 
IFNa (Figure 1.9 and Figure 1.10) and 70% homology to IFNro (originally lFNa II). 
There is also a highly conserved sequence (Cys-Ala-Trp-Glu) in all IFNs and oTP-1. 
The two interchain disulphide bridges are also conserved and the 
hydrophobicitylhydrophilicity plots of lFNa and oTP-l are barely distinguishable 
(Roberts 1991). As a consequence of this discovery, oTP-l and bTP-l were 
classified as Type I IFNs and named IFN"C. 
Although the main function of IFN"C appears to be that of a pregnancy recognition 
signal in ruminants its structural similarity to the other Type I lFNs has been borne 
out by its other biological activities. IFN"C can protect several cell types from lysis by 
viruses with at least an equal potency to that ofIFNa and, like the other type I lFNs, 
IFN"C is capable of up-regulating 2'-5' oligoadenylate synthetase which has a direct 
effect on antiviral activity (Roberts et al 1992). IFN"C can slow the proliferation of 
bovine kidney epithelial cells and human WISH cells over the same concentrations at 
which IFNa is growth inhibitory (Pontzer et aI1991). 
However, unlike IFN"C, the role of interferons during human pregnancy is unknown 
since the initial signal for maternal recognition is human chorionic gonadotrophin 
(hCG)(Lenton et al 1982). 
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Figure 1.9 Amino acid sequence alignment of IFN't and IFNa. c denotes the 
conserved cysteines which form the disulphide bonds. Other conserved amino 
acids are represented in green. Modified from Radhakrishnan et al (1999). 
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Figure 1.10 Amino acid sequence and secondary structure of the Type I 
interferons IFNa (A) and IFNT (B). From the Protein Data Bank 
(www.rcsb.org). 
o 
A 
- --
Indicates position of Cys residue and 
the disulphide bond 
eDl PQ1'HS l~·S RRTlMlLAQMRK 1 Sl F SCLKDRHDF~FP QEE F~N'QFQKAE1' 1 PVlHEMl 
5 16 1~ 26 2~ ]6 ]5 4b 4:§ 56 55 ro 
QQ 1 HfL F S TKDS SAAWDETLL DKFYTEL YQQU.fDLEAClr 1 Q:J VGVTETP LMKEDS 1 LAVR 
6S 7b 7~ sb S5 96 9'5 H!C liB 110 1 i5 12'0 
"1 "1 
KYFQR tTL Yl Kt::KKYS PCA~VVRAt:: [MRS: F SLS TNlQ!:Sl R SKt:: 
1 b 1 jo 1 j5 140 145 150 155 160 165 
B 
1 H:! H] 
/~~==9rn========~~ 
Ct'LSR KLMLDAR ENLKLLDR MNR LSP"H SC1..QD"RKDFGL PQEMVEGDQLQKDQA FPVL YEM 
4b 55 
H5 
~ 
LQQSFNLFYTEHSSAAWDTTLLEQLCTGLQQQ1..DHLDTCRG MDPIVTVTCKYFQGIYDY 
do d5 de 
lQt::KC YS DCAWt:: t VRVnolMR Al TV ST TlQ'T(R l "TK 
Ijl ' 140 J45 de 155 1~ 
22 
Interestingly, IFNa can stimulate hCG production in tumour cells (Iles and Chard 
1989) but it is unlikely that IFNa is responsible for triggering hCG production in the 
early human embryo. 
While IFN s have not been detected from the early human pre-embryo (Gunn et al 
1994) some function in human pregnancy is possible since significant levels of IFN~ 
and, in particular, IFNa are found in fetal tissue, placenta, membranes and amniotic 
fluid after implantation has been established (Chard et al 1986; Howatson et al 1988; 
Paulesu et al 1991). As these IFNs are found predominantly in the 
syncytiotrophoblast (Howatson et al 1988; Paulesu et al 1991) it is therefore possible 
that trophoblast IFN in the human may have a role as an immunomodulator of fetal-
maternal recognition rather than in signalling implantation as it does in ruminants. 
(Table 1.3 and 1.4). 
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Table 1.3 Interferon production in human pregnancy 
Reference 
Ray 1970 
Taguchi et al 
1985 
Duc-Goiran et al1983 
and Lorenzetti et al 1984 * 
Duc-Goiran et al1985 
Bocci et al 1985 
Chard et al 1986 
Howatson et al 1988 
Reiss et al 1989 
Toth et al 1991 
Bulmer et al 1990 
Aboagye-Mathiesen et al 1991 
Findings 
Normal 1FN response of fetal cells to 
virus induction 
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1FN present in normal amniotic 
fluid 
Cultured amniotic fluid can release 1FN 
(1FN~*) after viral induction 
1FN present in fetal blood, placenta and 
membranes 
1FN produced by perfused term placenta 
1FNa present in all fetal tissues, placenta 
membranes and amniotic fluid. 
1FN a present in syncytiotrophoblast and 
macrophages of chorionic villi 
Cultured amniotic cells release 1FN~ 
after exposure to Sendai virus 
Cultured trophoblast cells release 1FN~ 
in response to double stranded 
polyribonucleotide 
1FNa present in villous and extravillous 
syncytiotrophoblast and decidual 
leucocytes 
Cultured trophoblast releases 1FNa and 
1FN~ after exposure to Sendai virus 
Table 1.4 Interferon in animal pregnancy 
Reference 
Overall and Glasgow 1970 
Fowler et al 1980 
Barlow et al 1984 
Evans et al 1985 
Nakane et al 1985 
Yamada et al 1985 
Imakawa et al 1987 
Stewart et al 1987, 1989 
Imakawa et al 1989 
Cross and Roberts 1991 
Farin et al 1989 
Cross and Roberts 1989 
LaBonnardiere et al 1991 
Roberts et al 1992 
Spencer et al 1995 
Findings 
Viral infection of ewe produced low IFN 
response in mother but very high levels 
in fetus 
IFN present at high concentrations in 
mouse placenta but not in maternal or 
other fetal tissue 
Mouse embryo tissues produce IFN in 
response to viral induction 
IFN inducible in both mother and fetus 
Maternal IFN response to Listeria 
infection in mice suppressed during 
pregnancy 
IFN present in mouse placenta 
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Ovine trophoblast protein (oTP-1), 
the major secretory protein of the 
early conceptus is an IFN 
Bovine trophoblast protein (bTP-1) 
is an IFN 
mRNA for oTP-1localised to 
trophectoderm 
Porcine pre-attachment conceptuses 
secrete IFN 
oTP-1 and bTP-1 are named IFN't 
IFN't alters oestrogen and oxytocin 
receptors in the endometrium of ewes 
1.6 The mechanism of action of interferon 
To determine a role for IFN in human fetal-maternal recognition it is necessary to 
understand the nature of the interaction of interferon-receptor binding culminating in 
the generation of a response. 
In the sheep, the mechanism of action of IFNi has been studied in some detail and it 
is known to maintain pregnancy through its anti-Iuteolytic effects (Godkin et aI1984). 
This is achieved through maintained progesterone secretion by the inhibition of 
oestrogen receptors which, in tum, leads to an inhibition of oestrogen-induced up-
regulation of oxytocin receptors (see Figure 1.7). 
Together with an activation of cyclooxygenase inhibitors, there is a shift in the 
prostaglandin PGE2:PGF2a ratio to favour PGE2 over PGF2a with a subsequent 
continued secretion of progesterone (Spencer et al 1995; Mann et al 1999 and Hansen 
et al 1999). Interestingly, it has been shown that PGE2 has a variety of 
immunosuppressive activities (Goodwin and Ceuppens 1983) which include the 
down-regulating of IL-2 production by decidual Natural Killer (NK) cells and an 
increase in pregnancy loss associated with elevated NK cell activity after treatment 
with a prostaglandin inhibitor. 
Both natural and recombinant IFNi have been shown to suppress oxytocin-induced 
secretion of prostaglandins in bovine endometrial epithelial cells (Danet-Desnoyers et 
aI1994). 
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It is particularly significant that human lFNa not only competes with IFN't for the 
same ovine endometrial receptor (Stewart et al 1987; Russell et al 1993 ) but has the 
same effect as lFN't on the ovine endometrium as it inhibits prostaglandin synthesis 
(Mitchell and Smith 1992). In contrast, human lFNa does not result in inhibition of 
prostaglandin synthesis in the human endometrium, although it does attenuate the 
inhibitory effect of progesterone on PGF2u release (Mitchell and Smith 1992). 
Moreover, porcine trophoblast protein (PTP-1) actually stimulates prostaglandin 
synthesis in the porcine endometrium (Mitchell and Smith 1990). This suggests that 
the signalling mechanism for the same lFN must be different for individual species 
thus accounting for the difference in response. 
The signal transduction mechanisms that generate a response following Type I lFN-
receptor binding are only recently becoming clear. It is now accepted that lFNs 
ultimately exert their effects through the induction of gene transcription. 
Understanding of lFN signalling began with studies of lFN-inducible genes. Both 
Type I and Type II lFN s induce the transcription of an overlapping set of genes (Sen 
and Lengyel 1992; Pellegrini and Schindler 1993). Two DNA elements present in 
the promoters of inducible genes were defined by progressive deletion/mutation of 
reporter constructs and studies of lFN-dependent DNA-protein interactions. These 
two elements, called lFN-stimulated response element lSRE and y activation site 
GAS, are able to control gene expression in the absence of protein synthesis. It was 
originally thought these elements were mediated by lFNa/p (ISRE) or lFNy (GAS), it 
is now known that there is an overlap between both elements in that they respond to 
different extents to either type of lFN (Muller et a11994). 
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Binding of the Type I IFNs to their receptor results in the activation of the multimeric 
transcription factor, interferon-stimulated gene factor 3 (ISGF3). This is achieved 
through phosphorylation of latent cytoplasmic proteins known as signal transducer 
and activator of transcription (STAT) proteins (see section 8.1). Together these 
constitute ISGF3a. Binding of ISGF3a to another protein, ISGF3y, forms ISGF3. 
This complex migrates to the nucleus where it binds to the ISRE. The way in which 
the signal is transduced from the Type I IFN-receptor binding event to 
phosphorylation of the ISGF3a remained unclear for some time. Initially, protein 
kinase C (PKC) was implicated in mediating the effects of IFN a on gene expression 
in HeLa cells (Pfeffer et al 1990) and ovarian carcinoma cells (powell et al 1993). 
However, this assumption was based on studies conducted with inhibitors which are 
not specific for PKC. In contrast, other workers have shown that the induction of 
transcripiton by IFNa in HeLa cells is apparently mediated through a protein kinase 
distinct from PKC (Kessler and Levy 1991; Schindler et al 1992; David et al 1993). 
Although the IFNa/~ receptor does not have intrinsic protein kinase activity (see 
section 5.1) it has been demonstrated that the receptor is associated with tyrosine 
kinases of the Janus kinase (JAK) family which are required for the correct assembly 
of the receptor (see section 5.1) (Muller et al 1993; Darnell et al 1994). Binding of 
IFNa/~ to its receptor results in phosphorylation and activation of the JAKs which 
then phosphorylate the STAT proteins leading to ISGF3 activation (Muller et al 
1993; Darnell et al 1994). 
Although the IFNa/~ receptor response has been well characterised, it is not fully 
understood how the JAKs are activated. Furthermore, this model does not solve the 
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dilemma of how activation of the same receptor can lead to different responses in 
different cell types, or the diversity of responses induced by different isoforms of the 
same IFN subtype. It is possible that the specificity of the response may depend 
upon the activation of different subsets of STAT proteins or isozymes of the JAK 
family proteins. Alternatively, it may be regulated by the modification of similar 
proteins (Dr Ian Kerr, personal communication). In this regard, other signalling 
pathways activated by IFNs may possibly crosstalk with the JAKIST A T pathway to 
modify the response. 
Activation of membrane phospholipid hydrolysis is frequently used to generate 
second messengers as a mode of signal transduction. Activation of different 
membrane phospholipases following ligand receptor binding yields different second 
messengers which are each responsible for a variety of effects (see Figure 7.3). 
Pathways which generate second messengers have indeed been shown to be 
associated with Type I IFN responses and differ according to cell type. IFNa 
treatment of mouse fibroblasts transiently stimulates phospholipase A2 accompanied 
by a rapid release of arachidonic acid (Hannigan and Williams 1991) whereas 
interaction of IFNa with the human fibroblast or Daudi cell stimulates a rapid release 
of diacylglycerol and inositol phosphates (Yap et al 1986), presumably due to 
activation of a phosphoinositide-specific phospholipase C (Popescu et al 1989). On 
the other hand, preferential hydrolysis of phosphatidylcholine (PC) via phospholipase 
C has been demonstrated when HeLa cells are stimulated with IFNa (Pfeffer et al 
1990). In this study simultaneous activation of phospholipase D could not be ruled 
out. 
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Since there is a rapid but transient increase in diacylglycerol after exposure of several 
cell types to IFNa (Yap et al 1986; Cataldi et al 1993) it has been suggested that 
activation of PLC is the initial event in the IFNa induced transmembrane signalling 
pathway in these cells. 
Diacylglycerol is responsible for activating protein kinase C (PKC) (Nishizua 1988). 
Preliminary studies assaying histone III phosphorylation demonstrated that 
recombinant ovine IFN"C activates PKC in Madin-Darby Bovine Kidney (MDBK) 
cells, suggesting a role for PKC in mediating the IFN"C induced inhibition of 
expression of the oxytocin receptor (Commander et al 1993). However, the initial 
signal transduction mechanism for generating the second messenger diacylglycerol, 
which activates PKC in this system, is not fully understood. It is possible that 
activation of PKC in the sheep endometrium may even be triggered through 
alternative pathways. Interestingly, phospholipase C can be activated by epidermal 
growth factor receptor tyrosine kinase (Berridge 1993), py-passing G-protein 
associated receptor binding. Thus it is possible that the JAK family proteins may 
serve a dual function, that of STAT protein phosphorylation as well as phospholipase 
C activation resulting in PKC activation to achieve a full response. 
Since there are clear inconsistencies in the signalling mechanisms used by Type I 
IFN s depending on cell lineage and species, it is likely that the signalling mechanisms 
may be different in the human and the sheep endometrium. To date we are unaware 
of any studies which have specifically addressed the question of how Type I IFN 
interaction with the human endometrium receptor transduces its signal. 
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In summary, ruminant Type I interferon, IFNt, signals maternal recognition of 
pregnancy through inhibition of oxytocin receptor expression resulting m 
prostaglandin (PG) synthesis inhibition. Human Type I interferons, IFNs a and ~, 
are produced post-implantation but their role is unknown. Like IFNt, human IFNa 
inhibits PG synthesis in ovine endometrium. However, it is not inhibitory in human 
endometrium. This suggests that the signalling mechanism for the same IFN differs 
for individual species. Type I IFNs bind to a common receptor resulting in activation 
of tyrosine kinases (JAKs) which activate latent cytoplasmic signal transducer and 
activator of transcription (STAT) proteins. The dilemma remains of how activation 
of the same receptor by various IFN subtypes leads to a diversity of responses in 
different cells. The specificity of the response may depend upon activation of JAK 
isozymes or different STAT subtypes. Alternatively, other signalling pathways 
activated by IFNs may crosstalk with the JAKJSTAT pathway to modify the response. 
Activation of membrane phospholipid hydrolysis is frequently used as a mode of 
signal transduction and has been associated with Type I IFN responses differing 
according to cell type. 
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1.7 Cell signalling 
The hallmark of multicellular life is specialisation. Nearly all cells of a higher 
organism will have the same organelles, same metabolic pathways, the same genes 
and most of the same chemical constituents. However, each cell is unique in that it 
will express certain components to a greater degree to provide a specific function 
which is of use to that organism, for example, to secrete a specific product or to 
regulate homeostasis. If these specialised cells are to serve the organism there must 
be communication between them. 
Historically, one of the early breakthroughs In the understanding of cell-to-cell 
communication came at the end of the nineteenth century. In 1894, Schafer 
discovered that extracts of adrenal medulla had a striking effect on muscular tissue 
and this lead him to propose the concept of chemical messengers secreted into the 
blood from ductless glands. After Schafer's discovery the study of chemical 
signalling was largely confined to that of the neurotransmitters and hormones of the 
endocrine glands, such as the pituitary, thyroid, testes and ovary (Rasmussen 1991). 
It also became apparent that other tissues not known to be endocrine glands, for 
example the heart, liver, kidney and gastrointestinal tract, also secreted specific 
hormones and that molecules other than hormones, such as growth factors and 
cytokines, were also involved in cell communication. Initially it was thOUght that 
hormones exerted their effects either by acting as co-factors for enzymes or by 
internally releasing trace substances. A major advance in the understanding of how 
these molecules work was due to Sutherland and colleagues, in 1959, who discovered 
cyclic adenosine 3',5' -mono-phosphate (cAMP). They found that epinephrine did 
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not get into the liver cell and interact with an enzyme but, instead, interacted with a 
receptor on the cell surface. This interaction activates the enzyme adenyl ate cyclase 
which breaks down adenosine triphosphate (ATP) to cAMP and pyrophosphate. The 
cAMP generated then diffuses into the liver and activates the enzymes involved in 
catalysing the breakdown of glycogen to produce glucose. Sutherland then found 
that the cAMP messenger system was more or less universal to all mammalian cells 
and not only did the system activate the liver cells to release glucose but it activated 
adrenal cortical cells to secrete cortisol and thyroid cells to release thyroid hormone 
(Sutherland 1972). From these findings the concept was formed that using the same 
intracellular signalling pathway a variety of cells could be activated to perform their 
specific functions. Further studies by Krebs showed that cAMP activated an enzyme 
called a protein kinase (Walsh et al 1968). Protein kinase catalyses the reaction 
between ATP and a protein to form ADP and a phosphorylated protein. 
Phosphorylation alters the covalent structure of the protein molecule and in doing so 
alters its function. Many different protein kinases have since been discovered. Both 
cAMP and C~+ dependent protein kinases transfer the terminal phosphate on A TP to a 
serine or threonine residue on the protein. However, there is a group ofkinases where 
the phosphate is transferred to the tyrosine residue and these kinases are closely 
associated with growth factor receptors. 
The question arises is how does a change in cAMP act as an intracellular signal 
messenger in so many different types of cells expressing very different responses. 
How is the specificity of the response achieved? Firstly, the distribution of the cell 
surface receptors for specific signals are usually restricted to specific target cells. 
Thus, continuing to use examples already referred to, the receptor for epinephrine is 
found on the surface of liver cells but not on adrenal cortical cells. So no matter how 
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high the epinephrine concentration is in the blood there will be no recognition of this 
fact by adrenal cells, no rise in cAMP and no increase in cortisol secretion. 
Secondly, the specificity will be related to the functional capacity of the cell. The 
receptor for epinephrine is linked to the activation of adenyl ate cyclase in whatever 
tissue it is found. Receptor activation in the liver leads to glycogen breakdown and 
glucose release whereas in the heart there is an increase in heart rate and contractility. 
The difference in response of these two tissues to the same messenger is due to the 
difference in the substrates for cAMP dependent protein kinase. The heart does not 
possess the enzyme glucose-6-phosphatase and therefore glycogen breakdown does 
not occur and conversely the liver cells do not possess the contractile system of the 
heart so no matter how high the cAMP rises no contraction will occur. 
However, only a few intracellular signalling systems operate to couple an 
extracellular messenger to an intracellular response, most extracellular messengers 
activate various intracellular signalling pathways. 
Since Sutherland's discovery of the interaction of cAMP with a cell surface receptor 
many other signalling mechanisms have been elucidated. The different signalling 
mechanisms are as a result of the differences in cell surface receptors. A common 
feature of cell surface receptors is that their activation leads to an increase in 
phosphorylation of cytoplasmic proteins on tyrosine residues. This kinase activity 
can either reside in the receptor, for example, protein tyrosine kinase receptors or in 
an associated protein, for example, the cytokine class I and II receptors. There are 
receptors for the transforming growth factor - ~ superfamily which also signal via the 
activation of protein phosphorylation but with specificity for different residues, serine 
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and threonine. There are receptors for the tumour necrosis superfamily and receptors 
with seven transmembrane domains that couple to G proteins. 
1. 7.1 Signalling through receptor tyrosine kinases 
The hallmark feature which distinguishes the receptor tyrosine kinase (RTK) family 
from other receptor classes is the presence of a tyrosine kinase domain in the 
intracellular portion. Signalling through the R TK family is activated by the binding 
of growth factors which leads to the activation of several different pathways. The 
best described pathways are: 
a) the phospholipase Cy (PLCy) pathway which was the first RTK signalling 
pathway to be identified. PLCy hydrolyses PIP2 into DAG, an activator of 
protein kinase C, and IP3 which mobilises Ca:+ from intracellular stores 
b) PI3 kinase signalling where PI3 kinase catalyses the addition of phosphate to 
the 3' -position of phosphatidylinositol (PI) and other polyphosphoinositols. 
PI3K was the first signalling molecule to be shown to physically associate 
with the RTKs 
c) Ras signalling which is activated by the guanine nucleotide exchange factor 
(GNEF) known as the Son-Of-Sevenless (Sos) which binds to growth factor 
receptor-bound protein 2 (Grb2). Grb2, in turn, associates with RTK and 
leads to the activation of the Mitogen Activated Protein (MAP) kinase 
cascade. 
1.7.2 Signalling through cytokine Class I and II receptors 
The cytokine class I and II receptors lack their own tyrosine kinase activity but 
associate with cytoplasmic protein tyrosine kinases. 
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Cytokines binding to the class I and II receptors activate the JAK-STAT signal 
transduction pathway. This pathway consists of the JAKs, Janus kinases, which are a 
family of membrane-associated cytoplasmic protein tyrosine kinases and the ST ATs, 
Signal Transducers and Activators of Transcription, which are a family of SH2-
domain containing proteins. The ST A Ts are activated by the tyrosine 
phosphorylation within the receptor complex. The tyrosine phosphorylated STAT 
proteins either alone or in association with other proteins migrate to the nucleus where 
they bind to specific response elements in the promoters of inducible genes. This 
signalling pathway is a very direct route to transcriptional activation. 
1.7.3 Signalling through G-protein coupled receptors 
G-protein coupled receptors (GPCR) and their endogenous agonists are important in 
regulating the physiology of every major organ and system. The ligands for the 
GPCRs range from small amines and peptides to large glycoproteins. These ligands 
transduce signals through various mechanisms including stimulation or inhibition of 
adenylyl cyclase or through the activation of calcium release via the inositol-l,4,5-
triphosphate pathway. 
For all of these receptors the binding of the agonist is inhibited by GTP but this 
inhibition is reversed by the presence of guanine nucleotide binding protein (G 
protein). 
The GPCRs are proteins with seven hydrophobic transmembrane helices. All the 
receptors so far cloned are structurally and functionally related and all display the 
seven transmembrane motif. 
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The G-proteins are heterotrimeric proteins consisting of u, ~ and y subunits but it is 
the u subunit which plays the major role in the activation of the GPCR. The receptor 
is activated by ligand binding. There is an increase in the rate of dissociation of GDP 
which activates the G-protein. Then another guanine nucleotide, usually GTP, binds 
and causes the G-protein subunits to dissociate from each other and the receptor thus 
completing the activation process. The activated G-protein subunits bind to and 
modulate the activity of various enzymes, ion channels and receptors. 
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1.8 Aims of the thesis 
The aim of this project is to test the hypothesis that while Type I IFNs (IFNu, p and 
't) activate a common tyrosine kinase signalling pathway in the human endometrium. 
it is the simultaneous activation of different phospholipase pathways which confers 
the specificity of the IFN response. 
The specific aims of this thesis are: 
1) to culture long-term, primary human endometrial cells which have retained certain 
phenotypic features which are characteristic of the stage of the menstrual cycle at 
which the tissue was taken 
2) to determine whether primary human endometrial cells possess a functioning Type 
I IFN receptor and will respond to Type I IFN s 
3) to establish that phospholipid turnover occurs in primary human endometrial cells 
in response to Type I IFNs and to identify the species of phospholipid involved 
4) to establish the presence of JAKI STAT proteins in primary human endometrial 
cells in culture 
5) to determine if there is phosphorylation of the JAKIST AT proteins in response to 
Type I IFNs u, p and't. 
The elucidation of the signal transduction mechanisms of IFNs on the human 
endometrium may support the theory that the JAKISTAT pathway is a universal 
signalling mechanism used by Type I IFN s. 
Furthermore, we explored the possibility that the Type I IFNs trigger other pathways 
and, in doing so, show for the first time that there is crosstalk between different 
signalling pathways which confers specificity of the IFN response. 
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CHAPTER 2 
GENERAL MATERIALS AND METHODS 
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2.1 Major equipment 
MDH CLASS II LAMINAR FLOW CABINET Gift from Dr A Creighton, 
GALLENKAMPINCUBATOR 
CENTRIFUGES: 
a) MSE Coolspin 
b) Mistral 2000 
c) Haraeus Fresco Biofuge 
FLOWGEN E455 POWER SUPPLY UNIT 
GAMMA COUNTERS: 
a) NE 1600 multihead 
b) Hydragamma 16 
c) Wilj single well 
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St Bartholomew's Hospital, 
London, UK 
Gift from Dr A Creighton, 
St Bartholomew's Hospital, 
London, UK 
MSE, Crawley, East Sussex, UK 
PLS Ltd, Forest Row, 
East Sussex, UK 
PLS Ltd, Forest Row, 
East Sussex, UK 
Nuclear Enterprises, Edinburgh, 
Scotland 
Innotron Ltd, Oxford, Oxon 
Wilj Electronics, Ashford, Kent 
BETA COUNTER: 
Packard Minaxi 4000 
SALTER ELECTRONIC BALANCE 
pH METER 
COMPUTER SOFTWARE: 
a) Multicalc data reduction software 
b) Astute statistical software 
MICROSCOPES: 
a) Leica Hoffmann phase contrast 
b) Olympus CK 
ELECTROPHORESIS TANK 
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Packard, Berkshire, UK 
Phillip-Harris Scientific, 
Park Royal, London 
Sigma Chemical Company, Poole, 
Dorset 
EG and G Wallac, Milton Keynes, 
Bucks 
DSS software, Leeds, Yorkshire 
Leica Microsystems (UK) Ltd, 
Milton Keynes, Bucks 
Olympus Optical Company, 
Southall, Middlesex 
BioRad Life Science, 
Hemel Hempstead, Herts 
i 
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2.2 Minor equipment 
VORTEX MIXER 
MAGNETIC STIRRER 
GASES: 
a) 95% air and 5% carbon dioxide 
b) oxygen-free nitrogen 
STERILE PLASTICS: 
a) Tissue culture flasks 
b) 0.4 J.1m pore size well inserts 
c) centrifuge tubes 
d) Nunc 8 chamber slides 
e) graduated pipettes 
X-RAY FILM: 
Kodak X-Omat XAR5 
PIPETTES: 
a) Finnpipettes 
b) Multistep repeating pipette 
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Hook and Tucker, Croydon, Surrey 
Jencons Scientific Equipment, 
Hemel Hempstead, Herts 
BOC Limited, Guildford, Surrey 
Falcon, Becton Dickinson, Plymouth, 
Devon 
Invitrogen, Paisley, Scotland 
Western Lab Services, Aldershot, Wilts 
Sigma Chemical Company, Poole, UK 
Jencons Scientific Equipment, 
Hemel Hempstead, Herts 
Eppendorf, Hamburg, Germany 
BLOTTING MEMBRANE: 
Immobilon (PVDF) 
FILTERS: 
a) 0.22J..1m filters 
b) Whatman filter paper 
GLASSWARE 
SIGMACOAT 
TLCPLATES: 
a) Whatman LHP-K plates 
b) Silica gel 60 plates 
STATIONERY 
2.3 Reagents 
Millipore (UK) Limited, Watford, Herts 
Millipore (UK) Limited, Watford, Herts 
BDH, Lutterworth 
Jencons PLC, Leighton Buzzard, Beds 
Sigma Chemical Company, Poole, Dorset 
BDH, Lutterworth 
Niceday, Erith, Kent 
General laboratory chemicals (Analar or Molecular Biology grade) were supplied by: 
Sigma Chemical Company, Poole, UK or BDH Chemicals Limited, Lutterworth, UK. 
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2.3.1 Primary Cell Culture 
Dulbecco's modified Eagle's 
(DMEM) and Ham's F12 medium 
DMEM:Ham's F12 
phosphate-free medium 
L-glutarnine 
B estradiol 
Type II-s collagenase 
0.40/0 Trypan blue solution 
Poly-I-lysine 
Phosphate buffered saline tablets pH7.4 
(O.OIM phosphate buffer, 0.0027M 
potassium chloride, 0.137M sodium chloride) 
Fetal calf serum 
Antibiotic/antimycotic solution xl00 
(penicillin G 10 OOOunits/ml; streptomycin 
sulphate 10mglml; amphotericin B 25~g/ml) 
Trypsin:EDT A solution xl0 (0.5% 
trypsin:530 rnrnol EDTA) 
Sigma Chemical Company,Poole, 
Dorset, UK 
Invitrogen, Paisley, Scotland, UK 
Anti -vimentin 
V90) 
(mouse anti-human clone Dako Limited, High Wycombe, 
UK 
Anti-cytokeratin (mouse anti-human clone 
MNF116) 
Alkaline phosphatase mouse IgG Fast Red 
Where possible all materials for cell culture were purchased sterile. In other cases, 
solutions, for example, PBS, and implements, such as forceps and scissors, were 
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autoclaved. If autoclaving could not be carried out then solutions were passed 
through a 0.22 Jlm filter and implements were immersed in 70% ethanol for at least 
24 hours and then air dried in the sterile laminar flow cabinet. 95% air and 5% carbon 
dioxide gas was passed through a sterile plugged glass pipette prior to filling the 
flasks. 
2.3.2 Immunoassays 
PP 14 antigen Dr H Bohn, Behringwerke AG, 
West Germany 
Sheep polyclonal anti-PPl4 Gift from Dr B Teisner, 
(172-173 4/4 1995) Odense University Hospital, Denmark 
IGFBP-l antigen Gift from Professor T Chard, 
Department of Reproductive Physiology, St 
Sheep polyclonal anti-1GFBP-l (s515, 4th Bartholomew's Hospital, 
bleed) London, UK 
Chloramine T BDH Chemicals Limited, Poole, Dorset 
Sodium metabisulphite 
Polyethylene glycol 6000 
Heat inactivated horse serum Invitrogen, Paisley, Scotland 
Bovine serum albumin Sigma Chemical Company, Poole, Dorset 
Carrier-free sodium 1251 (IMS-30) Amersham International, Amersham, UK 
Sephadex G-l 00 Pharmacia, Uppsala, Sweden 
Enzyme immunoassay kits for LIF, IFNy, Gift from Dr E Bosmans, 
TNFu, lL6 and HGF Eurogenetics, Tessenderlo, Belgium 
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2.3.3 Immunocytochemistry and immunohistochemistry 
Giemsa stain Sigma Chemical Company, Poole, Dorset 
Human interferon a Peprotech EC Limited, London, UK 
Polyc1onal anti-human IFNa receptor Santa Cruz Biotechnology Inc., 
California, USA 
Monoclonal anti-human IFNa/p receptor Transduction Laboratories, Kentucky, 
USA 
Elite ABC kit Vector Laboratories, California, USA 
LL'I anti-digoxin Gift from Department of Chemical 
Pathology, 
St Bartholomew's Hospital, 
London, UK 
Biocell's EM grade immunogold Agar Scientific, Stansted, UK 
conjugate (goat anti-mouse IgG and IgM) 
2.3.4 Thin Layer Chromatography 
All phospholipids Sigma Chemical Company, Poole, Dorset 
Glycerol standards - monolein, diolein 
and triolein 
Potassium oxalate BDH Chemicals Limited, Poole, Dorset 
JJp orthophosphate Amersham International, Amersham, UK 
3H glycerol 
Ecoscint scintillation fluid National Diagnostics, Atlanta, Georgia, 
USA 
Scintillation vials 
Interferon p Peprotech EC Limited, London, UK 
Interferon l' Gift from Department of Reproductive 
Physiology, 
St Bartholomew's Hospital, London, UK 
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2.3.5 SDS-PAGE and Western blotting 
Control cell lines U3C and U4C 
Anti-STAT la p91 (c-l11) 
Anti-STAT 2 (c-20) 
Anti-JAK 1 (Q-19) 
Anti-Tyk 2 (c-20) 
Anti-phosphotyrosine PY20 
Anti-phosphotyrosine 4G 10 
Protein A sepharose CL-4B 
Gift from Dr Ian Kerr, Cancer Research 
UK, Lincoln's Inn Field, London, UK 
Santa Cruz Biotechnology Inc., 
California, USA 
ICN Pharmaceuticals Limited, 
Basingstoke, UK 
TCS Biologicals, Botolph Claydon, UK 
Pharmacia, Uppsala, Sweden 
Enhanced chemiluminescence (ECL) Amersham International, Amersham, UK 
Western blotting system 
Rainbow markers 
Peroxidase conjugated second antibodies 
Proto gel (acrylamidelbis-acrylamide National Diagnostics, Atlanta, Georgia, 
solution USA 
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2.4 Standard Solutions 
2.4.1 Primary cell culture 
2.4.1.1 Cell culture medium: 
Dulbecco's modified Eagles's medium (DMEM): Ham's F12 1:1 
supplemented with 200/0 heat-inactivated fetal calf serum, 1 % 
antibiotic/antimycotic mixture, 182.5 mg/l L-glutamine, 10 ng/ml ~ estradiol. 
2.4.1.2 Cell culture buffer: 
Prepare 10mM phosphate buffered saline pH 7.4 (PBS) by dissolving tablets 
in distilled water to give a solution containing 2.7mM potassium chloride and 
137mM sodium chloride. Autoclave prior to use. 
2.4.2 Immunoassays 
2.4.2.1 5 OmM phosphate buffered saline (PBS) pH 7. 4: 
7.1 g disodium hydrogen orthophosphate (anhydrous) 
6.8 g potassium dihydrogen orthophosphate (anhydrous) 
8.8 g sodium chloride 
1.0 g sodium azide 
Dissolve in 1 litre of distilled water. Adjust to pH 7.4 with sodium hydroxide. 
2.4.2.2 IGFBP-1 assay buffer: 
50mM PBS pH 7.4 containing 10% (v/v) heat-inactivated horse serum. 
2.4.2.3 P P 14 assay buffer: 
50mM PBS pH 7.4 containing 1 % (w/v) bovine albumin. 
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2.4.2.4 7.5% and 15% polyethylene glycol (PEG) solutions: 
Dissolve PEG 6000 in 50mM PBS to give 7.5% and 15% (w/v) solutions. 
2.4.3 Immunocytochemistry and immunohistochemistry 
2.4.3.1 50mMTris buffered saline pH 7.4: 
50mM Tris.HCI 
375mMNaCI 
Adjust to pH 7.4 with NaOH 
2.4. 3. 2 1 % paraformaldehyde with 0.1 % glutaraldehyde solution: 
1 % (v/v) of paraform.aldehyde and 0.1% (v/v) glutaraldehyde in 0.125M 
phosphate buffer pH 7.3. 
2.4.4 Thin Layer Chromatography 
2.4.4.1 Concentrated chromic acid wash: 
Dissolve 75g of sodium dichromate in 100 mls of distilled water followed by 
1300 mls of concentrated sulphuric acid. 
2.4.4.2 Solution for the extraction of total lipids: 
1:2 v/v chloroform.:methanol 
2.4.4.3 Solution for the extraction of total lipids with an increased extraction 
of polar phospholipids: 
200:400:5:1.6 v/v chloroform.:methanol:concentrated HCI:0.5M EDTA 
2.4.4.4 Total lipid TLC solvent system: 
25:25:25:10:9 v/v methyl acetate:chlorofonn:n-propanol:methanol:0.25O/o 
(w/v) potassium chloride. 
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2.4.4.5 Potassium oxalate solution: 
1 % w/v potassium oxalate in distilled water. 
2.4.4.6 Phosphoinositide TLC solvent system: 
48:40:7:5 v/v chlorofonn:methanol:water:concentrated ammonia. 
2.4.4. 7 Glycerol TLC solvent system: 
180:40:6:4 v/v hexane:ether:methanol:acetic acid. 
2.4.5 SDS-P AGE 
2.4.5.1 Lysis bu}7'ers: 
a) Morris White buffer (2x) pH 7.4 
To make 100 ml: 
6ml sodium chloride (5 M) 
2ml sodium vanadate* (20 mM) 
20ml sodium pyrophosphate (100 mM) 
40ml sodium fluoride (500 mM) 
400 J.!l EDTA, pH 8.0 (500 mM) 
300 J.!l magnesium chloride (l M) 
2.383 g HEPES 
20ml glycerol 
Make up to 100ml with distilled water and pH to 7.4. 
*to prepare sodium vanadate (Na3 V04) solution adjust pH to 10, boil until 
solution turns colourless and store at room temperature. 
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b) Working lysis/wash buffer 
To make 10 ml: 
5 ml 
100 J.lI 
(10 J.lI 
100 J.lI 
10 J.lI 
10 J.lI 
Morris White buffer (2x) 
Triton X-100 
Triton X-100 for wash buffer) 
100 mM PMSF (prepared in 100% isopropanol) 
aprotinin (3 mg/ml) 
leupeptin (l mg/ml) 
Make up to 10ml with distilled water. 
2.4.5.2 SDS-PAGE buffers: 
a) Loading buffer pH 6.8 
2% 
100mM 
0.05% 
30% 
100mM 
sodium dodecyl sulphate (w/v) 
Tris.HCI pH 6.8 
Bromophenol blue (v/v) 
glycerol (v/v) 
dithiothreitol (DTT) 
b) Separating/resolving gel buffer pH 8.8 
750mM 
0.2% 
Tris.HCI pH 8.8 
SDS (w/v) 
c) Stacking buffer pH 6.8 
250mM 
0.2% 
Tris.HCI pH 6.8 
SDS (w/v) 
d) Running buffer 
25mM 
192mM 
0.1% 
Tris base 
glycine 
SDS (w/v) 
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2.4.5.3 SDS-PAGE gels: 
a) Separating/resolving gel 
To make 30 ml of 6.5% acrylamide gel:-
6.5 ml 
15 ml 
8.25 ml 
250 ~l 
25 ~l 
Proto gel (30% acrylamide-bisacrylamide solution) 
Tris.SDS buffer pH 8.8 
distilled H20 
lO% ammonium persulphate 
TEMED 
b) Stacking gel 
To make 15 ml of 4% acrylamide gel:-
2.0ml 
7.5 ml 
5.4 ml 
90 ~l 
10 ~l 
Protogel (30% acrylamide-bisacrylamide solution) 
Tris.SDS buffer pH 6.8 
distilled H20 
10% ammonium persulphate 
TEMED 
2.4.6 Western blotting 
2.4.6.1 Western blotting buffers: 
a) Transfer buffer 
25 mM 
192mM 
20% 
Tris base 
glycine 
methanol (v/v) 
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b) Tris buffered saline with Tween-20 (TBST) 
10mM 
75mM 
1mM 
0.1% 
Tris.HCI pH 7.4 
sodium chloride 
EDTApH8.0 
Tween-20 
c) TBST with vanadate 
To make TBST with vanadate add 1 ml of20 mM sodium vanadate to 100 ml 
ofTBST buffer. 
2.5 General Methods 
2.5.1 Primary Cell Culture 
The first methods of tissue and cell culture used fragments of tissue imbedded in 
blood plasma or lymph, mixed with embryo extract and serum. These fragments were 
placed on a slide or coverslip. The plasma clotted and held the tissue in place while 
the embryo extract and serum mixture supplied nutrients and stimulated migration of 
cells across the surface of the slide (Freshney 1983). The basic technique remains the 
same. Tissue is chopped finely (Figure 2.1a, b, c and d), rinsed and the pieces seeded 
onto the culture surface in a small volume of medium supplemented with a high 
concentration of serum. Once there is adherence of the tissue to the culture surface 
outgrowth of cells will follow. Large pieces of tissue can be disaggregated using 
enzymes, for example, trypsin or collagenase. Once cell culture is established it 
becomes necessary to periodically change the medium for several reasons, for 
example, a change in pH or an increase in cell concentration. When the cells occupy 
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all the culture surface or the cell concentration exceeds the capacity of the medium the 
culture must be divided into subcultures - a process called passaging (Figure 2.1 e). 
The processes of changing medium and passaging are the basic steps in cell culture. 
(Figure 2.1 a-e). 
Figure 2.1 Primary culture technique 
a) b) ~~~ 
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2.5.2 Immunoassays 
2.5.2.1 Radioimmunoassay 
D 
1::===:0 
d) 
Both PP14 and IGFBP-1 were measured usmg radioimmunoassay (RIA). The 
principle of RIA depends upon the compound of interest (the antigen) and a 
radiolabelled form of the antigen competing for binding with an antibody - which has 
been specifically raised against the antigen - to form an antibody-antigen complex at 
equilibrium (Figure 2.2) 
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Figure 2.2 Principle of radioimmunoassay 
Antigen, 
Antibody 
~ Antigen-antibody complex 
Antibody 
125I-Antigen 1251 -Antigen-antibody complex 
In the presence of a fixed amount of labelled antigen and antibody, as the 
concentration of unlabelled antigen is increased the proportion of labelled antigen 
bound to antibody is reduced. This antibody-bound portion of the compound may be 
separated from the free by a variety of methods, for example, activated charcoal and 
polyethylene glycol, and the amount of free or bound labelled material can be 
determined using a ~ or y radioactivity counter. The concentration of the antigen of 
interest can be calculated by comparing the amount of labelled antigen bound to 
antibody to the amount present in samples containing known concentrations of 
unlabelled antigen (standards). 
2.5.2.2 Enzyme-linked immunosorbent assay 
The levels of cytokines were measured USIng commercial enzyme-linked 
immunosorbent assay (ELISA) kits. In ELISA systems a monoclonal antibody to the 
target antigen is attached to a plastic surface, in this case, to the wells of a microtitre 
plate. During incubation, the antigen of interest binds to the immobilised antibody. 
After removal of unbound material by a washing procedure, the target antigen is 
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bound to a second specific polyclonal antibody which is conjugated to biotin. After a 
second wash step the amount of biotin-conjugated monoclonal antibody is detected by 
a third reaction step by the addition of streptavidin-horse radish peroxidase (HRP). 
After removal of the unbound HRP-conjugate the wells are incubated with a substrate 
solution containing hydrogen peroxide and a tetramethylbenzidine buffer solution. A 
blue colour develops in proportion to the amount of the target antigen which is bound 
to the wells. The enzymatic reaction is stopped with 2N sulphuric acid and the 
absorbance values at 450nm are determined. A standard curve is obtained by plotting 
each absorbance value versus the corresponding standard value. The concentrations of 
the target antigen are determined by interpolation from a standard curve. 
2.5.3 Thin Layer Chromatography 
Thin layer chromatography (TLC) is a method which uses the differences in the way 
molecules behave between a mobile and stationary phase to separate components of a 
mixture. 
The physiochemical basis of TLC separation is principally distribution equilibrium. 
Distribution equilibrium is a term which describes the differences in solubility and 
adsorption of a component in two immiscible phases. 
In TLC, the stationary phase is a thin layer of adsorbent material, most commonly, 
silica gel, alumina or cellulose, which is applied to a flat carrier, for example, glass, 
aluminium or plastic. The mobile phase is an organic solvent or a specific mixture of 
solvents depending upon the compounds of interest. Different components in the 
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sample mixture travel different distances according to the strength of their attraction 
to the stationary phase versus the mobile phase. This separation allows for 
identification of components by the comparison with known standards. 
2.5.4 Sodium dodecyl sulphate - polyacrylamide gel electrophoresis (SDS-
PAGE) 
The electrophoresis was carried out based on the method of Laemmli (1970). 
Briefly, the principle of SDS-P AGE is that at a given pH the rate of migration of 
proteins through an electric field is dependent upon the ratio of their charge to their 
mass. The separation of proteins with different charge:mass ratio is achieved if the 
electric field is applied through a porous matrix such as polyacrylamide. When the 
pore size of the polyacrylamide is the same order of magnitude as the proteins to be 
separated molecular sieving occurs. In the case of SDS-PAGE the proteins are added 
to a buffer containing the ionic detergent SDS. As well as solubilising proteins 
allowing efficient entry into the polyacrylamide gel, binding to SDS gives the 
resulting SDS-protein complexes a uniform charge density. Under these conditions 
proteins migrate through a polyacrylamide gel according to molecular weight (Hames 
1981). 
A modification of this technique is discontinuous SDS-P AGE. Samples are loaded 
onto a stacking gel which has a different pH and pore size to the resolving gel. The 
stacking gel typically contains glycine/Tris Hel buffer. At pH 6.8 glycine is near to 
its isoelectric point and has low mobility through the gel. Chloride ions, however, 
have a high mobility at this pH. When the electric field is applied chloride ions 
migrate rapidly leaving a trailing zone which has low conductivity and a high voltage 
gradient. This gradient permits the accelerated migration of glycine until it reaches 
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the chloride ions. A steady state chloride and glycine will move at the same velocity 
with a sharp but narrow boundary between them. SDS-protein complexes, which 
have mobilities intermediate between chloride and glycine, will 'stack' within this 
sharp boundary until they have migrated to the resolving or separating gel. In this 
way, the discontinuous system allows relatively large samples to be loaded onto a gel 
whilst maintaining good resolution of proteins of different molecular weights (Figure 
2.3). 
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Figure 2.3 Operation of discontinuous SDS-P AGE. (a) sample loading, (b) 
protein stacking and (c) protein separation. Modified from Hames (1981). 
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2.5.5 Western Blotting 
Western blotting involves transferring proteins, previously separated by SDS-PAGE, 
onto polyvinylidine fluoride (PVDF) membranes. A small proportion of thi s protein 
in the membrane re-folds to its native conformation and can therefore be probed for 
immunoreactivity to a given antibody. Proteins contained within the polyacrylamide 
gel maintain a negative charge and they can be transferred onto PVDF membranes by 
applying a current across the gel enabling the proteins to migrate at 90 0 to the gel and 
onto the membrane. 
Figure 2.4 Method of protein transfer 
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I 
direction of 
protein transfer 
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Transfer cassette 
Transfer buffer pH 8.3 
Filter paper 
PVDF membrane 
PAGE gel 
Figure 2.5 Principle of Western immunoblotting and enhanced 
chemiluminescence (EeL) detection. 
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2.6 Statistical analysis 
All the data analysis was perfonned using the Astute programme supplied by Astute 
Statistical Software, DDS Software, Leeds University, UK, 
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CHAPTER 3 
THE ESTABLISHMENT AND 
CHARACTERISATION OF PRIMARY 
ENDOMETRIAL CELL CULTURE 
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3.1 Introduction 
In the human the endometrium lines the inner surface of the uterus and is composed 
of stroma and glands (Figure 3.1). The cells of the stroma, fibroblasts, are the 
structural support cells of the endometrium and are important in forming an interface 
during superficial invasion with the trophoblast of the blastocyst after implantation. 
The surface of the endometrium and the glands are formed from epithelial cells. The 
response of these cells to the hormones oestr~gen and progesterone, throughout the 
menstrual cycle, is what determines the activity of the endometrium (Figure 3.2). 
Under the influence of oestradiol the endometrium of the proliferative, or follicular, 
phase of the menstrual cycle is characterised by sparse glands and a thin surface 
epithelium surrounded by a proliferating dense stroma (Figures 3.1 and 3.2). After 
ovulation, the secretory or luteal phase of the menstrual cycle begins and the 
endometrium becomes exposed to progesterone from the corpus luteum causing the 
glands to enlarge and become secretory and the stroma to expand due to the uptake of 
fluids combined with tissue oedema (Figure 3.2). 
The studies in this thesis required 'consecutive experiments to be performed in the 
same batch of endometrial cells so as to maintain experimental consistency. It was 
therefore necessary (i) to establish a long term culture system for primary endometrial 
cells and (ii) to maintain the viability and function of these cells in culture. 
Short term cell culture of endometrial cells has been well documented (Chen et al 
1995; Laird et a1 1996; Laird et al 1997). For long term culture it has been common 
practice to use cell lines derived from endometrial adenocarcinomas (Fleming 1999) 
but as these cells have been transformed they are not representative of normal 
endometrial cells. 
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Figure 3.1 The human proliferative endometrium showing stromal and 
epithelial cells. The proliferative stage of the menstrual cycle is characterised by 
sparse glands and a thin surface epithelium surrounded by dense stroma. The 
stromal cells or fibroblasts are the structural support cells and the predominant 
cells of the endometrium. The stromal cells are also important in forming an 
initial interface with the trophoblast of the blastocyst at implantation. 
(Llewellyn-Jones 1978). 
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Figure 3.2 Diagram showing hormonal and endometrial changes which occur 
throughout the human menstrual cycle. Modified from Johnson and Everitt 
(1988). 
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To overcome these problems long-term primary human endometrial cell culture was 
established. 
For this study both proliferative and secretory derived endometrial cells were cultured 
in a media supplemented with only one hormone, oestradiol (lOng/ml). Although 
tissue taken from the secretory phase would have already been exposed to 
progesterone this was not included in the media as, in vitro, this leads to 
decidualisation of the endometrial tissue (Irwin et al 1989). Decidua is "pregnancy' 
endometrium and would have been inappropriate for this study. 
To confirm that the cultured cells from the excised tissue maintained some degree of 
the differentiated state that they acquired in vivo, measurement of proteins 
characteristic of that state was carried out. PP14 and IGFBP-1 measurements were 
carried out to confmn the function and characterisation of the endometrial cells in 
culture as both have been used in the past as markers of endometrial cell function 
(Fay et al 1990 and Giudice et al 1991 respectively) and are produced in greater 
quantity in the cells of endometrial tissue obtained from the secretory phase of the 
cycle compared with those of the proliferative phase. 
3.1.1 Placental Proteins 
3.1.1.1 Placental Protein 14: epithelial cell marker 
PP14, also termed glycodelin (Seppala 1999), is a glycoprotein with a molecular 
weight of 42,000 to 43,000 Daltons (Bohn et al 1982) and a structural homology with 
~-lactoglobulin (Huhtala et al 1987). The exact function of PP14 in the endometrium 
is not clearly understood but it has been found to inhibit sperm-zona pellucida binding 
in a dose-dependent manner suggesting it may play a role in the process of 
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fertilisation (Oehninger et al 1995). It has also been shown to have immuno-
suppressIve properties and therefore may have a role in the suppression of the 
maternal immune system during implantation (Bolton et al 1987, Pockley et al 1988, 
Okamoto et al 1991) which may account for its marked increase in production in the 
endometrium around the time of implantation and throughout the following secretory 
phase. It is the protein most commonly used as a marker of endometrial function in 
vivo and in vitro (Fay et al 1990). There is some dispute as to whether it is 
specifically secreted by the endometrium or is also secreted by the ovary (Seppala et 
al 1985). However, there is further evidence which suggests that it is solely 
synthesised by the glandular epithelium (Olajide and Chard 1992; Born et al 1998) 
which makes it an ideal candidate for confirming morphology and cell function of 
endometrial epithelial cells. 
3.1.1.2 Insulin-like growth/actor bindingprotein-1: a stromal cell marker 
IGFBP-1, formerly known as placental protein 12 (PPI2), is a 25,000 Daltons non-
glycosylated protein identified from placental extracts by Bohn and colleagues in 
1982. It is believed to modulate acute changes of serum insulin-like growth factors 
(lGFs) (Wang and Chard 1992; Hills and Chard 1995). IGFBP-l mRNA is not 
detected in proliferative phase endometrium but is present in the stromal cells of the 
secretory endometrium (Julkunen et al 1990; Zhou et al 1994). After ovulation 
increasing levels of progesterone stimulate the stromal cells to secrete IGFBP-l (Lui 
et al 1997). 
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3.2 Methods 
3.2.1 Collection of endometrial tissue 
Samples of endometrial tissue were obtained from the histopathology department at 
St Bartholomew's Hospital, London. The tissue was removed from the uteri of 
premenopausal women who had undergone hysterectomy for conditions not 
associated with endometrial malignancy. The tissue was collected into culture 
medium within 1-2 hours of excision. 
The phase of the menstrual cycle was determined by clinical history and histological 
examination when the endometrium was classified as proliferative, secretory, mid-
cycle or inactive. The classification was carried out by the duty histopathologist in 
the Department of Histopathology, St Bartholomew's Hospital, London, UK. 
The study was approved by the local Ethics Committee and informed consent was 
given by each patient prior to surgery. 
3.2.2 Preparation and culture of endometrial cells 
The preparation and culture of cells from endometrial tissue was carried out according 
to a modified method of Freshney (1983) and Chatzilci et al (1994). 
The resected endometrial tissue was collected into 1: 1 Dulbecco' s modified Eagle's 
medium (DMEM) and Ham's F12 mixture supplemented with 20% heat-inactivated 
fetal calf serum, 1 % antibiotic/antimycotic mixture, 182.5 mg/l L-glutamine and 10 
ng/ml ~ estradiol and stored at 4°C unless it was to be processed immediately. 
All the following tissue and cell manipulations were carried out in an MDH Class II 
laminar flow cabinet. The cells were cultured in a closed flask system which reduces 
infection and cross-contamination within the incubator. 
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Single cell suspensions of endometrial cells were obtained by mechanical disruption 
of the endometrial tissue using scalpels in 10 ml of medium. The single cells were 
separated from larger clumps of tissue by sedimentation. The resulting supernatant 
containing the finer material was panned out into a 25 cm2 flask, gassed for 20 
seconds using a 950/0 air and 5% carbon dioxide mixture and placed in a 37°C 
incubator. 
Cell aggregates from the sedimentation pellet were digested with collagenase (Type 
II-S, 200 units/ml) at 37°C for 2 hours. The cells were then washed twice with 10mM 
PBS, resuspended in medium and panned as previously described. 
Cell growth was monitored daily using a phase-contrast microscope and the medium 
was changed either at confluence, that is, when the cells cover one complete surface 
of the flask, at which point passaging took place or when the medium was spent -
about every 3-5 days. All conditioned media was stored at -20°C. 
When passaging was required the medium was either discarded or stored as 
previously mentioned and the cells washed twice with 5 to 10 ml of sterile 10mM 
PBS depending upon the surface area of the flask. Three mls of trypsin:EDT A, 
previously diluted 1: lOin PBS, were added to the flask which was returned to the 
37°C incubator for up to 20 minutes during which time the cells lift off from the flask 
surface. Addition of 7 ml of media containing fetal calf serum stops further 
trypsinisation. The suspended cells were then divided equally into two new flasks to 
which fresh media was added to the required amount. 
The flasks were gassed and returned to the incubator as previously described. 
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3.2.3 Cell number determination 
A cell count was obtained by taking a small amount of the cell suspension during 
passaging and using the Improved Neubauer haemocytometer to calculate the number 
of cells in a flask. The number of cells can be derived by employing the formula: 
c=nJv 
where c is cell concentration as cells/ml, n is number of cells counted and v is volume 
counted. For the Improved Neubauer slide the depth of the chamber is 0.1 mm and 
assuming only the central 1 mm2 is used v = 0.1 mm3 or 10-4 ml and the formula 
-4 becomes c = n x 10 . The average of three counts was calculated. 
3.2.4 Cell viability 
Cell viability was assessed using 0.4% Ttypan blue solution and observing the uptake 
of the stain into the cells. This test relies on the controlled permeability of living cells 
and the exclusion of certain dyes (Kaltenbach et al 1958). Cell death with consequent 
breakdown in membrane integrity results in uptake of Trypan blue into the cell. 
Cells were grown to confluence in a 25 cm2 flask. At this point each flask contained 
approximately 1 x 106 cells. The medium was removed and the cells washed with 
10mM PBS followed by the addition of 4 ml of a 1: 1 solution of Trypan blue in PBS. 
After 5 minutes the stain was discarded and the number of cells which had taken up 
the dye was counted by microscopy and recorded as the percentage non-viable. 
Viable cells, with intact membranes, exclude the dye. 
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3.2.5 Cell characterisation 
3.2.5.1 Cell morphology 
Stromal and epithelial cells were grown in separate flasks and their morphology was 
confirmed by histological examination using a Hoffmann phase-contrast microscope. 
3. 2. 5. 2 Immunocytochemistry 
Stromal and epithelial cells were further identified using antibodies against specific 
cell markers. 
Immunocytochemical staining of endometrial cells was carried out after 5 days in 
culture using anti-cytokeratin, an epithelial cell marker, and anti-vimentin, a stromal 
cell marker. 
Cells were grown onto sterile glass cover slips which were pre-treated with poly-l-
lysine (0.1 mg/ml solution) to aid cell adhesion. The cells were fixed after 5 days of 
growth using increasing percentages of methanol until 100% methanol was reached. 
The cells were then incubated with either: 
a) anti-cytokeratin at a dilution of 1 :50 in 10 mM PBS 
b) anti-vimentin at a dilution of 1:100 in 10 mM PBS 
for 2 hours at room temperature. The first antibody was then washed off with PBS 
and replaced with rabbit anti-mouse IgG antibody at 1 :20 in PBS for 30 minutes at 
room temperature. After a further wash with PBS the cells were incubated with anti-
alkaline phosphatase complex at 1 :20 for 30 minutes at room temperature. The cells 
were finally incubated with the enzyme substrate Fast Red (1 mg/ml) for 15 minutes. 
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3.2.6 Cell function 
The function of primary human endometrial cells in culture was assessed b\ 
measuring placental protein 14 (PP14) and insulin-like growth factor binding protein-
1 (IGFBP-1) levels, by radioimmunoassay, in samples of conditioned media from 
cells cultured for up to 31 days from seeding. The materials and methods used are 
described in sections 2.3.2,3.2.6.1 and 3.2.6.2. 
The proteins, PP14 and IGFBP-1, were assayed in media removed from the culture 
flasks containing endometrial cells at the time of passaging. 
endometrial cells is decribed previously in Section 3.2.2. 
3.2.6.1 Radioimmunoassay for P P 14 
The culture of 
PP14 was measured using a method similar to that described by Bolton et al (1983). 
To 100J..ll of each standard (0, 10, 20, 50, 100, 200 and 500J..lg/l PP14 prepared in 
horse serum) or sample were added 100J..ll 125I_PP14 (10,000 cpm) prepared according 
to the chloramine T method of Greenwood et al (1963) and 100J..ll of antibody at an 
initial dilution of 1: 1 0,000. Tubes containing assay diluent in place of antibody 
(assay blank or non-specific binding) and tracer alone (total counts) were set up. 
Three quality control serum pools which gave low, medium and high levels of PP 14 
were included in each assay. All tubes were set up in duplicate and incubated either 
overnight at room temperature or for 48 hours at 4°C. To separate bound and free 
antigen 50J..ll normal rabbit serum at an initial dilution of 1:50, 100J..ll anti-rabbit serum 
at an initial dilution of 1 :20 and 500 J..ll of 7.5% polyethylene glycol (PEG) 6000 were 
added to the incubation mixture. The assay was pre-incubated for 30 mins at room 
temperature before centrifuging at 18°C for 30 mins at 1800 x g. The supernatant was 
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aspirated and the precipitate containing the bound fraction was counted on a gamma 
counter. 
All dilutions were carried out usmg 50mM PBS containing 1 % bovine serum 
albumin. 
3.2.6.2 Radioimmunoassay for IGFBP-l 
IGFBP-1 was measured as previously described by Wang et al (1991). To 100~1 of 
each standard (0, 0.5, 1, 2, 5, and 10~g/l IGFBP-1 prepared in 50mM PBS with 10% 
v/v heat inactivated horse serum) or sample 100~1 of antibody at an initial dilution of 
1 :800 were added and incubated for 5 hours at room temperature. Tubes for non-
specific binding, total counts and quality controls were also set up. 50~1 of 1251_ 
IGFBP-1 (3000 cpm) were added to the incubation mixture and incubated overnight at 
room temperature. To separate bound and free antigen 1ml of 15% PEG and 100~1 of 
heat inactivated horse serum was used. The tubes were then centrifuged, aspirated 
and counted as previously described for the PP 14 assay. 
All dilutions were carried out using 50mM PBS containing 10% v/v heat inactivated 
horse serum. 
The intra- and interassay coefficients of variation of both protein assays were less 
than 10%. 
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3.3 Statistical analysis 
Levels of proteins from the culture of cells from proliferative and secretory 
endometrium were not normally distributed (Kolmogorov-Smirnoff test p<O.OS) and 
therefore it was necessary to compare the groups using the Wilcoxon Mann Whitney 
U-test. 
In all cases, differences between the groups were considered significant when the 
probability of the events occurring by chance was < O.OS. 
3.4 Results 
3.4.1 Cell Culture 
Primary human endometrial cells from the proliferative and secretory phase of the 
menstrual cycle were successfully cultured and some cultures remained viable for at 
least 60 days from initial seeding. 
3.4.2 Cell viability 
At confluence each 2Scm2 flask contained approximately 1 x 106 cells of which 
99.9% were considered viable according to Trypan blue staining (Figure 3.3) 
3.4.3 Cell morphology 
U sing a phase contrast microscope it was evident that both glandular epithelial and 
stromal fibroblasts had been cultured (Figure 3.4). 
Anti-vimentin and anti-cytokeratin staining revealed that the cell cultures were 
enriched with stromal cells from day 7 (Figure 3.S). 
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Figure 3.3 Trypan blue uptake by human endometrial cells used as a test for cell 
viability. Arrows indicate cells which have taken up the dye. Cells stained with 
Giemsa. Magnification x 200. 
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Figure 3.4 Primary human endometrial epithelial (A) and stromal (B) cells at 8 
days of culture. Magnification x 200. 
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Figure 3.5 Epithelial cell marker, anti-cytokeratin (A), and stromal cell marker, 
anti-vimentin (B) staining of human endometrial cells after 7 days in culture. 
Magnification x 400. 
A 
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3.4.4 Cell function 
3.4.4.1 PP14 
Measurable levels of PP14 were detected in the conditioned media from primary 
endometrial cells obtained from both the proliferative and secretory phases of the 
menstrual cycle. Figure 3.6 show graphs of PPl4 levels throughout culture in both 
proliferative and secretory phase cells from individual tissues. Levels of PP14 were 
found to be almost 17 times higher (p = <0.01) in the supernatants from secretory 
phase cells than those from proliferative phase cells during the first 5 days in culture. 
Release of PP14 from both proliferative phase and secretory phase cells declines over 
time in culture. By day 16 the difference in PP14 levels between proliferative and 
secretory phase levels was no longer significant (see Table 3.1). 
3.4.4.2 IGFBP-1 
Conditioned media from cultured cells from the secretory phase of the menstrual 
cycle had measurable levels of IGFBP-l which decreased over time (Figure 3.7) but, 
in the media from cultured proliferative phase cells, levels of IGFBP-l remained 
undetectable throughout cell culture (see Table 3.1), being below the limit of 
detection of the assay «0.5 JlglI). 
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Table 3.1 In vitro concentrations of PP14 and IGFBP-1 (total mass in ng) 
produced by primary endometrial cells taken from the proliferative and 
secretory phases of the menstural cycle. 
Proliferative phase secretory phase 
Protein days from Median (range)(ng) median (range)(ng) p value 
seeding (n) 
PP14 0-5 (5) 185.7 (29.4 - 242.9) 964.3 (250.0 - 8758.0) 0.009 
6 - 10 (5) 117.3 (29.4 - 323.7) 658.1 (250.0 - 964.3) 0.028 
11- 15 (4) 95.6 (29.4 - 227.6) 317.8 (220.0 - 810.4) 0.043 
16-20(4) 111.8 (56.0 - 166.7) 136.8 (82.4 - 195.0) 0.480 
21-25 (4) 58 (56.0 - 120.0 1l2.0 (17.0 - 165.0) 0.470 
26-30(4) 63 (58.0 - 80.0) 51.0(17.0-128.0) 0.290 
IGFBP-l 0-5 (4) undetectable 617.8 (3.1-3611) 0.021 
6 - 10 (4) " 555.8 (2.4 - 3675) '" 
1l - 15 (4) " 54.9 (1.1 - 3928) ,. 
16-20 (4) " 137.5 (3.7 - 829) " 
21- 25 (4) " 65.0 (4.8 - 130) " 
26-30(4) " 22.0 (0.6 - 54.0) '" 
(Cells seeded at 106 per 25cm2 flask) 
(p value indicates the difference between proliferative and secretory endometrial cells 
using the Mann Whitney U test) 
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Figure 3.6 In vitro concentrations of PP14 (total mass in ng) produced by 
primary endometrial cells taken from the proliferative and secretory phases of 
the menstrual cycle. Error bars represent maximum and minimum values. 
* significant difference between proliferative and secretory phases ( p<O.OS). 
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Figure 3.7 In vitro concentrations of IGFBP-l (total mass in ng) produced by 
primary endometrial cells taken from the proliferative and secretory phases of 
the menstrual cycle. Error bars represent maximum and minimum values. 
* significant difference between proliferative and secretory phases ( p<O.OS). 
Dotted line represents limit of detection. 
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3.5 Discussion 
The results of the measurement of proteins and cytokines produced by the primary 
human endometrial cells grown for this study indicate that the culture consists of a 
mixed population of both stromal and epithelial cells with stromal fibroblasts being 
the predominant cell type from day 8 onwards. F or the most part, these cells are 
producing proteins characteristic of that cell type and the phase of the menstrual cycle 
from which they have been taken. 
Production of PP 14 shows that epithelial cells from both phases of the cycle are 
present in the culture with production being significantly higher in the secretory phase 
cells and this is in agreement with the literature (Laird et al 1993; J ulkunen et al 1986; 
Wood et al 1989; Laird et al 1995). The production of PP14 becomes non-significant 
after the first 15 days of culture. In vivo production of PP14 is stimulated by 
progesterone (Julkunen et al 1986; Wood et al 1989) and it has been shown that 
progesterone also stimulates PP14 production by endometrial cells in vitro (Taylor et 
al1998; Bersinger et al 1995; Laird et alI993). However, in this study the media was 
not supplemented by progesterone (see section 3.1) and this may account for the 
reduction in PP 14 production by the secretory phase cells in culture. 
IGFBP-l is a protein which is very phase-specific being secreted solely by stromal 
cells of the secretory phase of the menstrual cycle. The results show that there were 
stromal cells present in the secretory phase cell culture producing IGFBP-l. However, 
the proliferative phase cell culture did not produce detectable levels of IGFBP-l. It 
would seem unlikely that there were no stromal cells present in the proliferative phase 
culture but these cells in vitro were representative of those in vivo in that stromal cells 
of the proliferative phase of the menstrual cycle do not produce IGFBP-l. Post 
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ovulation it is the increased levels of progesterone which stimulate the stromal cells to 
produce IGFBP-1 (Liu et al 1997). The secretory phase cells in this study show a 
reduction in production of IGFBP-1 over time with a large decrease in production 
from day 16 onwards. This reduction may be due to the lack of progesterone in the 
culture medium which has been observed by Bell et al (1991). The reduction in 
production of IGFBP-1 in response to a lack of progesterone is similar to the pattern 
ofPP14 production. 
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CHAPTER 4 
CYTOKINE PRODUCTION BY ENDOMETRIAL 
CELL CULTURES 
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4.1 Introduction 
Many of the events that occur in the endometrium during the normal menstrual cycle 
and early pregnancy are reminiscent of the processes of inflammation (Epifanova 
1971) and repair (Ferenczy et al 1979). It is therefore not surprising that there is 
evidence for a close involvement of cytokines in these tissues (Arai et al 1990; 
Wolvekamp et a11990; Chard and Rice 1998). Hypotheses include the possibility that 
they modulate the maternal immune response to the invading embryo-derived 
trophoblast during implantation. 
4.1.1 Cytokines 
4.1.1.1 Leukaemia inhibitory factor (LIF) 
LIF is a 38-67 kDa glycoprotein and was initially characterised by its ability to induce 
differentiation of mouse myeloid leukaemia Ml cells into macrophages (Gearing et al 
1987). Since then LIF has been found to have many activities in various tissues and 
cell types including the suppression of differentiation of normal embryonic stem cells 
(Williams et al 1988; Smith et al 1992). In mice LIF is expressed in large quantities 
at the time of implantation (Bhatt et al 1991) and implantation fails to occur in mice 
with deletion of the LIF gene (Stewart et al 1992). Synthesis of LIF by human 
endometrial cells in culture has been observed (Chen et al 1995; Laird et al 1997). It 
has been shown that LIF mRNA expression in human endometrium changes during 
the menstrual cycle and that expression in endometrial glandular epithelial cells is 
much greater than that by stromal cells (Kojima et alI994). 
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4.1.1.2 Interleukin 6 
Interleukin 6 (IL6) is one of a family of proteins typically produced by T lymphocytes 
and macrophages. Endometrial IL6 is heterogenous and consists of isoforms in the 
size range 23-30 kDa (May et al 1988). IL6 has been found to stimulate trophoblast 
in vitro to produce human placental lactogen (hPL) (Stephanou and Handwerger 
1994) and human chorionic gonadotrophin (hCG) (Nishino et al 1990). Cultured 
human endometrial stromal cells can be stimulated to produce IL6 by a number of 
inflammatory-associated cytokines, for example, 1NFa and IFNy and modulated by 
oestrogen (Tabibzadeh et al 1989). Other studies have shown that both epithelial and 
stromal endometrial cells can secrete IL6 and the levels vary according to the phase of 
the menstrual cycle (Laird et al 1993). 
4.1.1.3 Tumour necrosis factor a 
Tumour necrosis factor a (1NFa) is a 17kDa protein which exerts a variety of effects 
ranging from proinflammatory and cytotoxic to growth and immunomodulatory in 
many different types of cells. It has been suggested that 1NF a secreted during the 
secretory and menstrual phases plays a role in induction of programmed cell death in 
these cells (Tabibzadeh et al 1995). It will stimulate the production of IL6 in 
trophoblastic cells (Li et al 1992) and will induce interferon ~ production in human 
endometrial stromal cells (Tabibzadeh et al 1989) and dissociation of human 
endometrial epithelial cells (Tabibzadeh et al 1995). TNFa has been shown to be 
present within stromal, epithelial and leukocyte cells of the human endometrium 
(Tabibzadeh 1991a; Tabibzadeh 1991b; Hunt et al 1992) with the majority of it 
present in the glandular epithelial cells (Garcia et al 1994). The factors controlling 
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TNFa production are not clearly understood and studies show conflicting results as 
to the pattern of its production. Some have suggested that TNF a levels increase 
during the secretory phase of the menstrual cycle (Philippeaux and Piguet 1993; 
Tabibzadeh et al 1995) while others have shown an increase during the late 
proliferative phase (Hunt et al 1992; Laird et al 1996). 
4.1.1.4 Hepatocyte growth factor 
Hepatocyte growth factor, or scatter factor, is a heparin-binding glycoprotein 
consisting of two subunits, a 60 kDa a-chain and a 32 or 36 kDa ~-chain , linked by 
disulphide bonds and shares a 38% structural homology with plasminogen (Gherardi 
et al 1989; Weidner et al 1991). HGF is the most potent mitogen for hepatocytes in 
primary culture (Nakamura et al 1984) and is considered the major mediator of liver 
regeneration in vivo. The human liver has a tremendous regenerative capacity and in 
response to hepatic resection the hepatocyte, under the influence of mitogenic 
cytokines like HGF, can proliferate to restore the liver to its original mass. HGF not 
only stimulates the growth of hepatocytes and renal tubular epithelial cells but is 
produced by non-parenchymal cells in both the liver and kidney suggesting a role as 
a paracrine effector of cell-cell interactions (Gherardi and Stoker 1991). 
HGF has been shown to stimulate the proliferation, migration and morphogenesis of 
endometrial epithelial cells (Sugawara et al 1997; Negami et al 1995) and is 
considered to be involved specifically in the regeneration or reconstruction process of 
the endometrium after menstrual shedding (Negami et al 1995). The nature of 
endometrial tissue regeneration following menstruation is poorly understood. 
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However, as the endometrium is a regenerative tissue, undergoing regeneration every 
month, and HGF is able to stimulate regeneration of the liver, levels of HGF. 
produced by human endometrial cells in vitro, were measured. 
4.1.1.5 Interferon r 
Interferon y, the immune interferon, is a type II interferon - one that is labile at pH 2 -
produced by a variety of cells, in particular T-cell lymphocytes, following antigenic 
(viral) or mitogenic stimulation. 
IFNy is a 45 kDa heterodimeric molecule consisting of one subunit of 25 kDa and one 
of 20 kDa ( Yip et al 1982). It is a pleiotropic cytokine involved in the regulation of 
nearly all phases of immune and inflammatory responses including the activation, 
growth and differentiation of T cells, B cells, macrophages, natural killer (NK) cells 
and other cell types including fibroblasts and endothelial cells. It has anti-proliferative 
activity and potentiates the effect of interferons a and J3 (Vilcek et al 1985; Farrar and 
Schrieber 1993). 
In the human endometrium IFNy induces HLA-DR expreSSlOn and inhibits 
proliferation of epithelial cells (Tabibzadeh et al 1988). This evidence supports the 
concept of the paracrine effect of IFNy in the human endometrium. 
IFNy expression has been localised by immunohistochemistry to the glandular 
epithelial and stromal cells of the human endometrium during the secretory phase of 
the menstrual cycle (Chiang and Hill 1997). Yeaman and colleagues (1998) have 
shown that IFNy is produced by polymorphonuclear neutrophils in the human 
endometrium. 
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IFNy increases the production of the cytokines IL-6, monocyte chemoattractant 
protein-1 (MCP-1) and macrophage colony-stimulating factor (M-CSF) in human 
endometrial stromal cells in vitro (Nasu et al 1998). 
The cytokines leukaemia inhibitory factor (LIF), interleukin 6 (IL-6), tumour necrosis 
factor a (TNFa), hepatocyte growth factor (HGF) and interferon y (IFNy) were 
measured in the conditioned media from both proliferative and secretory endometrial 
cells. Endometrial cell expression and production of cytokines LIF, IL-6 and TNF a 
have been extensively studied (see above) and are similar to PP14 and IGFBP-1 in 
that they are good markers of epithelial and stromal cell function. While less has 
been published about the role and function of the cytokines HGF and IFNy in the 
human endometrium, these were also measured in the conditioned media from 
proliferative and secretory phase endometrial cultured cells. 
4.2 Methods 
All the following cytokines were assayed in media removed from the culture flasks 
containing endometrial cells at the time of passaging. The culture of endometrial 
cells is decribed previously in Section 3.2.2. 
4.2.1 Cytokine enzyme immunoassays 
All the kits used monoclonal antibodies. The basic protocol was the same for all the 
cytokines measured and was briefly as follows. To a well of a microtitre plate, 100JlI 
of standard or sample was added and incubated for 20 mins at 37°C. The contents of 
the plate were discarded and the wells were washed extensively using an automated 
plate washer. Then 100JlI of biotin anti-cytokine conjugate was added to each well 
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and incubated as before. After discarding the contents of the wells and washing as 
before 100JlI of streptavidin-HRP conjugate was added and incubated as above. 
Finally, the wells were incubated with a 1: 1 mixture of phosphate-citrate buffer with 
peroxide and tetramethylbenzidine (TMB) and the absorbance of each well at 450 run 
was determined using a plate reader. 
The minimum detectable concentrations of LIF, IFNy, TNFu, IL6, and HGF were 10 
pglml, 17.5 IU/ml, 20 pg/ml, 5 pg/ml and 0.25 ng/ml respectively. 
The intra- and interassay coefficients of variation of both the protein and cytokine 
assays were less than 10%. 
4.3 Statistical analysis 
Levels of cytokines from proliferative and secretory endometrium were not normally 
distributed (Kolmogorov-Smirnoff test p<0.05) and therefore it was necessary to 
compare the groups using the Wilcoxon Mann Whitney U-test. 
In all cases, differences between the groups were considered significant when the 
probability of the events occurring by chance was < 0.05. 
4.4 Results 
4.4.1 LIF 
Figure 4.1 show levels of LIF throughout culture in both proliferative and secretory 
phase cell supernatants from individual tissues. Levels were significantly higher in 
the media from secretory phase cells than those from the proliferative phase 
throughout culture except for the period 16-20 days (see Table 4.1). 
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4.4.2 IL-6 
Measurable levels of IL-6 were found in conditioned media from both proliferative 
and secretory phase cultured cells. Figure 4.2 shows IL-6 levels throughout culture 
from individual tissue taken from either the proliferative or secretory phase of the 
cycle. IL-6 levels steadily increase with time in medium from secretory phase cells 
reaching a plateau by day 16 in culture. Although proliferative phase cell production 
of IL-6 is lower than that produced by secretory phase cells, levels only become 
significantly different from day 21 of culture onwards (see Table 4.1). 
4.4.3 HGF 
Measurable levels of HGF were found in the conditioned media from both 
proliferative and secretory phase cultured cells. Figure 4.3 show levels throughout 
culture from individual tissue taken from either the proliferative or secretory phase of 
the cycle. However, at no period during culture was there a significant difference 
between secretory and proliferative phase cell HGF production (Table 4.1). 
4.4.4 TNFa. and IFNy 
Levels of TNFa. and IFNy produced by secretory and proliferative cells in culture 
were both negligible throughout the entire culture period, being below the limits of 
detection of the assays (20 pg/ml and 17.5 IU/ml respectively). 
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Table 4.1 In vitro concentrations of cytokines LIF, IL-6 and HGF (total mass in 
ng) produced by primary endometrial cells taken from the proliferative and 
secretory phases of the menstural cycle. 
Proliferative phase secretory phase 
Cytokine days from 
seeding (n) 
Median (range)(ng) median (range)(ng) p value 
LIF 0-5 (5) 2.5 (0.3 - 3.9) 8.9 (3.3 - 55.3) 0.016 
6-10(5) 1.7 (0.3 - 3.8) 11.5 (8.8 - 39.4) 0.014 
11- 15 (4) 1.7 (0.45 - 3.5) 10.3 (7.6 - 13.6) 0.020 
16-20 (4) 1.3 (0.1-2.5 2.6 (2.2 - 4.7) 0.110 
21- 25 (4) 0.7 (0.2 - 0.7) 2.6 (1.4 - 4.0) 0.034 
26-30(4) 0.4 (0.2 - 0.8) 2.9 (1.3 - 4.4) 0.034 
IL-6 0-5 (5) 36.9 (4.4-142.5) 81.0 (16.7-277.8) 0.350 
6 - 10 (5) 33.9 (4.4 - 87.0) 151.6 (59.3-234.3) 0.090 
11 - 15 (4) 31.3 (4.1-56.3) 144.7 (60.8-357.2) 0.083 
16-20(4) 31.2 (11.0 - 267.0) 281.3 (72.9-321.4) 0.160 
21-25 (4) 17.0(12.0-41.0) 283.0 (76.2-339.0) 0.034 
26-30(4) 28.0 (13.0 - 55.0) 254.0 (76.0-358.0) 0.034 
HGF 0-5 (5) 1.1 (0.7 - 1.8) 3.1 (0.9 - 25.6) 0.076 
6 - 10 (5) 1.0 (0.8 - 5.9) 3.8 (0.9 - 6.0) 0.210 
11 - 15 (4) 1.7(0.7-3.1) 3.3 (2.8 - 5.9) 0.140 
16-20 (4) 2.8 (1.4 - 4.2) 1.7 (1.3 - 1.9) 0.290 
21- 25 (4) 1.4 (1.4 - 3.0) 1.3 (0.5 - 2.8) 0.290 
26-30(4) 1.6 (l.5 - 2.0) 1.6 (0.6 - 3.0) 0.860 
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Figure 4.1 In vitro concentrations of cytokines LIF (total mass in ng) produced 
by primary endometrial cells taken from the proliferative and secretory phases 
of the menstrual cycle. Error bars represent maximum and minimum values. 
* significant difference between proliferative and secretory phases ( p<O.05). 
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Figure 4.2 In vitro concentrations of cytokines IL-6 (total mass in ng) produced 
by primary endometrial cells taken from the proliferative and secretory phases 
of the menstrual cycle. Error bars represent maximum and minimum values. 
* significant difference between proliferative and secretory phases ( p<O.05). 
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Figure 4.3 In vitro concentrations of cytokines HGF (total mass in ng) produced 
by primary endometrial cells taken from the proliferative and secretory phases 
of the menstrual cycle. Error bars represent maximum and minimum values. 
Not significant at any time point. 
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4.5 Discussion 
The production of LIF by the endometrial cell culture in this study follows that found 
by other workers (Chen et al 1995; Laird et al 1997). The production of LIF is 
significantly higher by those cells cultured from the secretory phase than those 
cultured from the proliferative phase. 
IL-6 was produced by cultured cells from both proliferative and secretory phase 
tissue. There is a greater production of IL-6 by secretory phase cells than that of 
proliferative phase cells although this difference is not significant until day 21 
onwards of culture. IL-6 has been demonstrated in normal endometrium throughout 
the menstrual cycle and can be produced by both stromal and epithelial cells 
(Tabibzadeh et al 1989; Laird et al 1993). Tabibzadeh et al (1989) showed that IL-6 
production by stromal cells is down regulated by physiological concentrations of 
oestradiol. However, there appears to be no reduction of IL-6 production by the 
cultured cells, if anything, there is a small increase from day 21 onwards in the 
secretory phase cell culture. Human endometrial stromal cells can be induced by a 
number of inflammatory-associated cytokines (IL-1a, IL-l~, TNFa and IFNy) 
(Tabibizadeh et al1989) to secrete IL-6 but TNFa and IFNy cannot be detected in the 
conditioned media from the cell culture so this would not be a possible explanation 
for the apparent increase of IL-6 in the secretory phase cell culture. 
Negami et al (1995) measured serum levels of HGF throughout the menstrual cycle 
and found that HGF increased throughout the luteal phase and reached a peak during 
the menstrual phase followed by a decline throughout the follicular phase. Groups 
studying the production of HGF by endometrial cells in culture did so using tissue 
taken from the proliferative phase only and found that production is confined to 
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stromal cells (Sugawara et al 1997; Fukaya et al 1999). However, Nasu et al (1999) 
found that levels of HGF in conditioned media were undetectable in their assay. No 
group to date has looked at the secretion of HGF by stromal cells from the secretory 
phase of the cycle. In this study HGF was detected in the conditioned supernatant 
from proliferative and secretory phase cell culture. The difference in production is not 
significant although the secretory phase levels are generally higher than those of the 
proliferative phase. 
Reports of TNF a production by the endometrium are inconsistent. TNF a has been 
shown by various methods, including mRNA expression, immunohistochemistry and 
quantitative assays to be present in the endometrium throughout the menstrual cycle 
with low levels in the proliferative phase and higher in the secretory phase (von Wolff 
et al 1999). Laird et al (1996) found that stromal cells did not produce TNFa at any 
stage of the menstrual cycle whilst Bergqvist et al (2000) found TNFa was detected 
in medium from most stromal cell cultures but less often in the media from epithelial 
cell culture. In this study TNFa was not detected in the supernatants from any of the 
cultures. The measurement of TNFa is fraught with difficulties (Coxon 1996). Most 
methods of detection rely upon the use of an antibody and, for TNFa, monoclonal and 
polyclonal antibodies are available. TNFa exists as a monomer but associates readily 
to form relatively stable trimers which are more biologically active and possess a 
higher binding capacity for an antibody. A monoclonal antibody, which is highly 
specific, will be directed against a single epitope and is unable to form a large 
antigen-antibody complex whereas a polyclonal antibody can be used for 
macromolecules with multiple epitopes, of which TNFa is an example (Coxon 1996). 
The kit used in this study uses a monoclonal antibody and all other reported assays 
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use a polyclonal antibody. The difference between assay systems may be explained 
by the use of these antibodies. During the formation of a multimeric isoform of the 
TNFa molecule the epitope to which the monoclonal antibody has been developed 
may be hidden thus preventing binding whereas a polyclonal antibody would be more 
likely to bind to more than one epitope. In summary, the TNFa molecule may be 
biologically inactive owing to unfolding, protease action or physical effects, such as 
temperature and pH, yet may preserve the immunoreactive epitope and therefore read 
'positive' in the immunoassay. 
IFNy has been shown to be localised to T-cell containing lymphoid aggregates and 
other cells in the stroma of the basalis region of the human endometrium (Tabibzadeh 
1994). Chiang and Hill (1997) found IFNy in both epithelial and stromal cells of the 
secretory phase endometrium with staining being more intense in the basalis layer. A 
group using confocal microscopy (Yeaman et al 1998) found IFNy in stromal cells 
and intraepitheliallymphocytes through all stages of the menstrual cycle. The stromal 
cells containing intracellular IFNy were later identified as polymorphonuclear 
neutrophils which on stimulation by certain ligands, for example, TNF a, produced 
IFNy (Yeaman et al 1998). 
To date no data has been published on the secretion of IFNy by endometrial cells in 
vitro. This study found that IFNy levels were undetectable in the conditioned media 
from a mixed endometrial cell population. It is possible that this lack of IFNy may be 
due to the absence of suitable stimuli, for example TNFa. 
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CHAPTERS 
ENDOMETRIAL CELL RESPONSE TO IFNa 
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5.1 Introduction 
Type I interferon signalling is mediated via a cytokine type II receptor. Cytokine 
receptors are transmembrane proteins with a single membrane-spanning region and 
are divided into two classes depending on their amino acid sequence and structural 
features. The majority of cytokine receptors fall into class I whilst the IFNa, ~ and y, 
IL-I0 and tissue factor receptor belong to class II. 
Early investigations revealed cell surface expression of both low and high affinity 
receptors for type I interferons (Branca and Baglioni 1981; Aguet 1980). Binding and 
cross-linking studies using radiolabelled IFNs suggested that the putative receptor had 
a multi-subunit structure (Joshi et al 1982). The existence of this multi-subunit 
structure was later demonstrated using specific monoclonal antibodies to the receptor 
subunits (Colamonici et al 1990; Colamonici et al 1992). 
The first receptor subunit to be cloned was the IFNaR (Uze et alI990). This is a 557 
amino acid glycoprotein which does not bind most IFNa subtypes nor IFN~ with 
high affinity but is required for signal transduction (Uze et al 1990). The extracellular 
region of the IFNaR is composed of two domains of about 200 amino acids (D200) 
each of which can be further subdivided into two homologous SDI00 domains (figure 
5.1). 
Subsequently the second receptor subunit was isolated. This was a 331 amino acid 
glycoprotein designated IFNa/~R which binds and responds to IFN~ and most of the 
IFNa subtypes (Novick et aI1994). The extracellular region of the IFNa/~R contains 
just two SDI00 domains (figure 5.1). 
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Figure 5.1 The Type I interferons bind to the same receptor which comprises of 
two transmembrane subunits that are classified as Type II cytokine receptors. 
The IFNaBR sub-unit, also known as IFNAR-1, has an extracellular region 
composed of two homologous regions of about 200 amino acids each of which 
contain two fibronectin type III domains. The IFNaJ~R sub-unit, also known as 
IFNAR-2, comprises of two FNIII domains. From Callard and Gearing (1994). 
COOH COOH 
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Unlike growth factor receptors, cytokine receptors do not possess any intrinsic 
tyrosine kinase activity directly. However, the IFNaR and the IFNa/pR constitutively 
associate with the Janus kinases, Tyk2 and JAKI respectively, which provide the 
tyrosine kinase activity necessary for receptor activation (Darnell et al 1994; Stark et 
al 1998). IFNaR, IFNa/~R, Tyk2 and JAKI are known to form the functional type I 
IFN receptor complex (Darnell et al 1994; Stark et al 1998). 
A soluble form of the receptor has been identified in human serum and urine (Novick 
et al 1992) and is a potent blocker of all Type I IFN s and it is thought to function as a 
modulator oflFN activity in vivo. 
Subunits of the receptor are expressed in all tissues (Haque and Williams 2001) 
however the pattern of expression in human endometrial tissue has not been fully 
elucidated. Lee and colleagues (1998) assessed the effects of IFNa on primary 
cultures of leiomyoma, myometrial and endometrial stromal cells and found that it 
was a potent inhibitor of proliferation for endometrial stromal cells. 
The aim of this study was to elucidate the signal transduction mechanisms of Type I 
interferons in human primary endometrial cells. Type I interferons are known to elicit 
an effect in mammalian endometrium (see Chapter 1 Introduction), yet it was 
important to establish that primary human endometrial cells maintained in vitro 
possess a functioning receptor, as this would be the model system used. 
Therefore, it was necessary to conduct an experiment to confirm the presence of a 
functioning IFNaI~ receptor on cultured endometrial cells. 
Inhibition of endometrial cell proliferation by IFNa would provide evidence for the 
presence of a Type I interferon receptor. 
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All IFNs demonstrate antiproliferative effects on many cell types grown in vitro 
(Pfeffer et al 1987). In the presence of IFN there is an increase in the time taken for 
completion of the cell cycle but it remains unclear which, of several mechanisms. are 
involved. 
In this study, human endometrial cells were cultured in the presence of increasing 
concentrations of human IFNa. The effect of IFNa on cell proliferation would 
provide evidence for a functioning receptor but would not localise it to a particular 
cell or cells. To do this immunohistochemistry was carried out (Chapter 6). 
5.2 Methods 
Endometrial tissue was seeded out and grown to confluence in a 75 cm2 flask. At this 
point the cells were trypsinised and passaged on equally into 5 x 25 cm2 flasks. Ten 
ml of supplemented DMEM:Ham's F12 medium, with or without IFNa, was added to 
each flask The concentration ofIFNa added was 100, 1000, 10,000 and 50,000 units 
per ml of medium. The flask containing medium without added IFNa served as the 
control. 
After 4 days growth the cells were assessed for viability using the Trypan blue 
exclusion method as described in section 3.2.4 before undergoing Giemsa staining. 
F or this process the cells were washed twice with PBS followed by PBS and 
increasing concentrations of methanol until a 50% methanollPBS solution was 
reached. This mixture was discarded and replaced with methanol alone. After 10 min 
the methanol was removed and 2ml of undiluted Giemsa was added to the flask. The 
stain was diluted with 8ml of water after 2 min and after a further 2 min was 
discarded. The cells were extensively washed in running tap water and finally 
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examined and photographed while still wet. Once stained, the cells could be stored 
dry and wetted for re-examination. 
To assess the reduction in proliferation of endometrial cells in response to IFNa the 
number of cells seen in 4 different fields of view at x 400 magnification was recorded 
for each concentration ofIFNa. From this data a mean cell count could be calculated 
for each IFN concentration. 
5.3 Results 
Primary human endometrial cells are capable of responding to IFNa since cell 
proliferation is clearly suppressed in the presence of 100 units and 50,000 units of 
IFNa per ml of media (Figure 5.2). The Trypan blue exclusion method showed that 
approximately 10 cells per 10,000 cells had taken up the dye. Therefore about 0.10/0 
of cells were non-viable. 
Table 5.1 shows the number of cells counted in the field of view at x 400 
magnification for each concentration ofIFNa used. 
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Figure 5.2 Primary human endometrial cells cultured in the absence of IFN a 
(A) or lD the presence of 100 units/ml (B) or 50,000 units/ml IFN a (C), 
Magnification x 100. 
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Table 5.1 Number of endometrial cells seen in a x 400 magnification field of 
view having been cultured in the presence of increasing concentrations of IFNu 
IFNa (ulmI) 15t count 2nd count 3rd count 4th count mean cell count (+/- SD) 
0 91 53 78 105 81.75 +/- 22.1 
100 45 38 21 38 35.5 +/- 10.2 
1000 35 28 15 20 24.5 +/- 8.8 
10000 10 21 3 18 13+/-8.1 
50000 5 6 17 13 10.25 +/- 5.7 
Figure 5.3 Effect of IFNu concentration on cell number. * indicates p < 0.01 
vs control cells without addition of IFN u. 
100 
80 
"U 
Q) 
..... 
........ 60 II) 
Q) 
0 
40 
* 
* 20 
o II~~----------'---------~------I 
o 100 1000 10000 50000 
IFNa (u/mll 
105 
5.4 Discussion 
The results provide direct evidence for the presence of an IFN receptor on 
endometrial cells because the primary endometrial cells in culture respond to IFN u. 
Endometrial cell proliferation was suppressed in the presence of 100 units and 50,000 
units of IFNa per millilitre of culture medium. Type I interferons have demonstrable 
anti proliferative effects on many cells and cell lines grown in vitro (Pfeffer et al 
1987). IFNa has been shown to be a potent inhibitor of human endometrial stromal 
cell proliferation (Lee et al 1998). 
In this study, stromal and epithelial endometrial cells from both the proliferative and 
secretory phases of the menstrual cycle showed an anti-proliferative response on 
exposure to IFNa, providing evidence for a functioning IFNa/~ receptor on these 
cultured cells. These results confirm the findings of Lee et al (1998) that IFNa is a 
potent inhibitor of endometrial stromal cell proliferation and, in addition, this study 
has shown that IFNa also inhibits the proliferation of epithelial endometrial cells in 
vitro. The antiproliferative effect seen in these cells must be considered to be due to 
the cells responding to IFNa and not to any cytotoxic effect the IFNa may have 
conferred as only a negligible number of cells «0.1 %) were found to be non-viable 
by the Trypan blue exclusion method. 
Since human endometrial cells in vitro respond to IFNa, one can deduce that they 
must possess a receptor through which this response is mediated. 
Nevertheless, the fact that the cells clearly respond to IFNa indicates that primary 
human endometrial cells of both cell.lineages possess a functioning receptor. 
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CHAPTER 6 
LOCALISATION OF A TYPE I INTERFERON 
RECEPTOR ON ENDOMETRIAL CELLS 
107 
6.1 Introduction 
To date, there have been relatively few studies on Type I IFN receptor expression in 
the human endometrium. The effect of IFNa on cell proliferation provides evidence 
for a functioning receptor in these cells (Chapter 5) but does not localise receptor 
expression to a particular cell or cells. To do this immunohistochemistry was carried 
out on proliferative and secretory endometrial tissue. 
F or the purposes of this thesis, it is essential to determine whether such expression is 
maintained in long term culture of isolated cells. As far as we are aware, there are no 
reports on the localisation of the Type I IFN receptor on primary human endometrial 
cells in culture. Thus, in this chapter we also investigate the presence of functioning 
Type I IFN receptor in these cells following long-term culture. 
6.1.1 Immunohistochemistry 
Immunohistochemistry, using a monoclonal antibody (anti-IFN a/~R) raised against 
the 27-210 amino acids of the human IFNa/~ receptor (IFNAR-2) and a polyclonal 
antibody (anti-IFNaR) raised against the 458-557 amino acids mapping the carboxy 
terminal end, the intracellular domain, of the human IFNa receptor (IFNAR-1), was 
performed on paraffin embedded and frozen sections of endometrial tissue taken from 
various stages of the menstrual cycle (see section 6.2.1). Immunohistochemistry on 
biopsied tissue localises the receptor to cells within that tissue but would not indicate 
the presence of a receptor on the cells grown for this study. To do this, it was 
necessary to carry out further experiments to try and locate a receptor on cultured 
cells using radiolabelled ligand binding and electron microscopy using a gold 
conjugated second antibody. 
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6.1.2 Binding of 125I_IFNa. 
Endometrial cells were cultured in media supplemented with labelled IFNa and then 
visualised according to the methods explained in section 6.2.2. 
6.1.3 Electron microscopy 
Cells were cultured in small mesh-bottomed inserts as described in section 6.2.3 and 
then incubated firstly with the monoclonal IFNa./~R first antibody and then with the 
mouse second antibody conjugated to gold before being fixed, embedded and 
prepared for electron microscopy (see section 6.2.3). 
6.2 Methods 
6.2.1 Immunohistochemistry 
Paraffin embedded and frozen slides of endometrial tissue from various stages of the 
menstrual cycle were prepared by the Department of Histopathology, St 
Bartholomew's Hospital, London. These slides underwent immunoperoxidase 
staining using the monoclonal anti-IFNa/~ receptor at 1:100 dilution and the 
polyclonal anti-IFNa. receptor at a dilution of 1 :50. The paraffin embedded slides 
were pre-treated by brief, high temperature, heat denaturation pressure cooking to 
increase antigen retrieval (Norton et aI1994). 
Briefly, the slides were blocked for endogenous peroxidase activity using a 30/0 
hydrogen peroxidase in methanol solution. Then washed and blocked for non-specific 
binding using 10% normal rabbit serum in 50 mM Tris-buffered saline. The blocking 
solution was replaced with the primary antibody of interest. After incubation the 
slides were washed and reagents from the ABC kit were applied according to the 
109 
manufacturer's protocol. Next diamino benzidine (DAB) solution was added to the 
slides, washed off and counter-stained with haematoxylin. Finally, the slides were 
dehydrated, cleared, mounted, examined by microscopy and photographed. 
6.2.2 125I_IFNa method 
IFNa was labelled with 125Iodine using a modification of the technique used by 
Greenwood et al (1963). 
Into a vial was placed 5J.!g of IFNa in 5J.!1 of 50mM PBS and 5J.!1 of 250mM PBS. 
To this was added 500J.!Ci (5J.!l) of sodium 125iodide followed by 12.5j.lg of 
chloramine T in 5J.!1 50mM PBS, pH 7.5. After mixing for 15s the reaction was 
stopped by the addition of 31.25J.!g of sodium metabisulphite in 5j.ll of 50mM PBS. 
The contents of the vial were mixed thoroughly and 75J.!1 of 50mM PBS containing 
0.1 % BSA was added before applying the contents to a 1 x 60 cm column of 
Sephadex G-I00 previously equilibrated with 50mM PBS/O.l % BSA, pH 7.5 to 
separate 125I_IFNa from damaged materials or unreacted sodium 125iodide. 
Appropriate fractions were assessed for immunoreactivity by binding in the presence 
and absence of IFNa antibody at an initial dilution of 1:100. Fractions showing 
greatest binding were pooled, aliquoted and stored at -20°C. 
Endometrial tissue was grown to confluence and then trypsinised. The resulting cell 
suspension was divided equally into the 8 chambers of two Nunc chamber slides. As 
an enclosed system for incubating cells was being employed the chamber slides had to 
be incubated in an enclosed unit containing 95% air and 5% carbon dioxide. This was 
achieved by using a small, sterilised dessicator with a tap which allowed the gas to be 
introduced. After 5 days the medium was discarded and the cells washed x 3 with 
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sterile PBS. Then 125I_IFNa, diluted in PBS to give 10,000 counts in 100J.11, was 
added to the chambers of one slide and as a control iodinated anti-digoxin, diluted to 
give the same counts as the 125I-IFNa, was added to another. Anti-digoxin was used 
as a control because many radio labelled ligands available would bind to their specific 
receptors whilst anti-digoxin would only bind to the drug digoxin. Both slides were 
then incubated for 1 hr at 37 cC. The radioactive material was then discarded and the 
slides washed extensively with PBS and the cells fixed using increasing 
concentrations of methanol until 100% methanol is reached. The dried slides were 
exposed to x-ray film using an intensifying screen for 5 days at -20°C and then 
visualised. 
6.2.3 Electron microscopy 
On the recommendation of the Department of Photomicrography, St Bartholomew's 
Hospital, London, who carried out the fixing, embedding and electron microscopy, 
the endometrial tissue was seeded out onto Falcon cell culture inserts with a O.4J.1m 
pore size membrane. Cells were grown in 5 inserts, one for control purposes and the 
other 4 for different dilutions of first antibody. After 5 days of growth the medium in 
the inserts was discarded and the cells were washed with PBS. The medium was 
replaced with either 200J.11 of PBS containing 1 % BSA for the control or monoclonal 
anti-IFN a/f3 receptor at an initial dilution of 1:50 1:100, 1:500 or 1:1000. The cells 
were incubated for 1 hr at room temperature. The first antibody was discarded and 
the cells washed with PBSIBSA prior to the addition of the second antibody - gold 
conjugate goat anti-mouse antibody. The cells were then incubated and washed as 
above and fixed in 200J.11 of 1 % paraformaldehyde with 0.1 % gluteraldehyde in 
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0.125M phosphate buffer, pH 7.3. They were then embedded and examined by 
electron microscopy in the Department of Photomicrography. Alterations to the 
method included incubating at 37°C for 2 hours, using 400~1 of first and second 
antibody and treating the insert membranes with poly-I-lysine to enhance adhesion. 
6.3 Results 
Localisation of the IFNaR and IFN a/BR. 
6.3.1 Immunohistochemistry 
Figures 6.1 and 6.2 show that antibodies to the IFNaR and IFNa/BR bind to the cells 
of endometrial tissue. Both IFN receptor subunits were expressed in stromal and 
glandular epithelial cells from both proliferative and secretory phases of the menstrual 
cycle. Expression of both receptor subunits was more intense in glandular epithelium 
compared with the surrounding stromal tissue. 
A more intense staining of the IFNAR-1 receptor subunit was observed in the 
glandular epithelium of secretory compared to the proliferative phase tissue. IFNAR-2 
expression was similar in secretory and proliferative tissue. 
6.3.2 1251 IFNa. binding 
The autoradiograph of endometrial cells labelled with 1251 IFNa (Figure 6.3a) shows 
a few cells have been radiolabelled. There was no radioactivity detected on the 
autoradiograph of the control experiment (Figure 6.3b). 
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6.3.3 Electron microscopy 
No results were obtained using electron microscopy as a means of local ising the Type 
I interferon receptor to endometrial cells in culture. The endometrial cells were 
grown on a mesh within an insert within the wells of an 8 well culture dish 
specifically for the purposes of electron microscopy. The cells did not adhere well 
and the mesh had to be treated with poly-I-lysine to enhance adhesion. Generally. 
endometrial cells grow as a monolayer and because of the small surface area of the 
mesh, the growth of a large number of endometrial cells was restricted. Although the 
adhesion of the cells was improved and they remained fixed to the mesh throughout 
the incubation with the first and second antibody once they went through the fixing 
and embedding process they became dislodged and were subsequently lost within the 
block of Araldite. Larger well sizes, and thus a greater mesh surface area, were used 
to raise the number of cells grown, however, this did not improve the recovery of cells 
once they had been embedded in Araldite. Finally, attempts to localise the receptor 
by this method were abandoned. 
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Figure 6.1 Immunostaining of endometrial tissue with polyclonal IFNa receptor 
antibody at 1 in 50 dilution. Magnification x 200. 
proliferative phase 
secretory phase 
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Figure 6.2 Immunostaining of endometrial tissue with monoclonal IFN aJ~ 
receptor antibody at 1 in 100 dilution. Magnification x 200. 
proliferative phase 
secretory phase 
I • ,---
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Figure 6.3 Autoradiograph showing cultured primary endometrial cells 
incubated with (A) 1251 IFNa and (B) 1251 anti-digoxin 
A 
B 
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6.4 Discussion 
The results provide evidence for the presence of an IFN receptor on human 
endometrial cells. This is because (a) there was binding of radiolabelled IFNa to 
cells in culture and (b) there was binding of antibodies to both subunits of the IFN 
receptor (IFNAR-l and IFNAR-2) on epithelial and stromal endometrial cells from 
tissues taken from the proliferative and secretory phases of the menstrual cycle. 
Indirect evidence for the presence of a Type I IFN receptor on human endometrial 
cells in culture was demonstrated using 125I_IFNa which showed some radioactive 
binding to the cells in vitro. However, this does not localise this receptor to a 
particular cell or cell types found in the endometrium. To do this, antibodies raised 
against the receptor subunits IFNaR (IFNAR-l) and IFNa/~R (IFNAR-2) were used 
in immunohistochemical staining of endometrial tissue sections taken from both the 
proliferative and secretory phases of the menstrual cycle. The immunohistochemistry, 
showed staining in both stromal and glandular epithelial cells in both proliferative and 
secretory tissue. 
These results are in agreement with Ozaki et al (2005) who also found expression of 
both subunits in proliferative and secretory endometrial tissues. 
Our results also confirm those of Russell and colleagues (1993) who found the 
radiolabelled IFNa bound to endometrial tissue. 
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CHAPTER 7 
PHOSPHOLIPID TURNOVER FOLLOWING 
TYPE I INTERFERON STIMULATION 
118 
7.1 Introduction 
For a cell to generate a response it must be stimulated by an extracellular signal which 
interacts with a receptor to activate a set of second messengers which will elicit the 
response. 
Since the discovery of cyclic adenine monophosphate (cAMP) and its mechanism of 
action, which provided the basis for the concept of second messengers, many other 
signal pathways have been discovered. The first indication that a lipid molecule could 
be involved in a signalling pathway came from the observations of Hokin and Hokin 
(1953). They reported that the administration of acetylcholine to pancreatic tissue 
increased the incorporation of radioactive phosphate groups (P04 groups containing 
32p) into phosphatidylinositol (PI) - one of the constituent lipids of the plasma 
membrane. Like other membrane lipids it has a hydrophobic constituent (two fatty 
acid chains attached to a glycerol molecule) and a hydrophilic constituent (the inositol 
phosphate 'head' group). The administration of acetycholine caused the PI to cleave 
into its two major constituents - diacylglycerol and inositol phosphate while the 
observed increased incorporation of 32p was due to the resynthesis of PI. 
Subsequent studies established that increased turnover of membrane lipids occurred in 
response to many stimuli. In 1975 Michell and colleagues noted a strong correlation 
between stimulated lipid turnover and internal cell calcium signals and that it was 
another lipid, phosphatidylinositol-4,5-bisphosphate (PIP2), whose hydrolysis was, in 
part, responsible for the increase in intracellular calcium. Phosphatidylinositol--4,5-
bisphosphate (PIP2) is converted from PI by the addition of two extra phosphate 
groups derived from adenine triphosphate (ATP) to the carbon 4 and carbon 5 
positions on the six-carbon inositol ring (Figure 7.1). Further experiments (Haslam 
& Davidson 1984; Gomperts & Cockcroft 1985) found that guanosine triphosphate 
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Figure 7.1 The formation of PIP2 from its precursor PI and its subsequent 
hydrolysis in response to an external stimulus with the formation of IP3 and 
DAG, leading to an increase in intracellular Ca2+. PLC = Phospholipase C, P = 
Phosphate group, AAAAAA = fatty acyl chains, ADP = adenine diphosphate, ATP 
= adenine triphosphate 
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(GTP) is necessary for the IP3 and DAG signalling mechanism. The G protein 
couples the surface receptor to the enzyme phospholipase C (PLC) which then cleaves 
the PIP2 into IP3 and DAG. IP3, being water soluble, diffuses into the cytoplasm 
where it releases Ca2+ from storage in the endoplasmic reticulum. The role of IP3 as 
a novel second messenger in cellular signal transduction was confirmed by 
experiments carried out by Berridge and Irvine (1984). The demonstration of Ca2+ 
release induced by IP3 has since been shown in many cell types (Berridge 1991). IP3 
also elicits many of the early events of fertilisation and the injection of IP3 into eggs 
can cause waves of Ca2+ to travel across the egg mimicking that seen by spermatozoa 
at fertilisation (Rice et al 2000). 
The diacylglycerol formed from the hydrolysis of PIP2 remains within the plasma 
membrane where it also acts as a second messenger by activating protein kinase C 
(PKC) which phosphorylates several proteins involved in cellular mechanisms, for 
example, cell growth. IP3 and DAG are rapidly recycled to form PIP2 and complete 
the inositol-lipid cycle (Figure 7.2). 
However, the generation of second messengers as a result of phospholipid turnover is 
not restricted to PLC hydrolysis of PIP2 (Figure 7.3). Indeed, activation of different 
membrane phospholipases which hydrolyse other phospholipids to generate second 
messengers are also responsible for a variety of cellular effects. For example, PLA2 is 
known to act upon PC to release arachidonic acid (AA) which is converted by 
cyclooxygenases to prostaglandins and thromboxanes and by lipoxygenases to 
leukotrienes (Figure 7.3a). The sites of action of the phospholipases A2, C and D are 
shown in Figure 7.4. 
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Figure 7.2 Inositol-lipid cycles replenish the supply of second messengers made 
from inositol lipids. An external signal acts through a PIP2 phosphodiesterase, 
phospholipase C, which cleaves PIP2 into DAG and IP3• These two messengers go 
through a series of chemical reactions which require ATP and CTP as sources of 
phosphate groups PI to form PI and eventually reform PIP2• PDE = 
phosphodiesterase, CMP cytosine monophosphate, CTP cytosine 
triphosphate. From Rasmussen (1991). 
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Figure 7.3 Transmembrane signalling mediated by phospholipid hydrolysis. (a) 
phospholipase A2 (PLA2); (b) phospholipase C (PLC); (c) phospholipase D 
(PLD). PM = plasma membrane; L = ligand; R = receptor; PE = 
phosphatidylethanolamine; LPE = lysophosphatidylethanolamine;PC = 
phosphatidylcholine; LPC = Iysophosphatidylcholine; AA = arachidonic acid; 
PIP2 = phosphatidylinositol 4,S-bisphosphate; IP3 = inositol 1,4,S-trisphosphate; 
DG = diacylglycerol; P A = phosphatidic acid; PAP = P A phosphatase. 
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DAG is also hydrolysed by lipases leading to production of arachidonic acid (AA). 
Prostaglandins are important molecules in the regulation of endometrial processes 
such as menstruation, implantation and particularly that of parturition (Salamonsen et 
a11999; Giudice 1999; Challis et al 1997). 
Phospholipase D catalyses the hydrolysis of phosphatidylcholine with the production 
of phosphatidic acid (P A) and a free polar head group - inositol. Phosphatidic acid 
can be further cleaved by the enzyme phosphatidic acid phospho hydrolase (PAP) to 
form DAG which is a protein kinase C activator (Figure 7 .3c). 
Phospholipid turnover is now known to be mediated by numerous signals including 
neurotransmitters, releasing factors, hormones, growth factors, spermatozoa and Type 
I IFNs (Berridge 1991). 
IFNs produce a variety of responses known to be associated with phospholipid 
turnover and phospholipid turnover generates all kinds of second messengers which 
could possibly mediate an IFN response. However, while phospholipid turnover has 
been linked to IFN signalling the relationship between Type I interferons and 
phospholipid signalling is unclear, although it does appear to be involved. IFNa 
stimulates diacylglycerol (DAG) production in HeLa cells which is accompanied by 
an increase in PC hydrolysis (Pfeffer et al 1990). 
IFNa induces transcriptional responses with the activation of a cytoplasmic 
transcription factor known as interferon-stimulated gene factor (ISGF3) (Levy et al 
1988) and an inhibitor of PKC blocks this activation (Reich and Pfeffer 1990). A 
possible activator of the ISGF3 is arachidonic acid (Kessler and Levy 1991). 
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Figure 7.4 Diagram of phosphatidyinositol showing sites of action of 
phospholipases A2, C and D. R, and Rl denote long chain hydrocarbon which 
are linked to the glycerol backbone and X denotes, in this case, an inositol polar 
head group, although it could be one of a variety of bases, for example, choline 
or ethanolamine. 
phospholipase Al 
0 
\ \ 
0 
CH2 -0- C - Rl 
\ \ ~ 
R2 - C o -CH 0 
\ \ \ 
CH2 - 0 P 0 - X 
.. 
\ i 0-
phospholipase ( 
125 
Subsequently, Cataldi and colleagues studied IFNa and P stimulated 
phosphoinositide hydrolysis in Daudi cells and human lymphocytes (Cataldi et al 
1990 and 1995). In response to IFNa treatment of Daudi cells an increase in DAG 
mass was observed (Cataldi et al 1990), whilst IFNP treatment of human 
lymphocytes produced an increase in DAG levels associated with a rapid and transient 
PIP2 hydrolysis derived from the sequential activation of the PLC and PLD pathways 
(Cataldi et al 1995). 
Following the identification of the Type I interferon receptor (Class II cytokine 
receptor, Chapter 5 section 5.1) attention was focussed on the JAK (Janus kinases) 
and STAT (signal transducers and activators of transcription) proteins and the current 
model for IFNa and J3 signalling was established (see Chapter 8). Subsequently, 
work on the effects of Type I interferons on phospholipid turnover with the 
production of second messengers has been largely overlooked. However, it is 
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important that phospholipid turnover in response to Type I IFNs continues to be 
investigated because to accept that the JAKISTAT pathway is the only signal 
transduction pathway through which the IFNs mediate their response may not be 
sufficient to explain the diversity of responses seen as a result of stimulation by the 
IFNs. It has already been shown that IFNs induce phospholipid turnover (Pfeffer et al 
1990; Cataldi et al 1990 and 1995) and it is possible to conjecture, therefore, that the 
JAKISTAT pathway is perhaps regulated by second messengers generated by 
phospholipid turnover. However, to date, Type I IFN induced phospholipid turnover 
in the human endometrium has not been reported. Yet, induction of phospholipid 
turnover in endometrium has been reported as a result of oxytocin stimulation in the 
porcine endometrium which subsequently leads to prostaglandin secretion (Uzumcu et 
a12000). 
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The aim of this thesis was to elucidate the mechanism by which Type 1 interferons 
exert their effects by using human endometrial cells as the model. Endometrial cells 
have been shown to undergo phospholipid turnover and respond to stimulation by 
IFNs. The IFN receptor has been well characterised in endometrial cells. So it is 
these properties that make endometrial cells a good model in which to study the 
mechanisms of Type I IFNs. It is known that Type I IFNs stimulate the JAKJSTAT 
pathway in many cell types and in this study the stimulation of this pathway in human 
endometrial cells in response to IFN s u, ~ and 't was investigated as one of the 
possible mechanisms (see Chapter 9). Another possible mechanism is the stimulation 
of phospholipid turnover. In this chapter the following questions have been 
addressed: 
i) do Type I interferons stimulate phospholipid turnover in primary human 
endometrial cells in vitro? 
ii) and if so, what species of phospholipid are involved? 
To examine Type I IFN-induced phospholipid turnover, primary human endometrial 
cells were prelabelled with e3pJ orthophosphate and then exposed to IFNs u, ~ and T 
for increasing lengths of time. The phospholipids were extracted from the cells and 
then separated into their different types using TLC. The individual phospholipids 
were then removed from the TLC plated and counted to assess the change in 
radioactive content. 
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7.2 Methods 
Before use, all glassware was thoroughly cleaned using chromic acid (75g of sodium 
dichromate initially dissolved in 100ml of distilled water followed by 1300ml of 
concentrated sulphuric acid) overnight, rinsed thoroughly in distilled water and then 
dried completely prior to siliconising using Sigmacoate (Sigma) to prevent adhesion 
of lipids to glass. 
7.2.1 Extraction of lipids 
The isolation of lipids from cells or tissues is neither simple nor straightforward and 
so it was important to recognise the potential problems in extraction procedures. 
The most widely used method for extraction of total tissue lipids is that of Bligh and 
Dyer (1959). This procedure uses a mixture of chloroform and methanol in a ratio 
with tissue water of 1 :2:0.4. However, there would be some loss of the polar 
phosphatidylinositols, so to increase the extraction of these lipids the method of 
Shukla and Hanahan (1984) was evaluated which uses an extraction mixture of 
chloroform:methanol:concentrated HCL (12N):0.5M EDTA in the ratio 200:400:5:1.6 
v/v. The use of salt and acid solutions in the upper phase prevents the loss of the 
polar or acid phospholipids, for example, pho sphatidylethanol amine, 
pho sphatidyl serine and phosphatidylinositol. Thus for experiments where 
phospholipid turnover was examined, the method of Shukla and Hanahan was used, 
while for experiments primarily investigating the release of diacylglycerol, Bligh and 
Dyer was the method of choice. 
7.2.1.1. Extraction of total lipids by the method of Bligh and Dyer (1959) 
Briefly, Iml of endometrial cell suspension was extracted with 3.75ml of chloroform: 
methanol (1:2 v/v), followed by 1.25ml of chloroform and finally 1.25ml of distilled 
water. After the first two additions the mixture was shaken vigorously and left to 
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stand for 30 min at room temperature, following the fmal addition the mixture was 
shaken and left to stand overnight at 4°C. The lower organic phase was carefully 
removed into a siliconised tube and the aqueous phase was washed twice with 2ml of 
chloroform. All the organic phases were combined and blown dry under a stream of 
oxygen-free nitrogen. The residue was reconstituted in 2ml of chloroform:methanol 
(1:2 v/v). 
7.2.1.2 Extraction of total lipids with an increased extraction of polar phospholipids 
by the method of Shukla and Hanahan (1984) 
Briefly, the method follows that of Bligh and Dyer as described above except that 
3.75ml of chloroform:methanol (1:2 v/v) was replaced with 3.75ml of 
chloroform:methanol:conc HCl:0.5M EDTA (200:400:5:1.6 v/v). 
7.2.2 Thin layer chromatography methods 
7.2.2.1 TLC for total lipids 
Before carrying out any chromatography the solvent tank was prepared and 
equilibrated. The tank was rinsed with chloroform and dried in the fume hood. The 
solvent - methyl acetate, chloroform, n-propanol, methanol and 0.25% (w/v) 
potassium chloride (KCl) in the ratio 25:25:25:10:9 by volume - was added to the 
tank and mixed by gently swirling. Whatman filter paper was wrapped completely 
around the inside of the tank and the lid was firmly placed on top. The tank was left to 
equilibrate, that is when the paper was fully wetted with solvent. 
The Whatman LHP-K plate was then spotted with the samples and standards 
phosphatidylethanolamine (PE), phosphatidylinositol (PI), phosphatidic acid (P A), 
phosphatidylserine (PS), phosphatidycholine (PC) and lysophosphatidy1choline (LPC) 
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at a concentration of 1 mg/ml in individual lanes. One lane contained a combination 
of standards to verify separation. 
The standards, if not already purchased in chloroform, were dissolved into chlorofonn 
to give a concentration of 1 mg/m!. 
The plate was then placed in the chromatography tank until the solvent front was 
close to the upper edge of the plate when it was removed and air dried for about 15 
min. The lipids were then visualised by placing the plate into a tank of iodine crystals 
for about 10 min or when the spots were clearly visible. The standards and unknowns 
were marked by lightly drawing around the spots with a pencil (Figure 7.6). 
7.2.2.2 TLC for phosphoinositides 
The silica gel 60 plates were pre-treated by spraying with a 1% (w/v) potassium 
oxalate solution and then heating to 110°C for 1 hour. To avoid any interference by 
Ca2+ on the mobility of PIP2 Gonzalez-Sastro and Folch-Pi (1968) used plates 
including 1 % potassium oxalate to bind any traces of Ca2+. The tank was prepared as 
described for phospholipid TLC. The solvent system was 
chloroform:methanol:water:concentrated ammonia in the ratio 48:40:7:5 by volume. 
The plate was run and visualised as described previously in section 7.2.2.1. The 
standards used were PE, PI, P A, phosphatidylinositol 4 phosphate (PIP) and 
phosphatidylinositol 4,5 bisphosphate (PIP2) (Figure 7.5a). 
7.2.3 Cell viability in phosphate-free medium 
For the purposes of the following experiments in which phosphoinositide turnover 
was monitored by the production of radiolabelled phosphoinositides it was necessary 
to determine how long endometrial cells would remain viable in medium which 
contained no source of unlabelled phosphates. 
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Figure 7.5 (a) The separation of phosphoinositides by TLC using silica gel 60 
plates impregnated with 10/0 (w/v) potassium oxalate and (b) the separation of 
phospholipids using Wbatman LHP-K plates. 
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Two 75 cm2 flasks containing cells at confluence were trypsinised as previously 
described and the cell suspensions were pooled into a silicon-coated glass tube. The 
tube was centrifuged for 5 min at 300 x g and the supernatant was discarded. The 
pellet of cells was resuspended in 1ml of medium which was free of phosphate, fetal 
calf serum, antibiotics and antimycotics. The suspension was centrifuged as before 
and the cells were once again resuspended in 1ml of depleted medium. The cells were 
then placed in the 37°C incubator but prior to this 100J..LI of the cell suspension was 
removed, this was time 0, and added to 5mls of fully supplemented media, as used in 
the cell culture protocol, which was then gassed and returned to the 37°C incubator 
for 1 hr. After this time, the tube was centrifuged, the supernatant discarded and 1 ml 
of a 1: 1 Trypan blue solution (in PBS) was added. After 5 min the sample was tipped 
into a Petri dish and the proportion of dead to live cells was ascertained by visual ising 
several groups of 10 cells and taking the average. The above procedure was repeated 
by removing 100J..LI from the cell suspension in the depleted medium at 30 min, 1, 2, 
2.5, 3.0, 3.5 and 4 hr from time O. 
7.2.4 Equilibration of e3p] orthophosphate uptake by endometrial cells 
Trypsinised endometrial cells were transferred to a siliconised glass tube and 
centrifuged at 300 x g for 5 min at room temperature. The cell pellet, after an initial 
wash in phosphate-free medium, was resuspended in 5.1 ml of phosphate-free 
medium. 100J..LI of the cell suspension was removed for cell count. To 5 ml of cell 
suspension 25J..LI (250J..LCi) of e3pJ orthophosphate were added and mixed thoroughly. 
One millilitre of the suspension was removed immediately (time 0) and transferred 
into a siliconised glass tube containing 4ml of ice-cold 10mM PBS were added. 
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Following centrifugation at 300 x g for 5 min at RT, the supernatant was discarded 
and the pellet resuspended in 3m! of PBS which was divided into 3 x 1 ml aliquots 
which proceeded to lipid extraction using the methods of Shukla and Hanahan and 
Bligh and Dyer. The phospholipids and phosphosinositides were separated by TLC as 
previously described in section 7.2.2. The TLC plate was then exposed to X-Omat 
XAR-5 (Kodak) film using an intensifying screen overnight at -20°C. The film was 
then developed using an automatic developer (Department of Radiography, St 
Bartholomew's Hospital, London, UK). A 1ml cell suspension was removed at 
increasing time intervals (30, 60, 90, 120, 150 and 180 min), transferred into ice cold 
PBS and processed as described above. In each case, the remaining cell suspension 
was returned to the 37°C incubator and gassed periodically with 50/0 CO2 in air. Once 
the sample of cell suspension had been removed all the steps leading to lipid 
extraction were executed as quickly as possible. 
After visualisation (Figure 7.6) each individual phospholipid and phosphoinositide 
spot was scraped off the plate using a scalpel (and, if necessary, the silica gel was 
moistened with distilled water to prevent cracking) and put into a vial containing 5m} 
scintillation fluid. Each vial was capped and shaken vigorously and then allowed to 
settle in the dark before being counted on a p counter (Packard Minaxi 4000 series, 
Packard, Berkshire, UK) using the 32p channel. 
Until recently the most commonly used phosphorus isotope was 32p. The counter 
used for the measuring e3p] labelled phosphoinositides was designed to detect the p 
emitters 3H, 14C and 32p. Although the counter did not have a channel dedicated to 
counting 33p it would seem appropriate to count it on the 32p setting. However. 32p 
and 33p have very different energies (1710 and 249 KeV respectively). In fact. the 
energy of 33p is nearer to that of 14C at 155 KeV. The scintillation counter could be 
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programmed to measure one of three regions of energy, (i) 2-19 KeV, (ii) 4-156 KeV 
and (iii) 50-1700 KeV. The energy of 33p falls just outside region (ii) and is at the 
low end of region (iii). Therefore, to ascertain which is the channel of choice one of 
the preliminary lipid extraction experiments was counted on all three channels and the 
resulting counts were compared (Table 7.1). There was not much difference in the 
counting efficiency of the 32p and 14C channels where there were many counts. 
However, the 32p channel was more sensitive where there were fewer counts and, as a 
result of this comparison, the 32p setting was used for all subsequent experiments. 
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Figure 7.6 Time course of 33p uptake by phospholipids separated by thin layer 
chromatography. The migration of unlabelled standard material is indicated by 
pencil outline. PE = phosphatidylethanolamine, PI = phosphatidylinositol, P A = 
phosphatidic acid, PS = phosphatidylserine, PC = phosphatidylcholine and LPC 
= lysophosphatidylcholine. 
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Table 7.1 A lipid extraction experiment was counted on th th h 
available on the scintillation counter e ree c annels 
experimental details 32p channel cts/min 14C channel cts/min 3 
H channel cts/min 
Blank 0' 19 26 15 
PC 0' 56 49 22 
LPC 30' 196 210 82 
PC 30' 1468 1363 593 
PS 30' 244 189 75 
PA 30' 71 76 33 
PE 30' 69 71 29 
LPC 60' 524 423 217 
PC 60' 4736 4363 1884 
PS 60' 909 864 357 
PA 60' 445 439 171 
PE 60' 291 276 115 
LPC 90' 902 820 343 
PC 90' 8211 7453 3327 
PS 90' 2194 1979 943 
PA 90' 777 698 309 
PE 90' 452 442 188 
33p has a half-life of25.4 days and the experiments were carried out at various times 
from its reference date sometimes a month or more away. To correct for this an 
equation was devised so that the counts per 105 cells could be adjusted for specific 
activity. Therefore, if an experiment took place using 33p on, for example, day 1 or 
day 20, the counts would be adjusted to give values that would have been obtained on 
day 0 - the reference date of the isotope. 
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A graph was drawn of the decay profile of 33p against the days from the reference date 
(Figure 7.7) and using this information the following formula was derived: 
If there are 5 x 105 cells per ml removed at each time point and the isotope is 7 days 
from its reference date then it follows:-
where 
X a = Xi5 per 105 cells 
Xa are the counts after adjusting for specific activity 
X are the counts from the ~ counter 
the decay from the graph for day 7 is 0.826, therefore, if counted on day 0 
Xa = Xi5 x 1/0.826 per 105 cells 
so Xa = Xi4.13 per 105 cells 
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Figure 7.7 The decay profile of 33p 
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7.2.5 Phospholipid turnover following IFN stimulation 
Endometrial cell suspensions were prelabelled with e 3p] orthophosphate for 90 min at 
37°C using the method previously described in section 7.2.4. After this time the cells 
were washed, centrifuged and resuspended in 6.5ml of 10mM PBS. One ml of cell 
suspension was aliquoted into 6 siliconised glass tubes. To the fIrst tube 3.75ml of 
acidifIed chloroform:methanol was added (time 0). To subsequent tubes 2 through to 
6, IFN (u, ~ or 't) at a concentration of 100 units per ml of cell suspension was added. 
Ice-cold acidified chloroform:methanol was added at 2, 10, 30, 60 and 120 second 
intervals. The phospholipids and phosphoinositides were extracted according to the 
method of Shukla and Hanahan and separated by TLC as previously described in 
sections 7.2. After autoradiography 33p activity in the individual phospholipids and 
phosphoinositides was measured as described in section 7.2.4. 
7.2.6 Equilibration of eH] glycerol uptake in endometrial cells 
Established endometrial cells were passaged on into 5 x 25 cm2 flasks ensuring that 
cell numbers were approximately the same for each flask. These cells were grown to 
confluency at which point the old medium was discarded and replaced with 10ml of 
normal fully supplemented medium containing 20J.lCi eH] glycerol 
(2J.lCi eH] glycerol per ml of medium). The flasks were gassed and returned to the 
37°C incubator. The uptake of eH] glycerol was assessed at 3, 6, 24, 30 and 48 hr 
after its addition to the flasks. At the allotted time point a flask was taken and the 
cells trypsinised as previously described in section 7.2.4. One millilitre of the 
resulting cell suspension was extracted using the method of Bligh and Dyer. After 
drying down in a stream of N2 the precipitate was resuspended in scintillant, poured 
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into a vial and then counted using the 3H channel on the scintillation counter. The 
levels of eH] glycerol at the given time points were compared. 
7.2.7 Measurement of diacylglycerol levels following IFN stimulation. 
Endometrial cells were grown to confluency and prelabelled with eH] glycerol for 48 
hr as previously described in section 7.2.6. One millilitre of cell suspension was 
aliquoted into 6 siliconised glass extraction tubes. To the fIrst tube 3.75 ml of ice-
cold chloroform:methanol (1:2 v/v) was added (time 0). To the other 5 tubes 100J.lI of 
IFN (a, J3 or 't), at a concentration of 100 units per ml of cell suspension, was added 
for 2, 10, 30, 60 and 120 sec the reaction being stopped by the addition of 3.75 ml of 
ice-cold chloroform:methanol. The phospholipids were extracted using the method of 
Bligh and Dyer and separated by TLC. TLC for mono-, di- and triacylglycerol used a 
Silica gel 60 plate and the solvent system was hexane:ether:methanol:acetic acid in 
the ratio 180:40:6:4 by volume. Tritiated glycerol cannot by visualised by 
conventional autoradiography therefore to aid visualisation of the sample spots in 
iodine vapour a small amount of the unlabelled standards were run with the samples. 
The mono-, di- and triacylglycerol spots were scraped off the plate and put into vials 
containing scintillant and counted. 
7.3 Statistical analysis 
The data obtained from the analysis of phosphoinositide production and hydrolysis in 
response to different stimuli was normally distributed and the paired T test was used 
to compare values. 
In all cases, differences between the groups were considered signifIcant when the 
probability of the events occurring by chance was < 0.05. 
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7.4 Results 
7.4.1 Cell viability in phosphate-free medium 
To allow the maximum uptake of e3p] orthophosphate into endometrial cell 
phospholipids, the cells should, ideally, be cultured in the presence of radiolabel but 
in the absence of unlabelled phosphate. As the addition of radio label would represent 
such a minute source of phosphate for the cells, it was necessary to determine the 
viability of cells in phosphate-free medium. Endometrial cells were cultured in the 
absence of phosphate for up to 4 hours and the viability assessed at regular intervals 
using the Trypan Blue exclusion method. The experiment shows that the majority of 
endometrial cells remain viable in phosphate-free medium for at least 90 minutes 
which allows enough time for the equilibration of e3p] orthophosphate (Table 7.2). 
Table 7.2 Endometrial cell viability with increasing incubation time in 
phosphate-free medium (cell count represents mean of 4 experiments). 
Time (minutes) Mean number of non-viable cells per 10 cells % live cells 
0 1.0 90 
30 2.0 80 
60 2.5 75 
90 2.5 75 
120 4.5 55 
150 5.0 50 
180 7.0 30 
210 7.5 25 
240 7.5 25 
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7.4.2 Equilibration of [33p] orthophosphate uptake in endometrial cells 
To determine the rate of uptake of radiolabelled e3p] orthophosphate. cells were 
cultured for an increasing period of time in phosphate-free media to which the 
radiolabel was added. At various times, phospholipids were extracted by the method 
of Shukla and Hanahan (1984), as described in Materials and Methods, to determine 
the incorporation of e3p] orthophosphate. The experiments demonstrated that 
unstimulated human endometrial cells from primary culture rapidly incorporated the 
radio label into the various phospholipid classes within 60 millS of exposure to e3p] 
orthophosphate. There were no statistically significant increases in the uptake of e3p] 
orthophosphate after 90 mins (Figure 7.8 A and B). For all subsequent experiments 
examining phospholipid turnover in response to IFN, endometrial cells were 
prelabelled with 33p for 90 mins prior to stimulation. 
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Figure 7.8 A and B. Uptake of eJp] orthophosphate into phospholipids by 
human endometrial cells. A. 33p uptake into the phospholipids PC, PIIPS, LPC 
and PE (n-3). B. 33p uptake into the phospholipids PI, P A, PIP and PIP2 (n=2). Error bars represent SEMs. 
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7.4.3 Phospholipid turnover following stimulation by IFNa. 
Primary endometrial cells, pre-labelled with e3p] orthophosphate, were stimulated 
with IFN a. (100 units per ml of cell suspension) and the reaction was stopped at 2.10, 
30, 60 and 120 second intervals. The phospholipids and phosphoinositides were then 
extracted, separated and counted as previously described in this chapter. The 
response of endometrial cell phospholipids to stimulation by IFNa. is summarised in 
Table 7.3. The data in Table 7.3 shows the means and SEMs calculated on counts 
from three experiments. The counts for each experiment are represented as a 
percentage of the total counts incorporated into the cells initially. This data (means 
and SEMs) is represented graphically in Figure 7.9. 
There is significant hydrolysis of PIP2 at 2 seconds (p = 0.007) with a significant 
recycling ofPIP2 from 2 seconds to 10 seconds (p = 0.029). 
In addition, there is significant hydrolysis at 2 seconds of PIP (p = 0.038) and PA (p = 
0.040). 
There was no significant hydrolysis or production of any of the other phospholipids. 
7.4.4 Phospholipid turnover following stimulation by IFN(3 
The methods used were the same as those described for stimulation by IFNa, section 
7.4.3. The response of endometrial cell phospholipids to stimulation by IFN~ is 
summarised in Table 7.4. 
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Table 7.3 IFNa. induced changes in e3p] orthophosphate labelled endometrial 
cell phospholipids with time. The values are given as cpmJl05 cells. 
lipid Time in seconds 
0 2 10 30 60 120 
PIP2 
n 3 3 3 3 3 3 
mean 9144 5786 7411 7021 7002 7133 
SEM 1574 1624 1104 1421 1962 875 
PIP 
n 3 3 3 3 2 3 
mean 8653 7361 8123 7750 7731 7764 
SEM 1651 1393 1350 1308 2156 969 
PI 
n 3 3 3 3 3 3 
mean 22692 21959 25284 22471 23518 23128 
SEM 3518 2230 4001 3585 3109 3654 
PA 
n 3 3 3 3 3 2 
mean 9023 6843 7369 8666 5909 5805 
SEM 204 717 660 2055 644 1034 
PC 
n 3 3 3 3 3 2 
mean 37600 29093 27556 29903 25055 26537 
SEM 8225 3735 5060 2320 3752 5843 
PE 
n 3 3 3 3 3 2 
mean 3187 2872 2959 3166 2589 2438 
SEM 177 402 527 800 543 163 
LPC 
n 3 3 3 3 3 2 
mean 8072 6573 8585 8129 8704 7603 
SEM 637 1245 857 1185 1425 1353 
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Figure 7.9 Endometrial cell phospholipid response to IFNa. represented as a 
percentage of the total counts incorporated initially (means +/- SEMs). * 
indicates significant hydrolysis of PIP2, PIP and P A at 2 seconds (p = 0.007, 0.038 
and 0.04 respectively) and # indicates significant recycling of PIP2 between 2 
and 10 seconds (p = 0.029). 
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Table 7.4 shows the means and SEMs calculated on the raw data. Figure 7.10 shows 
the same data represented as a percentage of the total counts added at the beginning of 
each experiment. 
There is no significant hydrolysis or production of any of the phospholipids following 
stimulation by IFN~. 
7.4.5 Phospholipid turnover following stimulation by IFN't 
The methods used were the same as those briefly described for stimulation by IFNu, 
section 7.4.3. The response of endometrial cell phospholipids to stimulation by IFN-r 
is summarised in Table 7.5. 
Table 7.5 shows the means and SEMs calculated on the raw data. Figure 7.11 shows 
the same data represented as a percentage of the total counts added at the beginning of 
each experiment. 
In response to IFN't there is no significant hydrolysis of PIP2 at 2 seconds but there is 
significant hydrolysis ofPIP2 at 10 seconds (p = 0.048) with maximal hydrolysis at 30 
seconds (p = 0.0007). Following hydrolysis, there is significant recycling of PIP2 
from 30 to 60 seconds (p = 0.014). 
Similarly, there is significant hydrolysis of PIP at 10 seconds (p = 0.012) with 
maximal hydrolysis at 30 seconds (p = 0.0004) followed by significant recycling of 
PIP from 30 to 60 seconds (p = 0.05) although at 60 seconds levels of hydrolysed PIP 
are still significantly reduced (p = 0.003). 
There is no significant hydrolysis or production of any of the other phospholipids 
measured. 
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Table 7.4 IFNJ3 induced changes in e3pJ orthophosphate labelled 
endometrial cell phospholipids with time. The values are given as cpmJl05 cells. 
lipid Time in seconds 
0 2 10 30 60 120 
PIP2 
n 5 5 5 5 5 4 
mean 13283 15330 13590 14749 12315 12501 
SEM 1962 3357 4103 4930 3130 3445 
PIP 
n 5 5 5 5 5 4 
mean 9197 11394 9934 10499 9337 8427 
SEM 1567 2875 2951 3109 2485 3074 
PI 
n 5 5 5 5 5 4 
mean 24145 27388 25432 27997 26125 26038 
SEM 2260 3860 5172 4747 4269 5795 
PA 
n 5 5 5 5 5 4 
mean 34757 43630 40284 42367 40601 38312 
SEM 10912 14083 14086 14186 13087 16089 
PC 
n 3 3 3 3 3 2 
mean 21330 29117 29356 27422 31730 29873 
SEM 3855 8501 9884 7887 7627 13116 
PE 
n 5 5 5 5 5 4 
mean 5935 7489 6598 7939 7042 6277 
SEM 2085 2721 2752 3173 2520 3036 
LPC 
n 3 3 3 3 3 2 
mean 1232 1475 1531 1948 1766 1687 
SEM 104 223 326 185 145 231 
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Figure 7.10 Endometrial cell phospholipid response to IFNJ3 represented as a 
percentage of the total counts incorporated initially (means +/- SEMs). 
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Table 7.5 IFN't induced changes in e3p] orthophosphate labelled 
endometrial cell phospholipids with time. The values are given as cpmJl05 cells. 
lipid Time in seconds 
0 2 10 30 60 120 
PIP2 
n 6 6 6 6 5 6 
mean 4828 4443 3699 2720 3740 3541 
SEM 634 704 771 388 698 776 
PIP 
n 6 6 6 6 5 6 
mean 4497 3728 3299 3020 3030 3112 
SEM 486 534 554 415 469 476 
PI 
n 5 5 5 5 4 5 
mean 17087 16230 16879 17137 15487 15857 
SEM 2618 2542 3264 3447 3651 1977 
PA 
n 5 5 5 5 4 5 
mean 10997 10617 9698 8711 9953 9410 
SEM 1506 1544 1877 1445 2001 1048 
PC 
n 6 6 6 5 5 6 
mean 28026 25537 27599 29031 27420 28349 
SEM 5891 5591 6748 7300 4784 5113 
PE 
n 5 5 5 5 4 5 
mean 1707 1638 1440 1301 1241 1207 
SEM 301 201 187 166 60 179 
LPC 
n 6 6 6 5 5 6 
mean 2657 3413 3150 2327 2982 2846 
SEM 703 926 872 685 1052 503 
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Figure 7.11 Endometrial cell phospholipid response to IFN t represented as a 
percentage of the total counts incorporated initially (means +/- SEMs). * 
indicates significant hydrolysis of PIP2 and PIP at 10 and 30 seconds (p = 0.048, 
0.0007 and 0.012, 0.0004 respectively) and PIP at 60 seconds (p = 0.003). # 
indicates significant recycling of PIP2 and PIP from 30 to 60 seconds (p = 0.014 
and 0.05 respectively). 
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7.4.6 Equilibration of eH] glycerol uptake in endometrial cells. 
Production of DAG was measured using incorporation of eHJ glycerol. 
To detennine the rate of uptake of radio labelled eH] glycerol, unstimulated cells were 
cultured for up to 72 hours in media to which the radio label was added. At various 
times total lipids were extracted by the method of Bligh and Dyer (1959) and the 
neutral lipids were separated by TLC, as previously described in section 7.2.2. The 
experiments demonstrated that unstimulated human endometrial cells from primary 
culture incorporated the radio label into diacylglycerol after 48 hours of exposure 
(Figure 7.12). For all subsequent experiments examining diacylglycerol turnover in 
response to IFN, endometrial cells were prelabelled with eHJ glycerol for 48 hours 
prior to stimulation. 
7.4.7 Diacylglycerol turnover following stimulation by Type I interferons 
The methods used were basically the same as those briefly described for stimulation 
by IFNa, section 7.4.3. The response of endometrial cell diacylglycerol to 
stimulation by Type I IFNs is summarised in Table 7.6. 
Table 7.6 shows the means and SEMs calculated on the raw data. Figure 7.13 shows 
the same data represented as a percentage of the total counts added at the beginning of 
each experiment. 
In response to stimulation by IFNa there is significant production of DAG at 2 
seconds (p = 0.009) followed by a significant hydrolysis of DAG from 2 to 10 
seconds (p = 0.019). 
There is no significant production or hydrolysis of DAG on exposure to IFN~. 
On exposure to IFN't there was significant production of DAG at 10 seconds (p = 
0.04) and this production was more significant at 60 seconds (p = 0.026). 
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Figure 7.12 Uptake of eH] glycerol into diacylglycerol by human endometrial 
cells over time. 
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Table 7.6 IFNa., J3 and 1: induced changes in eH] glycerol labelled 
endometrial cell diacylglycerol (DAG) with time. The values are given as 
cpm/l05 cells. 
IFN Time in seconds 
0 2 10 30 60 120 
IFNa. 
n 3 3 3 3 3 3 
mean 292 332 296 261 283 300 
SEM 107 116 100 89 85 102 
IFNJ3 
n 5 5 5 5 5 5 
mean 363 400 414 353 370 372 
SEM 70 69 78 74 65 37 
IFN't 
n 5 5 5 5 5 5 
mean 207 228 231 199 238 235 
SEM 28 34 26 25 19 32 
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Figure 7.13 Endometrial cell diacylglycerol response to IFNs a, ~ and 't 
represented as a percentage of the total counts incorporated initially (means +/_ 
SEMs). * indicates significant production of DAG. # indicates significant 
hydrolysis of DAG. 
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7.5 Discussion 
These experiments show for the first time that IFNs a and "C activate phospholipid 
signalling pathways in primary endometrial cells in vitro. In contrast, IFN~ is not 
apparently associated with any phospholipid signalling pathway. 
7.5.1 The response to IFNa 
This study shows that IFNa stimulates rapid hydrolysis of PIP2, PIP and PAin 
primary human endometrial cells with a concomitant release ofDAG at 2 sees. DAG 
and IP3 are rapidly recycled to form PIP2 (see Figure 7.2) which is shown in these 
experiments by the significant incorporation of label into PIP2 at 10 seconds with 
significant decrease in radiolabelled DAG at the same time. In response to IFNa 
there is significant decrease of PIP at 2 seconds. Some of these findings agree with 
other studies which found that the interaction of IFNa with other cell types, Daudi 
and HeLa cells, stimulates the production of DAG (Cataldi et al 1990; Pfeffer et al 
1990). 
However, neither of these previous studies detected phosphoinositide turnover in 
response to IFN a, although one group found an increase in P A which paralleled that 
of DAG formation (Pfeffer et al 1990). This disparity of results could be because of 
the different cell types used; which would, therefore, support the theory that IFN s 
can activate different signalling mechanisms in different cell types and, in doing so, 
can have different effects. 
However, there is an alternative explanation. In the current study the hydrolysis of 
the phosphoinositides and the production of DAG occurred within 2 seconds of 
exposure to IFNa. It is known that the initial event following the binding of the 
ligand to its receptor is a rapid formation of second messengers usually within 30 
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seconds. The studies which report no phosphoinositide turnover may not see a 
change because their experimental procedures have the first time points for the 
measurement of the phospholipids at 1 and 2 minutes after IFN stimulation (Cataldi et 
al 1990; Pfeffer et al 1990). It could be argued, therefore, that these previous studies 
have missed the response and that the investigators were looking at levels of 
phospholipids which have returned to those found prior to IFN exposure. 
Alternatively, it could be because different cell types are involved, DAG can be 
generated by the action of phospholipase C on PIP2 with the simultaneous production 
of another second messenger IP3• The results reported here suggest that IFNa-
receptor binding activates a PLC to produce a signalling mechanism involving 
phosphoinositide turnover. In addition, the results suggest that P A turnover is also 
involved. The levels ofPA are significantly reduced even at 1 minute (p = 0.01) PA 
can be hydrolysed by the enzyme phosphatidic acid phosphohydrolase to form DAG 
(Figure 7.3 C). Therefore, the increase in DAG seen after IFNa stimulation may be 
derived not only from PIP2 but also from P A. 
7.S.2 The response to IFNJ3 
The results of the present study show that IFN~ does not stimulate hydrolysis of any 
of the phosphoinositides investigated nor does it stimulate production of DAG in 
primary human endometrial cells. This is in contrast with the findings in human 
lymphocytes and Daudi cells where exposure to IFN~ led to an increase in DAG 
together with hydrolysis of PIP2 in the former (Cataldi et al 1995) and an increase in 
DAG production but no changes in the levels of PI, PIP or PIP2 in the latter (Yap et al 
1986). Yap and colleagues measured this change in DAG within 30 seconds of 
exposure of IFN~ but, in the present study, there was no significant increase in 
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labelled DAG from 2 to 60 seconds and at 30 seconds (p = 0.469). This could again 
reflect differences in response to IFN s depending upon cell types. 
However, for this study the cells were stimulated with 100 units of IFN~ per ml of 
cell suspension whereas Yap and colleagues used 20,000 units/ml IFN~. These high 
levels of IFN~ are way beyond those found in vivo and the observations in the study 
presented here are more likely to represent the physiological situation. There is no 
evidence to suggest that IFN~ is detectable in normal tissue unless stimulated in 
someway or by external administration. Following subcutaneous administration, 
serum levels of IFN~ between 40-475 IU Iml, depending upon the method of 
measurement used, have a marked effect on the course of multiple sclerosis (Khan et 
al 1996). It would, therefore, be possible to assume that levels of approximately 100 
unitslml of IFN~ would be sufficient to cause an effect in cells that are responsive. 
Likewise, Cataldi and colleagues used a ten-fold higher concentration of IFN~ (1000 
IVlml) to stimulate the human lymphocytes compared to the concentration used in the 
current study. 
It would appear that the response to IFN~ is very different to IFNa in endometrial 
cells with respect to phospholipid signalling which may reflect the different binding 
affinity of IFN~ for the endometrial IFN receptor. 
Although IFNa and ~ transmit their actions via the same IFNaI~ receptor there is 
much evidence to suggest that there is differential interaction of a and ~ IFNs with 
their receptor. Mutant IFNAR-2 proteins in the N-terminal subdomain confer 
complete resistance to IFNa but not to IFN~ whilst, in complete contrast, an alanine 
substitution of Tyr 127 in IFNAR-2 prevents IFN~ binding but not IFNa binding 
(Lewerenz et al 1998). Certain highly conserved amino acids in the loops of the IFN 
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a/~ receptor are important for functional IFNa binding because mutational studies 
reveal that substitution of these amino acids reduce the binding of IFNa but not that 
of IFN~ (Runkel et al 1998). Studies have shown that both IFNa and IFN~ need to 
make physical contact with IFNAR-l and IFNAR-2 for intracellular signal 
transduction although IFNAR-l appears to engage IFN~ differently than IFNa 
(Novick et al 1994; Lutfalla et al 1995; Rani et al 1996). Differences have been 
observed between cell signalling by IFNa and IFN~. Mutant UIA cells are 
completely defective in response to recombinant or natural IFNa but retain a partial 
response to IFN~ (Pellegrini et al 1989). Identification of a gene which is selectively 
induced by IFN~, but not IFNa, provides further evidence that IFN~ may use a 
distinct pathway for cell signalling (Rani et al 1996). It is also of interest that IFNa 
and IFN~, although both Type I interferons having many characteristics in common, 
are, structurally, only 30% homologous. Therefore, it may be possible to speculate 
that the IFN receptor found on human endometrial cells is more suited for IFNa 
binding rather than IFN~ binding. 
These studies may go someway in explaining that phospholipid signalling pathway is 
not triggered in response to IFN~ on primary human endometrial cells. 
7.5.3 The response to IFNt 
This data shows for the first time that IFNt can stimulate a response through the 
IFNa/~ receptor on human endometrial cells in vitro. 
At the present time there is no published data on the activation of phospholipid 
signalling mechanisms by IFNt in any cell type, although there is a single report on 
the effects of IFNt (OTP) on oxytocin-induced phosphatidylinositol turnover in sheep 
endometrium (Vallet and Bazer 1989). The results of the experiments carried out for 
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this study show that IFN-r stimulates the hydrolysis of PIP2 and PIP with maximal 
hydrolysis taking place at 30 seconds after exposure to IFN-r (p = 0.0007 and 0.0004 
respectively). The patterns of PIP2 and PIP hydrolysis are very similar but are 
different to that seen with IFNa. The response to IFN-r is far less rapid than that by 
IFNa. Significant hydrolysis is first seen at 10 seconds (PIP2 p = 0.048; PIP P = 
0.012) , not 2 seconds as with IFNa, and this hydrolysis continues to be significant 
becoming maximal at 30 seconds. This is followed by significant production of both 
PIP2 and PIP (PIP2 p = 0.014; PIP P = 0.05) by 60 seconds after exposure to IFN-c 
although these levels have not returned to those found prior to stimulation by IFN-c. 
The pattern of DAG production mirrors that of PIP2 and PIP hydrolysis. There is a 
significant increase in DAG production in response to IFN-c at 10 seconds (p = 0.04) 
and there is continued production with levels still significantly raised at 60 seconds (p 
= 0.026). 
IFNa and IFN-c bear a striking sequence homology, approximately 70% (Stewart et al 
1987; Imakawa et al 1987), and they share a common receptor in the bovine 
endometrium (Li and Roberts 1994). The ovine Type I interferon receptor 
(oIFNAR1) is a 560 amino acid transmembrane protein which has 80% homology 
with the human IFNAR1 and 95% homology with the bovine IFNAR1 (Kaluz et al 
1996). It appears from the results obtained in this study that IFN-c binds to the 
IFNa/~ receptor on human endometrial cells and that this interaction stimulates a 
similar pattern of phospholipid turnover. The response is not as rapid as that which 
occurs with IFNa (figure 7.9 and figure 7.11) and is slow to return to pre-stimulated 
levels. The relative slowness of the response may be due to differences in the IFNa 
and IFN-c interaction with the IFN receptor. In this regard it is of interest to note that 
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studies have shown that IFN't can slow the proliferation of bovine kidney epithelial 
cells and human WISH cells whereas the same concentration of IFNa significantly 
inhibit growth (Pontzer et al 1991). Subramaniam and colleagues found that although 
IFN't is as potent an antiviral and antiproliferative agent as IFNa on MDBK cells, it is 
far less cytotoxic at the same concentrations and this cytotoxicity is associated with 
maximal receptor occupancy (Subramaniam et al 1995). They found that IFNa at 
high concentrations has approximately a 10-fold lower Kd, and hence a greater 
binding affinity for the receptor than does IFN't. The higher binding affinity of IFNa 
for the receptor and the differential competition properties of IFN't and IFNa also 
suggest that these IFNs recognise the receptor differently (Subramaniam et al 1995). 
This report may help to explain why we observe minor differences in phospholipid 
signalling in response to stimulation by IFNa and't. 
However, the phospholipid response to IFNa and IFN't stimulation in endometrial 
cells is very similar compared to the lack of response observed when the cells are 
stimulated with IFN~. IFNa and IFN't are structurally very similar, 70% homology, 
whereas the structural similarity between IFNa and IFNP is only 30%. This 
difference may possibly help to explain the differences in response. 
In summary, this study shows that Type I interferons stimulate phospholipid turnover 
in human primary endometrial cells. We found a distinct difference in the activation 
of this pathway between the IFNs tested. The greatest response followed incubation 
with IFNa and IFN't , whereas IFNP did not stimulate this pathway. These differences 
may be explained by differences in the structures of these IFNs and their interaction 
with the IFN receptor. 
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CHAPTER 8 
DETERMINATION OF THE PRESENCE OF JAK 
AND STAT PROTEINS IN UNSTIMULATED 
ENDOMETRIAL CELLS 
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8.1 Introduction 
8.1.1 The classic IFN signalling pathway 
The elucidation of IFN signalling via the JAK and STAT pathway began with studies 
oflFN-inducible genes in the early 1990s. It was known that when Type I IFNs bind 
to their receptor the end point is transcriptional activation of a sequence called the 
IFN-stimulated response element (ISRE) in the absence of de novo protein synthesis 
(Sen and Lengyel 1992; Darnell et aI1994). This DNA sequence is present in IFNu 
and IFN~ inducible genes. For the activation of ISRE containing genes a complex 
known as IFN-stimulated gene factor 3 (ISGF3) is required. ISGF3 is present in an 
inactive form in the cytoplasm where it becomes activated immediately after IFN 
receptor binding. The activated ISGF3 complex moves to the nucleus and binds to 
the ISREs. What was less certain was how the signal was transduced from the initial 
binding of the ligand to the receptor through to the activation of the ISRE. It had 
been reported that certain protein kinases blocked lPN-induced gene expression (Sen 
and Lengyel 1992) and that IFNu binding caused activation of phospholipase A2 with 
the formation of arachidonic acid in mouse fibroblasts (Hannigan and Williams 
1991). 
Further studies showed that the ISGF3 complex consisted of two biochemically 
distinct activities. The u component (ISGF3u) was shown to be rapidly and 
specifically activated in the cytoplasm in response to IFNu. The y component 
ISGF3y, also known as p48 or interferon regulatory factor-9 (IRF -9), was found to be 
present in both cytoplasmic and nuclear compartments and possessed intrinsic DNA 
binding activity (Levy et al 1989). Later it was demonstrated that ISGF3u was made 
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up of 3 proteins p84, p91 and p 113 all of which contain one SH2 domain and a weak 
SH3 domain. 
The potential involvement of kinases in the signal transduction mechanism had 
already been suggested by previous studies and with the use of antibodies against the 
ISGF3 proteins it was shown that IFNa and IFN~ activate the rapid tyrosine 
phosphorylation of the three ISGF3a proteins (Pellegrini and Schindler 1993). These 
events trigger the association of these proteins which form the ISGF3a complex and 
translocate to the nucleus. These proteins serve dual roles as signal transducers as 
well as activators of transcription and so the generic name of STAT (Signal 
Transducers and Activators of Transcription) was given to this family of proteins 
(Darnell et al 1994). Proteins p91 and p84 are STATla and STATl~ respectively 
and p113 is STAT2. 
The family of STATs consists of six mammalian members which participate in 
numerous signalling pathways (Briscoe et al 1994; Ihle and Kerr 1995). The STAT 
proteins contain several conserved regions scattered throughout their entire length 
including a highly conserved SH2 domain and a conserved tyrosine residue carboxy-
terminal of the SH2 domain. SH2 domains bind phosphotyrosine residues. ST AT 
activation requires protein tyrosine phosphorylation at the conserved carboxy-
terminal tyrosine (Darnell et al 1994). The non-phosphorylated STATs exist as 
monomers in the cytoplasm and upon phosphorylation they form homo- or 
heterodimers through interactions of their SH2 domains and the phosphotyrosine 
residues. The tyrosine phosphorylation of the STATs occurs at the cell membrane in 
association with the receptor components. ST AT2 is probably constitutively 
associated with the IFNAR2 subunit of the IFNa/~ receptor. 
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Activation of STATI at the IFN receptor depends upon the presence of STAT2 and 
receptor engagement. 
As a result of studies using IFN response mutant cell lines a gene, tyk2, was identified 
as being responsible for restoring the mutant cell's response to IFNa. This gene 
encodes a protein tyrosine kinase lacking a SH2 domain but containing two kinase-
like domains. This protem kinase was named Tyk2 and is necessary for the IFN a/~ 
response (Pellegrini and Schindler 1993). A further protein tyrosine kinase was 
identified as being necessary for a response to IFNa and IFN~ and this was called 
JAKI. 
The JAK family is a novel family of cytoplasmic kinases which are involved in the 
signalling of a wide range of cytokines. The acronym JAK stands for Janus kinase 
which refers to the two-faced Roman god of gates and doorways and the J AKs ' 
structural feature of two kinase domains. In mammals, there are 4 family members 
(JAK 1, JAK 2, JAK 3 and Tyk 2). JAKs uniquely contain two kinases homology 
domains JHl and JH2. Experiments using mutant cell lines show that a pair of JAKs 
are required for Type I interferon signalling. JAK 1 is required for signalling through 
both the Type I and Type II interferon receptors, whereas Tyk 2 is necessary for IFN 
a/~ responses and JAK 2 for IFNy signalling (Velazquez et al 1992; Muller et al 
1993). There is interdependence between the pairs of kinases - if either pair is 
missing, the remaining kinase is not activated. 
JAKs associate with conserved motifs in the membrane proximal regIOn of the 
receptor. There is constitutive association of Tyk 2 with IFNAR1 and JAK 1 with 
IFNAR2 subunits of the IFN a/~ receptor (Novick et al1994; Abramovich et al 1994; 
Colamonici et al 1994). Protein tyrosine phosphorylation is a key reaction in the 
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activation of cytokine receptors (Velazquez et al 1992; Levy 1995; Hague and 
Williams 1998). 
However, unlike most growth factor receptors, the cytokine receptors do not possess 
any cytoplasmic tyrosine kinase domain, instead they constitutively associate with 
members of the JAK family of tyrosine kinases that provide tyrosine kinase activity 
necessary for receptor activation and subsequent signal transduction (Velazquez et al 
1992; Ihle and Kerr 1995; Stark et aI1998). 
In summary, IFNa and IFN~ binding to the Type I IFN receptor leads to dimerisation 
of the different subunits of the receptor. This receptor aggregation brings JAK1 and 
Tyk2 into close proximity through their constituitive association with receptor 
subunits. This results in tyrosine phosphorylation of the receptor components. The 
phosphotyrosine residues in the receptor complex recruit STA T1 and ST A T2 through 
their SH2 domains which are, in turn, phosphorylated on their carboxy-terminal 
tyrosine residue. The activation of the STAT proteins leads to dimerisation of the 
proteins to form the complex ISGF3a. This complex moves into the nucleus where it 
associates with the 48kD DNA-binding protein, ISGF3y/IRF-9, and forms a stable 
multimeric complex, ISGF3, on the ISRE with the IRF -9 protein interacting directly 
with the DNA (Figure 8.1). 
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Figure 8.1. The mechanism of Type I interferon signalling via the JAKfST AT 
pathway (A-D). 
Key to symbols: 
• represents the ligands IFNa and IFN~, 0 represents tyrosine phosphorylation 
A The initial event in cell signalling by the Type I interferons is the activation of 
the cell surface cytokine class II receptor byIFNa and IFN~. 
A 
IFNAR2 IFN ARI 
CELL MEM BRANE 
CYTOPLASM 
STATI 
NUCLEAR MEMBRAN E 
1 
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B The signalling mechanism is initiated when, after ligand-receptor binding, the 
receptor subunits dimerize bringing the associated kinases, JAKI and Tyk2, into 
close proximity. This action results in tyrosine phosphorylation and an increase 
in catalytic activity. 
B 
STATI 
1 
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C The phosphotyrosine residues in the receptor complex recruit STAT! and 
ST AT2 through their SH2 domains which, in turn, are phosphorylated. The 
activation of the ST ATs facilitates heterodimerization of the proteins by SH2-
phosphotyrosine interactions leading to the formation of the ISGF3u. The 
ISGF3u then translocates to the nucleus and the DNA-binding protein p481IRF-9 
(ISGF3y). 
c 
STAT I § STAT2 } ISGF3u 
n ~ 
p48/1RF-9 I } ISGF3y 
1 
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D Within the nucleus the ISGF3u associates with the DNA-binding protein 
p481IRF-9 (ISGF3y) to form a stable ISGF3 complex on the ISRE. This 
association leads to the induction of the target genes. 
D 
I STATI ~ ST AT2 I } ISGF I p48/1RF-9 I 
~
ISRE 
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It is known that Type I IFNs stimulate the JAKISTAT pathway in many cell types 
but, to date, there have been no reports showing the activation of the JAKISTAT 
pathway in response to Type I IFNs in human endometrial cells in culture. However. 
it has been shown th~t the Type I IFN, IFN-r, activates the JAKISTAT pathway, with 
the tyrosine phosphorylation of STATs 1 and 2, in bovine and ovine endometrial 
epithelial cells (Stewart et al 2001; Binelli et al 2001). However, before any of the 
stimulation experiments involving human endometrial cells were carried out it was 
important to determine that JAK and STAT proteins were present in human 
endometrial cells in culture as this had not been previously reported. It was also 
possible that even if these proteins were present in endometrial cells it may be 
difficult to culture enough primary human cells to produce adequate quantities of 
these proteins for the experiments to be carried out (Dr Ian Kerr, personal 
communication). 
8.2 Methods 
8.2.1 Immunoprecipitation of the JAK and STAT proteins 
The method for the immunoprecipitation of the JAK and STAT proteins was carried 
out according to the protocols provided by Dr Ian Kerr, ICRF, London. 
Three x 106 unstimulated endometrial cells, 2 x 106 control cells U3C (STAT 1 a 
negative) and 2 x 106 control cells U4C (JAK 1 negative) were lysed in 500JlI of lysis 
buffer. Each lysate was placed in an Eppendorf tube and put on ice for 15 min mixing 
vigorously at regular intervals throughout this time. The cells were then centrifuged 
at 4 °C for 5 min at 13 000 x g. The cell supernatants were then immunoprecipitated 
overnight at 4°C using polyclonal rabbit antibodies to JAK1 and STAT 2 and 
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monoclonal antibodies to STATI a together with 50~1 of Protein A sepharose 
(prepared as a 50% slurry in lysis buffer). 
8.2.2 SDS-P AGE 
The gel was prepared by pouring the freshly made resolving gel solution between two 
20 cm x 20 cm glass plates separated by 1 mm spacers. The gel was left to set and to 
prevent oxidation the top of the gel was covered with a solution of butan-1-01 
saturated with water. After the gel had solidified the butanol solution was decanted 
and the top of the gel rinsed several times with water before adding the stacking gel. 
Once this solution had been added the 10 well comb was carefully put into place 
between the glass plates and the gel was left to set. 
The immunoprecipitated cell lysates prepared in section 8.2.1 were centrifuged for 5 
minutes at 13,000 x g at 4°C and the supernatant was discarded (if necessary the 
supernatant could be cleaned with a protein A Sepharose incubation followed by 
immunoprecipitation with different antibodies from those already used). The protein 
A Sepharose beads were washed once in lysis buffer and once in wash buffer. The 
resulting pellet was resuspended in 50~1 of loading buffer then boiled for 5 min prior 
to loading onto the gel. Molecular weight markers were used for size estimation and 
run in one or more lanes. The samples were run through the stacking gel at 150 V 
(Volts) and 105 rnA (milliAmps) and through the resolving gel at 255 V and 222 rnA 
in running buffer. The electrophoresis was stopped when the bromophenol blue line 
reached the bottom of the gel. 
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8.2.3 Western blotting 
Western blotting involves transferring proteins, previously separated by SDS-PAGE. 
onto polyvinylidine fluoride (PVDF) membranes. A small proportion of this protein 
in the membrane re-folds to its native conformation and can therefore be probed for 
immunoreactivity to a given antibody. Proteins contained within the polyacrylamide 
gel maintain a negative charge and they can be transferred onto PVDF membranes by 
applying a current across the gel enabling the proteins to migrate at 90 ° to the gel and 
onto the membrane. The PVDF membrane was cut to fit the gel and soaked in 
methanol for a few minutes. Meanwhile the gel was removed from the 
electrophoresis tank and placed on a bed of approximately 6 Whatman filter papers 
wetted with transfer buffer. The moistened PVDF membrane was placed onto the gel 
and more wet filter papers placed on top of that. To ensure there was good contact 
between all the components it was important to remove all traces of air. This was 
done by gently rolling a pipette across the membrane and then the papers. This 
'sandwich' of gel, membrane and filter paper was placed between two pads of 
Scotchbrite and the two parts of the cell which were placed into the vertical transfer 
tank ensuring at all times that the gel faced the cathode and the membrane faced the 
anode. 
The transfer was carried out at 4 °C overnight using 0.1 A. The timings had been 
assessed by the efficiency of the transfer of the pre-stained protein markers. After the 
transfer the membranes were rinsed in TBST + vanadate and then blocked for 1 hr at 
4 °C in 5% BSA in TBST + vanadate with 0.01% sodium azide (NaN3). After 
blocking, the membrane was washed in TBST (no vanadate) and then incubated on a 
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rocking platform overnight at 4°C in TBST + 1 % BSA + 0.01 % NaN3 containing the 
primary antibody (antibody specific to the protein of interest). 
8.2.4 Detection of proteins by enhanced chemi-luminescence (EeL) 
After incubation with antibody solution the membrane was washed for 5 min x 3 in 
TBST to ensure the removal ofNaN3. The membrane was then incubated for 45 min at 
room temperature with secondary anti-mouse or anti-rabbit peroxidase conjugated 
antibodies at 1 in 1500 dilution in TBST + 1 % BSA. The membrane was then washed 
extensively with TBST for at least 1 hr with as many changes of buffer as practical. 
The membrane was then visualised using the ECL kit. This involved mixing the EeL 
reagent' l' with reagent '2' in equal volumes and then pouring them onto the surface 
of the blot. The solution was left for 1 min after which time the unbound reagent was 
drained off and the membrane was blotted gently with filter paper. The blot was 
placed in cling film and then exposed to X-Omat XAR-5 (Kodak) film for 30 seconds 
to 3 min and then developed using an automatic developer (Department of 
Radiography, St Bartholomew's Hospital, London, UK). 
The membrane could be stripped with 2M glycine.Hel pH 2.5 for 30 min, neutralised 
with 1M Tris.Hel pH 7.4 and then rinsed in TBST before re-probing with other 
specific antibodies. 
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8.3 Results 
Using 3 x 106 human endometrial cells it was possible to detect the presence of 
unactivated JAK and STAT proteins - JAK1, Tyk2, STATla and 2. (Figure 8.2). 
Figure 8.2 (A) shows that following immunoprecipitation and Western blotting with 
anti-JAK1 a band corresponding to a molecular weight of approximately 100 kDa can 
be seen in the lane containing U3C cells. This band was not seen in lysates from U4C 
cells which are known to be JAK1 deficient (Muller et al 1993) but was also present 
in lysates from primary human endometrial cells. 
In Figure 8.2 (B) a band of protein corresponding to a molecular weight of 
approximately 115-120 kDa, that of Tyk2, can be seen in lanes 1, 2 and 3 following 
immunoprecipitation with anti-Tyk2. Control cell lines U3C and U4C are not 
deficient in Tyk2 and therefore act as positive controls. This protein band is also 
present in primary human endometrial cell lysates although to a lesser extent 
confirming that Tyk2 can be found in endometrial cells. 
Immunoprecipitation and Western blotting with anti-STATla gives rise to a band in 
U4C lysates of approximately 90kDa and a similar band can be seen in human 
endometrial celllysates. U3C cells, deficient in STATla (Muller et al 1993) show no 
band at all so confirming that STAT 1 a is present in human endometrial cells (Fig 8.2 
C). 
Figure 8.2 (D) shows bands migrating to an approximate molecular weight of 113 
kDa, that of ST AT2, in U3C, U4C and human endometrial celllysates. 
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Figure 8.2 Autoradiographs showing the presence of JAKI (A), Tyk2(B), 
STATla (C) and ST AT2 (D) in cultured human endometrial cells. Control cell 
lines U4C (JAKl negative) and U3C (ST ATla negative) are also shown. 
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The protein bands of JAKl, Tyk2 and STATla (Fig 8.2 A, B and C) in human 
endometrial celllysates are very similar to those found in the control celllysates in 
that they all appear as single bands. However, in endometrial celllysates ST AT2 has a 
second band of protein at approximately 80-90 kDa. Using a Ferguson plot oflog lO 
molecular weight against distance migrated by the molecular weight it was possible to 
calculate the approximate molecular weight for the lower molecular weight band of 
STAT2 to be 84 kDa (Fig 8.3). Both molecular weight forms ofSTAT2 protein 
appear to be present in endometrial celllysates in equal quantities. 
Figure 8.3 Ferguson plot of LOgIO molecular weight against distance migrated 
by molecular weight for ST AT2 proteins 
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In all cases the protein bands corresponding to the JAK and STATs in human 
endometrial cell lysates are less intense than their counterparts in the control cell 
lysates. 
8.4 Discussion 
STAT1u expression has been reported in cultured human endometrial cells 
(Zoumpoulidou et al 2004). However, to our knowledge this is the first time that 
expression of other members of this signalling pathway, JAK1, Tyk2 and STAT2 has 
been demonstrated. 
One area of concern associated with the investigation into the activation of JAK and 
STAT proteins in response to Type I IFN stimulation was the possibility that there 
would not be enough endometrial cells cultured to produce JAK and STAT proteins in 
adequate quantities to be detected by the experimental methods. 
The results show that JAK1, Tyk2, STAT1a and STAT2 could be detected in 3 x 106 
endometrial cells in culture. As a consequence, it was possible to carry out the 
investigation into the activation of these proteins in response to Type I IFN s (see 
Chapter 9). 
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CHAPTER 9 
PHOSPHORYLATION OF JAK AND STAT 
PROTEINS FOLLOWING TYPE I INTERFERON 
STIMULATION IN ENDOMETRIAL CELLS 
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9.1 Introduction 
One of the aims of this study was to detennine whether Type I IFNs exert their effects 
through the JAKISTAT pathway in cultured human endometrial cells. 
Experiments were carried out to investigate the stimulation of the JAKJST AT 
pathway in human endometrial cells in response to the Type I IFNs, IFNs u, ~ and't. 
To examine Type I IFN-induced phosphorylation of the )AK and STAT proteins, 
primary human endometrial cells were exposed to IFN s u, ~ and 't for 15 minutes. 
The cells were lysed and the proteins of interest, JAKl, Tyk2, STATI and STAT2. 
were immunoprecipitated with specific antibodies. The proteins underwent SDS-
PAGE and Western blotting followed by incubation with antibodies to 
phosphotyrosine. The membranes were visualised by autoradiography and ECL 
chemiluminescence. 
9.2 Methods 
Endometrial cells were grown to confluency in 175 cm2 flasks. The medium was 
discarded and replaced with either 10 ml of fresh fully supplemented medium 
containing IFN (u, J3 or 't) at a concentration of 1000 units per ml of medium or 10 ml 
of medium not containing IFN which acted as the control. The flasks were returned to 
the 37°C incubator for 15 min after which time the medium was discarded and the 
cells washed with ice-cold PBS with 1% BSA (w/v). The cells were lysed and 
transferred to vials and then the proteins of interest were immunoprecipitated using 
specific antisera as previously described in section 8.2.1. The proteins then 
underwent SDS-PAGE and Western blotting as described in sections 8.2.2 and 8.2.3. 
The PVDF membrane was then incubated overnight at 4°C with a solution containing 
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two monoclonal antibodies to phosphotyrosine (PY20 and 4G 10) at a dilution of 1 in 
2000 in TBST + 1% BSA + 0.01% NaN3• These antibodies targeted those 
immunoprecipitated proteins which had been phosphorylated in response to IFN 
stimulation. Visualisation was carried out as previously described in section 8.2.4 
using an EeL kit. 
9.3 Results 
Autoradiographs of the experiments using anti-phosphotyrosine antibodies show that 
all the protein lanes show an extra 2 bands present at molecular weights of 
approximately 50 kDa and 25 kDa (Figure 9.1). These bands are equivalent to the 
heavy and light chains of immunoglobulin (Kunisada et al 1996) and will not be 
shown in subsequent figures. 
9.3.1 Phosphorylation status of JAK and STAT proteins in unstimulated 
endometrial cells. 
Throughout the following experiments control lanes (cell lysates not stimulated by 
IFN) show that JAK1, Tyk2 and STAT2 are not present in endometrial celllysates in 
a.phosphorylated form prior to stimulation. However, it does appear that STATlu is 
present in endometrial celllysates in a phosphorylated form prior to IFN stimulation 
(Figure 9.1). 
9.3.2 Stimulation by IFNa. 
In response to 1000 units of IFNu, endometrial celllysates show a relative increase in 
STAT1u phosphorylation compared with the control together with phosphorylation of 
Tyk2 and STAT2. 
There is no phosphorylation of JAKI. 
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Figure 9.1 Probing with anti-phosphotyrosine antibody shows ST ATla is 
present in unstimulated endometrial cells constitutively phosphorylated. 
Immunoglobulin (Ig) heavy and light chains are also shown. 
STATl a ----7 
Ig 50 kDa ----7 ... ._ 
'heavy' chain 
19 25 kDa ----7 ....... 
'light' chain 
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- 97.-+ kDa 
- 66 kDa 
- .f6 kDa 
- 30 kDa 
- ::: 1 .5 kDa 
- 1..+.3 kDa 
Both the 113 kDa and 84 kDa bands of STAT2 protein seen in endometrial cell lysate 
are phosphorylated on stimulation with IFNu. However, the 113 kDa STAT2 protein 
appears to be phosphorylated to a greater extent than the 84 kDa form (Figure 9.2A). 
9.3.3 Stimulation by IFN~ 
In response to stimulation with 1000 units of IFN~ endometrial cell lysates show 
phosphorylation of Tyk2, both the 113 kDa and 84 kDa bands of STAT2 and a 
marked increase in phosphorylation of STAT1u. 
JAK1 remains unphosphorylated after stimulation with IFN~. 
Interestingly, in contrast to the phosphorylation pattern of STAT2 after stimulation by 
IFNu, IFN~ phosphorylates both the 113 and 84 kDa forms to the same extent (Figure 
9.2B). 
9.3.4 Stimulation by IFN't 
Following stimulation with 1000 units of IFN't endometrial cell lysates shows 
phosphorylation of Tyk2, no phosphorylation of STAT1u and, in contrast to IFNu 
and IFN~, no phosphorylation of either of the two bands of STAT2. 
Stimulation by a IFN't fails to produce phosphorylation of JAK1. 
However, the pattern of phosphorylation of STAT1u is different to that seen in the 
unstimulated control and after stimulation with IFNu and ~ in that there appears to be 
de-phosphorylation ofSTAT1u (Fig 9.2C). 
In summary, in human endometrial celllysates: 
• IFNu, IFN~ and IFN't all stimulate the phosphorylation of Tyk2. 
• Only IFNu and ~ activate the phosphorylation of STAT2. 
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• Only IFNu and IFNB stimulated an increase in phosphorylation of STATla. 
however, in contrast, in response to IFN't there was de-phosphorylation of 
STATlu. 
• There is no phosphorylation of JAKI by any of the Type 1 IFNs. 
Table 9.1 The results of the stimulation of endometrial cell lysates by Type I 
IFNs are summarised in the following table: 
JAKI Tyk2 STATlu STAT2 
control - - ++ -
IFNu - + +++ ++ 
IFNB - + ++++ ++ 
++ - -IFN't -
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Figure 9.2 Phosphorylation of JAKl, Tyk2, STATla and ST AT2 in endometrial 
celllysates after stimulation with (A) IFNa, (B) IFN~ and (C) IFN't. 
(A) Tyk2 STAT2 STAT ] a JAK 1 
220 kDa -
97.4 kDa -
66 kDa-
-1-6 kDa-
(B) 
Tyk2 STAT2 STAT I a Jak I 
220 kDa -
97. -1- kDa -
66 kDa-
(C) Tyk2 STAT2 STATl a Jakl 
220 kDa-
97 .-1- kDa -
66 kDa-
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9.4 Discussion 
These experiments show for the fIrst time that Type I IFNs stimulate phosphorylation 
of the JAK and STAT proteins in primary human endometrial cells in vitro. The 
degree to which these proteins are phosphorylated varies depending upon which Type 
I IFN is used to stimulate the cells. However, none of the Type I IFNs are associated 
with phosphorylation of JAKl. 
Despite extensive searching of the literature I have been unable to fmd any other 
studies of Type I IFN signalling in human endometrial cells. 
As previously described, JAK1 is required for signalling through both the Type I and 
Type II IFN receptors. However, the results show that JAK1 is not phosphorylated in 
response to Type I IFN stimulation in endometrial cells even though the protein is 
present in the cell lysates. However, there is phosphorylation of Tyk2 which is 
necessary for IFN a/f3 signalling (Velasquez et al 1992 and Muller et al 1993). 
In the experiments in this study there appears to be phosphorylation of ST AT2 and an 
increase in phosphorylation of STATla when cells are stimulated with IFNs a and f3 
even in the absence of JAK1 phosphorylation. IFN-r phosphorylates Tyk2 but not 
JAK1 but, in contrast to IFNs a and f3, there is no phosphorylation of the STAT 
proteins 1 a and 2. These observations suggest a complex regulation of components 
involved in intracellular signalling via IFN-Type I receptor. 
There is constitutive association of Tyk2 with the IFNAR1 subunit of the IFNa/f3 
receptor and JAK1 with the IFNAR2 subunit (Novick et al 1994 Abramovich et al 
1994; Colamonici et aI1994). 
As previously stated IFNa and IFN-r have approximately 70% sequence homology 
(Stewart et al 1987; Imakawa et al 1987) and they share a common receptor in the 
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bovine endometrium (Li and Roberts 1994). The Type I IFN receptor is highly 
conserved across species; the ovine and bovine Type I IFN receptors sharing 80% and 
95% homology with the human IFNAR1 (Kaluz et al 1996). It appears from the 
results obtained in our studies that IFN't binds to the IFN a/~ receptor on human 
endometrial cells and this interaction stimulates the phosphorylation of Tyk2 and 
phosphoinositide turnover. It has been stated that IFN't interacts with the IFNARI 
subunit of the receptor and it is known that the IFNAR1 subunit is constituitively 
associated with Tyk2. Thus, the response observed in these studies with IFN't is 
consistent with what is known about Type I IFN signalling in that with only one 
receptor-associated kinase being phosphorylated there is no down-stream 
phosphorylation of STAT1a and STAT2. However, the results for IFNa and ~ are 
inconsistent with this because although there is phosphorylation of Tyk2 but no 
phosphorylation of J AK1 there is still phosphorylation of the STAT proteins. These 
results are similar to those found by Grumbach and colleagues who found that human 
myocardial fibroblasts did not show activation of JAK1 in response to IFNa although 
there was some degree of activation of STAT1 (Grumbach et al 1999). 
However, there may be many reasons for the lack of JAK1 phosphorylation following 
IFN stimulation. It is possible that our method of detection was not sensitive enough 
to detect phosphorylated JAK1. However, the method is perfectly adequate for 
detecting Tyk2, STAT1a and STAT2. Also, the native proteins are found in 
endometrial celllysates in similar quantities (Fig 8.2). 
It may be possible that the anti-phosphotyrosine antibodies used in our study are not 
recognising the JAK1 phosphotyrosine. However, many groups use the same anti-
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phosphotyrosine antibody and phosphorylated JAKI can be detected (O'Brien et al 
2002; Binelli et al 2001). 
Cross-competition by different receptors for the same cellular component may be 
occurring. Class I and II cytokine receptors emerged in evolution after the tyrosine 
kinase receptors (Ruvkun and Hobert 1998). To date over 40 distinct members of 
these receptor families have been described but, in contrast, there are only four JAKs. 
Consequently, different cytokine receptor complexes share common JAK family 
members (Dondi et al 2001). Therefore, if receptor numbers exceed the amount of 
available JAK there would be competition for this component. Dondi and colleagues 
(2001) have shown that there is down-modulation of Type I IFN responses by 
receptor cross-competition for a share of JAK kinase. It is possible that this 
mechanism may explain the lack of JAKI phosphorylation seen in this study when 
endometrial cells are exposed to Type I IFN s. 
It is possible that JAKI phosphorylation is not seen in response to IFNs a and ~ 
because, like IFN't, IFNs a and (3 are only binding to the IFNARI subunit of the 
receptor and therefore in response to activation there is only phosphorylation of Tyk2, 
the kinase which is associated with the IFNARI subunit. 
Finally, it is possible that the experiments carried out in this study show that JAK 1 
phosphorylation is not a pre-requisite for activation of the JAKIST AT pathway by 
Type I IFNs in human endometrial cells. 
In our study it appears that the STATla protein is present in endometrial cells in a 
phosphorylated form prior to stimulation by the Type IIFNs, in other words, STATla 
is constitutively activated. The phenomenon of constitutive activation of the STAT 
proteins, including STATl, has been demonstrated by other groups, for example, in 
acute myelogenous leukaemia (AML) cell lines, breast carcinoma cells, T cells, 
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peripheral blood cells and B lymphocytes (Speikermann et a12001; Garcia et a11997: 
Migone et al 1995; Gouilleux et al 1996; Franks et al 1997). Interestingly. 
Speikermann and colleagues could not detect tyrosine phosphorylation of JAK1. It 
could be argued that AML cell lines differ significantly in their biological and genetic 
characteristics from primary cells. However, constitutive activation of STAT proteins. 
including STAT1, has been described in primary AML and erythroleukaemia cells 
indicating that this observation is not an artefact of continuous cultivation or selection 
(Grouilleux et a11996; Hayakawa et a11998; Kirito et aI2002). 
The mechanism of constitutive activation of the STAT proteins IS not fully 
understood. The lack of phosphorylation of the JAK1 kinase seen in our experiments 
and those of Spiekermann and colleagues is a confounding observation. It is possible 
that due to the short-lasting tyrosine phosphorylation of the JAKs after ligand binding 
(Spiekermann et al 2001), phosphorylation of the JAK1 may not be detectable in our 
experiments. However, in our experiments the receptor is exposed to the ligand for 
15 minutes and therefore it would be expected that as a result of continuous ligand-
receptor binding there would be continuous phosphorylation. It would be expected 
that if JAK1 was rapidly de-phosphorylated then Tyk2 would behave in the same way 
but Tyk2 remains phosphorylated. 
Another proposal for the mechanism of constitutive phosphorylation of the ST AT 
proteins is the autocrine production of cytokines, for example, IL6. IL6 has been 
shown to cause constitutive activation of STAT 1 , STAT3 and STAT5 in a variety of 
cell types (Gerhartz et al 1996; Schuringa et al 2000; Mizuki et al 2000). The work 
carried out in this thesis has shown that human endometrial cells taken from both the 
proliferative and secretory phases of the menstrual cycle produce large quantities of 
IL6 (see Section 4.4.2). The proposal that autocrine IL6 production may be 
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responsible for constitutive STAT1 activation would be consistent with the results 
presented here. In addition, there is evidence from chemical cross-linking 
experiments, that gp 130, the signal transducer for the IL6 family of cytokines, exists 
in close proximity to the IFNAR1 sub-unit of the IFNa/~ receptor which is necessary 
for effective IL6 signalling by providing 'docking sites' for STATl and STAT3 
(Mitani et al 2001). This data would help to reinforce the hypothesis that the 
constitutive phosphorylation of ST AT1 seen in this study may be due to the autocrine 
production of IL6. 
To investigate if constitutive activation of STAT proteins might contribute to the 
autonomous proliferation of AML cells Spiekermann and colleagues carried out 
inhibitor experiments which showed that there was a dose-dependent growth arrest. 
Therefore, it is possible that the proliferative nature of endometrial cells may be as a 
result of constitutive activation of STAT 1. 
However, although autocrine IL6 production may go someway towards explaining 
the presence of phosphorylated STAT1 a prior to stimulation with Type I interferons, 
it does not explain the increase in phosphorylation of STATla observed in response 
to stimulation by IFNa and f3. 
There is recent evidence that, in addition to tyrosine phosphorylation, there is serine 
phosphorylation which is required for the transcriptional properties of STAT1 (Uddin 
et al 2002b). It has been shown that STAT1 is phosphorylated on serine during 
binding of IFNa to the Type I IFN receptor (Uddin et al2002a; Su and David 2000). 
It has been demonstrated that a member of the PKC family of proteins may be 
involved (Uddin et al 2002a). The possibility that it is the activation of a PKC by 
diacylglycerol, a known activator of PKC and a product of phospholipid turnover, 
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which phosphorylates the serine in STAT1 in response to stimulation by IFNa d A an ...... 
This is discussed further in Chapter 10, Section 10.3. 
The ST AT2 protein (p 113) has been shown in this study to appear as a single protein 
band in both U3C and U4C cell lines. However, in endometrial cell lysates there 
appeared a second band of protein at approximately 80-90 kDa. U sing a Ferguson 
plot of 10glO molecular weight against distance migrated by the molecular weight 
standards produced a linear relationship (Fig 9.7). The resulting linear regression 
equation was used to estimate a more accurate molecular weight for the lower 
molecular weight band of STAT2 (estimated at 84 kDa). Both the 113 kDa and the 
84 kDa band became phosphorylated in response to IFNs a and~. 
Sugiyama and colleagues identified alternatively spliced forms of ST A T2 in human 
and mouse mRNAs (Sugiyama et al 1996). They found that in the human short form 
of STAT2, 231 C-terminal amino acid residues were replaced by novel 32 amino 
acids. The fragment of 231 amino acids represents 27% of the total protein and this is 
replaced by 32 amino acids which are 3.80/0 of the full length protein. Therefore, it 
follows that the short form would have a molecular weight of approximately 87 kDa. 
This is very close to the estimated weight of 84 kDa calculated for the lower 
molecular weight band ofSTAT2 seen in endometrial celllysates. 
This band may be evidence for the existence of the spliced form of S T A T2 in human 
endometrial cells. 
The results obtained suggest that selective activation of the JAKIST AT proteins may 
account for the occurrence of differences in the properties of distinct Type I IFNs in 
certain cell types. 
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CHAPTER 10 
SUMMARY AND 
GENERAL DISCUSSION 
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10.1 Objectives of this thesis 
The principle purpose of this study was to test the hypothesis that although Type I 
interferons activate a common tyrosine kinase signalling pathway in the human 
endometrium there is simultaneous activation of different phospholipase pathways 
which confer the specificity of the IFN response. 
However, in order to carry out the work it was necessary to establish the following: 
1) long-term primary human endometrial cell culture 
2) that primary human endometrial cells possess a functional IFNu/P receptor 
3) that phospholipid turnover occurs in endometrial cells in response to Type I IFNs 
and the identity of the phospholipids involved 
4) the presence of the JAKISTAT proteins in primary human endometrial cells in 
culture 
5) that there was phosphorylation of the JAKISTAT proteins in response to Type I 
IFNs. 
10.2 Summary of principle findings 
10.2.1 Primary human endometrial cell culture 
The use of primary human endometrial cells for experimental study is common place. 
However, the vast majority of studies use short term culture using cells within several 
days of the initial seeding out. To be able to study the effects of Type I interferon 
stimulation on ,phospholipid turnover and JAKIST AT phosphorylation it was 
necessary to culture the cells long enough to allow consecutive experiments on the 
same material to be carried out thus maintaining experimental consistency. For 
long-term endometrial cell culture it has been common practice to use cell lines which 
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have the major disadvantage of not being representative of cells in vivo. Bv 
measuring PP14 and IOFBP-l, markers of endometrial function and cell morphology. 
we have shown that primary human endometrial cells can be cultured for up to 15 
days whilst maintaining features characteristic of their cell type and phase of the 
menstrual cycle. 
The cells also produced cytokines LIF, IL-6 and HOF in accordance with published 
data on endometrial cell cytokine production. However, in contrast to the findings of 
other groups, we have demonstrated for the first time that HOF is produced by 
primary human endometrial cells in both the proliferative and secretory phases of the 
menstrual cycle. In response to the lack of data on the production of IFNy by 
endometrial cells in vitro we examined IFNy production by a mixed population of 
endometrial cells from both the proliferative and secretory phases of the menstrual 
cycle and found that IFNy was undetectable in all cases. With an established 
endometrial cell material we were able to continue with the objectives laid out in the 
thesis. 
10.2.2 IFN alP receptor 
Before embarking on a series of experiments looking at phospholipid turnover and 
phosphorylation of JAK and STAT proteins in endometrial cells in response to type I 
IFN s it was important to establish that primary human endometrial cells in culture 
respond to Type I IFN s in other words they possess a functional receptor. We found 
both direct and indirect evidence for a functioning receptor. Radiolabelled IFNa 
showed binding to endometrial cells in vitro and immunohistochemistry using mono-
and polyclonal antibodies to the receptor localised it further to both the stromal and 
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epithelial cells in endometrial tissue from both the proliferative and secretory phases 
of the menstrual cycle. These results provided evidence for the IFN alp receptor 
being present on endometrial cells. 
In addition, endometrial cells from both phases of the menstrual cycle showed an anti-
proliferative response to IFNa and thus demonstrated that the endometrial IFNa/p 
cell receptor functions in vitro. 
10.2.3 Phospholipid turnover in endometrial cells in response to Type I IFN 
stimulation 
Having established long-term cell culture of human endometrium and the presence of 
a functioning IFNa/~ receptor it was possible to investigate the pattern of 
phospholipid turnover in response to the Type I IFN s. 
It is well recognised that Type I IFNs on binding to the IFNa/J3 receptor result in the 
activation of the receptor-associated JAKI and Tyk2 kinases which regulate 
phosphorylation of multiple signal elements and the engagement of several 
downstream pathways including the STAT, the IRS-PI3'-kinase, the Crk and the 
mitogen-activated protein (MAP) kinase pathways (Uddin S et al 2002b). 
However, the experiments carried out in this study have shown for the first time that 
Type I IFNs will,. in human endometrial cells, stimulate a pathway involving 
phospholipid second messengers. Interestingly, phospholipid turnover is activated by 
both IFNs a and 't but, in contrast, IFN ~ does not appear to elicit a phospholipid 
turnover response. Other groups, using Daudi and HeLa cells (Cataldi et al 1990~ 
Pfeffer et al 1990), reported production of DAG in response to IFNa but the work 
carried out for this thesis has demonstrated for the first time that IFNa not only 
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activates production of DAG but the hydrolysis of the phosphoinositides PIP2, PIP 
andPA. 
To date there is no published data on the activation of phospholipid mechanisms by 
IFN't in any cell type. However, we can report that IFN't stimulates hydrolysis of 
PIP2 and PIP with concurrent production ofDAG in human endometrial cells in vitro. 
10.2.4 JAK and STAT proteins in endometrial cells and their phosphorylation 
following Type I IFN stimulation 
Having established the presence of the unphosphorylated JAKI, Tyk2, STATla and 
ST AT2 proteins in human endometrial cells it was possible to detennine if there was 
phosphorylation of these elements in endometrial cells in response to stimulation by 
Type I IFNs. We have shown that both IFN a and ~ will activate the phosphorylation 
of Tyk2, STATla and STAT2. However, in contrast IFN't does not stimulate the 
phosphorylation of STAT2 or STATla. Moreover, none of the IFN isotypes used in 
the experiments activated the phosphorylation of JAKI. 
General Discussion 
In summary, we have shown that: 
1) Type I interferons a, ~ and 't elicit a signal transduction response in cultured 
human endometrial cells 
2) Type I interferons activated both the phospholipase and JAKISTAT pathways 
3) the nature of the response appears to differ depending upon which interferon is 
used to stimulate the cells. 
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The results show that IFNa stimulates hydrolysis of PIP2 with the production of the 
metabolite diacylglycerol in human endometrial cells. These [mdings agree with 
other workers who found that the interaction of IFN a with several cells types. 
including human fibroblasts and Daudi cells, stimulates the release of DAG and 
inositol phosphates (Pfeffer et al 1990; Yap et al 1986). This is due to activation of 
phosphoinositide-specific phospholipase C (popescu et al 1989) and it has been 
suggested that this activation is the initial step in the interferon a induced 
transmembrane signalling pathway in these cells. 
Interferon 't, like IFNa, induces hydrolysis of PIP2 but it also induces hydrolysis of 
PIP and a reduction of PI levels over a period of 2 minutes after stimulation. 
However, in contrast, IFN't appears to have a more limited affect on the JAKIST A T 
pathway with phosphorylation ofTyk2 only. 
Interferon B does not stimulate hydrolysis of any of the phosphoinositides nor does it 
stimulate production of DAG, but, in stark contrast to these [mdings, it does stimulate 
strong phosphorylation of Tyk2, STAT 1 a and ST AT2. 
JAK 1, on the other hand, is not phosphorylated after stimulation by any of the Type I 
IFNs. This finding is at odds with published data as it is known that JAKI is required 
for the assembly of the IFNa/B receptor leading to the activation of the JAK and 
STAT proteins (see Chapter 8). 
It has been established that the JAKISTAT pathway plays a critical role in interferon-
dependent gene regulation and that one of the most important steps in this signalling 
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mechanism is the association of the JAKs with the receptor and their subsequent 
regulation of the tyrosine phosphorylation of the STAT proteins. The STAT protein 
complexes that are formed as a consequence translocate to the nucleus to initiate gene 
transcription by binding to distinct elements in the promoters ofIFN-activated genes. 
However, the picture that has emerged from the work carried out in this thesis is that 
there appears to be phosphorylation of the STAT proteins without any 
phosphorylation of the JAKI kinase. Since we have shown that IFNa exhibits an 
anti-proliferative effect on human endometrial cells in vitro it would appear that the 
phosphorylation of the STAT proteins leads to a functional response without the 
requirement of JAKI phosphorylation. There is strong evidence that, in addition to 
tyrosine phosphorylation, phosphorylation on serine is required for the transcriptional 
properties of STAT 1 (Uddin et al2002b). STATI has a phosphorylation site on its C 
terminus serine 727. The functional relevance of serine phosphorylation of STAT1 
has been demonstrated in studies performed in the Type II IFN system in which it was 
shown that complementation of STATI-deficient cells with a Ser-727 mutant fails to 
restore induction of the anti proliferative and antiviral properties of IFNy whereas re-
expression of the wild type restores the deficiencies. However, there is evidence that 
STAT 1 is also phosphorylated on serine during engagement of the Type I IFN 
receptor with IFNa (Uddin et al 2002a; Su and David 2000) suggesting a role for 
serine phosphorylation of STATI in the generation of Type I interferon responses. 
The mechanisms regulating Type I IFN-inducible phosphorylation of ST A T1 on 
serine 727 have not been elucidated. The serine kinase regulating such 
phosphorylation remains unknown although it had been thought that p38 MAP kinase 
would be a good candidate but extensive studies by Uddin and colleagues (Uddin et al 
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2002a) established that it does not function as a serine kinase for STATI 
phosphorylation. Uddin and colleagues have demonstrated that a member of the 
PKC family of proteins, PKC-b, is phosphorylated during binding of the Type I IFN 
receptor by IFNa and that its kinase domain is induced (Uddin et a1 2002b). With this 
information it is possible to suggest that in our experiments IFNa/~ receptor binding 
on endometrial cells leading to antiproliferative activity, in the absence of JAKI 
phosphorylation but the presence of STATI phosphorylation, can be explained by 
serine phosphorylation of STATI instead of tyrosine phosphorylation of STATl. 
However, the question arises is how does the STATI serine become phosphorylated? 
It is possible that the phospholipid second messenger signalling pathway may give an 
answer. In this study it has been shown that in response to IFN a stimulation there is 
hydrolysis of phospholipids with a concurrent production of DAG. Diacylglycerol is 
an activator of PKC (Nishizuka 1988) and it is known that a Type I IFN, IFN't, 
activates PKC in MDBK cells (Commander et al 1993). Therefore, it could be 
proposed that it is the production of DAG in response to IFNa stimulation that leads 
to the activation of PKC which may, in turn, be responsible for the serine 
phosphorylation of STAT!. These results suggest the existence of a cross-talk 
mechanism by which PKC participates in co-operation with JAKISTAT signalling 
pathway to regulate Type I IFN-dependent responses. The PKC element being 
generated by the phospholipid second messenger DAG as a product of phospholipid 
hydrolysis by IFNa activation. Guanosine triphosphate (GTP) is necessary for the 
IP3 and DAG signalling mechanism (Haslam & Davidson 1984; Gomperts & 
Cockcroft 1985) with the G protein coupling the surface receptor to the enzyme 
phospholipase C (PLC) which then cleaves the PIP2 into IP3 and DAG. However, to 
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have cross-talk between signalling pathways it would be expected that the JAK/STAT 
and the phospholipid pathways would be activated simultaneously upon ligand-
receptor binding. Therefore, it would be important to have close association of the G 
protein with the Type I IFN receptor and Mitani and colleagues (200 I) have shown, 
using chemical cross-linking experiments, that the IFNARI subunit does exist in close 
proximity with the G protein gpI30. It has also been shown that other cytokines 
activate a signalling pathway through a G protein. Leukaemia inhibitory factor. 
(LIF), will activate the JAK and STAT pathway through gp130 in cardiac myocytes 
(Kunisada et al 1996). 
However, IFN't appears to behave differently from IFNa. In our studies, IFN't, like 
IFNa, activates the generation of phospholipid second messengers with the 
production of DAG. It is therefore possible that as a result of the production of DAG 
there will be activation of PKC. Although there is phosphorylation of Tyk2 , through 
the binding of the IFNARI subunit of the receptor, there is no observed 
phosphorylation of either STATI or STAT2 in response to IFN't stimulation. The 
lack of STAT1 phosphorylation would cast doubt on the suggestion that it may be a 
PKC which phosphorylates the STATI serine 727. However, IFNa binding to the 
Type I interferon receptor on human endometrial cells stimulates the hydrolysis of P A 
within 2 seconds of exposure and that these levels remain significantly reduced even 
at 1 minute (p = 0.01) suggesting that PA turnover may also be involved. In contrast, 
there is no hydrolysis of PAin response to IFN't stimulation. Interestingly, P A can be 
hydrolysed by the enzyme phosphatidic acid phosphohydrolase to form DAG. It is 
therefore possible that the DAG seen after IFNa stimulation may be derived not only 
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from PIP2 hydrolysis but also from P A hydrolysis. This additional DAG may be 
sufficient to activate PKC on IFNa stimulation leading to serine phosphorylation of 
STATl. However, since PA is not involved in the response to IFN-r stimulation, the 
only source of DAG is from PIP2 hydrolysis. Therefore, it is possible that the 
amount of DAG produced by PIP2 hydrolysis alone may not be sufficient to activate 
PKC and this may explain the absence of STATl phosphorylation in response to IFN-r 
stimulation. 
10.4 Future directions 
To determine whether there IS a relationship between the JAKfST AT and 
phospholipid signalling pathways it would be necessary to establish if 1) the Type I 
IFN binding with the receptor activates the JAKfSTAT and phospholipid pathways 
independently of one another and 2) phospholipid turnover and second messenger 
generation is a prerequisite for the activation of the tyrosine kinases and/or STAT 
proteins. 
To address the question do the JAKfSTAT and phospholipid pathways signal 
independently it would be necessary to look at the activation of the JAKfST AT 
proteins in the presence of phospholipase inhibitors and phospholipid turnover in the 
presence of the tyrosine kinase inhibitors. Phospholipase inhibitors include 
aristolochic acid, 4-( 4-octadecyl)-4-oxobenzenebutenoic acid (OBAA) for A2 and 
7,7-dimethyl-5,8-eicosadienoic acid (DEDA) which is a potent inhibitor of 
recombinant human placental phospholipase A2; tricyclodecan-9-yl xanthogenate 
(D609) for C; neomycin sulphate for C and D and D,L-erythrodihydrosphingosine for 
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A2 and D. Inhibitors of tyrosine kinase include genistein, tyrphostins, lavendustin A 
and herbimycin A. 
The effect of second messengers generated from phospholipid turnover on JAKIST AT 
activation following exposure to IFN can be investigated using inhibitors of PKC 
(calphostin C, chelerythrine chloride), cyclooxygenase and lipoxygenase inhibitors 
(indomethacin, salicylic acid) and intracellular calcium chelators (I,2-bis(2-
aminophenooxy)ethane-N,N,N'N'~tetraacetic acid (BAPTA)). However, if no effect 
is found on the JAKISTAT proteins in the presence of phospholipase inhibitors this 
does not rule out the possibility that phospholipid turnover may exert an effect further 
downstream. 
It would be interesting to establish if, in the absence of IFN stimulation, there would 
be activation of the JAKISTAT pathway and the fonnation of ISGF3 in endometrial 
cells incubated in the presence of one of the following: 
i) phospholipid-generated second messengers, for example, arachidonic 
acid and prostaglandins 
ii) PKC activators, for example, phorbolI2-myristate I3-acetate (PMA) 
iii) calcium ionophores, for example, ionomycin. 
It is possible that the specificity of the IFN stimulated response is dependent upon 
modifications of ISGF3. An alteration of this complex may result in binding to a 
different ISRE which would consequently trigger the expression of different genes. 
Differences in ISGF3 complexes may arise either through activation of different 
subtypes of latent transcription factors or through activation of different 
phospholipase pathways resulting m second messenger modification. ISGF3 
modifications can be determined usmg 35S-methionine, SDS-PAGE and 
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autoradiography. These experiments could then be repeated ill the presence of 
phospholipase inhibitors. 
Having established that the phospholipid pathways are used by IFNs a and 't in the 
human system the next step would be to repeat the experiment in sheep endometrial 
cell culture to investigate if the pattern of phospholipid turnover differs not only 
between the IFN isotypes but also between species. Ovine caruncle (sheep 
'endometrium') material was collected during the latter part of the work carried out in 
this thesis. However, the material was heavily contaminated and required increasing 
concentrations of antibiotics, including the use of gentamycin, to maintain uninfected 
cultures. 
10.5 Conclusions 
We have confirmed that the JAKISTAT pathway is the universal signalling 
mechanism used by Type I IFN s and we have shown for the first time that the Type I 
IFNs also activate a different signalling pathway that of phospholipid hydrolysis. We 
have shown that the pathways are activated differently depending on the Type I IFN 
isotype used. 
It is hoped that the results from this study will not only shed further light on the 
mechanism of action of Type I IFN s in general and their function in human pregnancy 
but may also contribute to our understanding of the processes involved in human 
fetal-maternal recognition. 
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